

Professor Usha Menon

PERSONAL DETAILS

Current **Group Leader, Gynaecological Cancer Research Centre**

Appointments: Department of Women's Cancer
Institute for Women's Health (IfWH)
Faculty of Population Health Sciences
University College London, UK

Academic Lead, Integrated Clinical Academic Training (ICAT) Programme
IfWH

Consultant Gynaecologist

University College London Hospitals NHS Foundation Trust, London, UK

Work Address: Gynaecological Cancer Research Centre, IfWH
Suite 1B, 1st Floor, Maple House
149 Tottenham Court Road, London, W1T 7DN, UK
Tel: +44 (0)20 3447 2107
Fax: +44 (0)20 3447 2129
Email: u.menon@ucl.ac.uk

EDUCATION/QUALIFICATIONS

Dates	Detail of degree, diploma other qualification	Institution
11/2007	Fellow of the Royal College of Obstetricians and Gynaecologists (FRCOG)	Royal College of Obstetricians and Gynaecologists (RCOG), London, UK
07/2007	MD (Research)	University of London, UK
04/2000	Certificate of Completion of Specialist Training (CCST) Obstetrics and Gynaecology	RCOG, London, UK
09/1999	Accreditation in Colposcopy	British Society of Cytologists and Cytopathologists, London, UK
11/1994	Member of the Royal College of Obstetricians and Gynaecologists (MRCOG)	RCOG, London, UK
10/1990	MD in Obstetrics and Gynaecology	Christian Medical College (CMC), Vellore, Madras University, India
10/1988	Diploma in Gynaecology and Obstetrics (DGO)	
09/1985	Bachelor of Medicine & Surgery (MBBS)	
01/1979	Indian School Certificate (ISC)	La Martinière for Girls, Kolkata, India

PROFESSIONAL HISTORY

Dates	Detail of position held	Institution
01/10/2009 –	Professor of Gynaecological Oncology	Department of Women's Cancer, IfWH, UCL, UK
01/10/2004 –	Group Leader GCRC	
01/04/2004-	Consultant Gynaecologist	UCLH NHS Foundation Trust, London, UK
01/09/2016 –	Academic Training Programme (IAT) Director for North Central and East London	London Speciality School of Obstetrics & Gynaecology
01/09/2016 –	Academic Lead, IAT Programme	IfWH, UCL, UK
01/07/2016 – 31/03/2017	Interim Director (job-share)	IfWH, UCL, UK
2004 – 2009	Senior Lecturer	Department of Women's Cancer, IfWH, UCL, UK
2001 – 2004	Senior Lecturer / Consultant	Gynaecological Oncology, Bart's and the London Queen Mary's School of Medicine and Dentistry, Queen Mary University of London (QMUL), London, UK
2000 – 2001	Locum Senior Lecturer / Consultant	
2000	Lecturer	
1999 – 2000	Specialist Registrar (SpR) Obstetrics and Gynaecology, South West Thames Region (SWTR)	St George's Hospital NHS Trust, London, UK
1997 – 1999	Clinical Research Fellow, Gynaecological Oncology	Bart's and the London Queen Mary's School of Medicine and Dentistry, QMUL, London, UK
1996 – 1997	SpR Obstetrics and Gynaecology, SWTR	St Helier Hospital, London, UK
1995 – 1996		St Peter's Hospital, Surrey, UK
1994 – 1995		Queen Mary's University Hospital, London, UK
1993 – 1994	Senior House Officer, Genitourinary Medicine	St Thomas' Hospital, London, UK
1991 – 1993	Registrar Obstetrics and Gynaecology	Royal Infirmary of Edinburgh and Simpson Memorial Maternity Pavilion, Edinburgh, UK
1990	Tutor	Obstetrics and Gynaecology, Christian Medical College (CMC), Vellore, India
1988 – 1990	Registrar	
1986 – 1988	Senior House Officer	
1985	Intern	CMC Hospital, Vellore, India

OTHER APPOINTMENTS AND AFFILIATIONS

Dates	Appointments
2012 –	Honorary Senior Consultant, Tata Medical Center, Kolkata, India
2004 – 2011	Honorary Consultant Gynaecologist, Bart's and the London NHS Trust, London, UK
2004 – 2009	Honorary Consultant Gynaecologist, Guy's and St Thomas' NHS Foundation Trust, London, UK
2004 – 2006	Honorary Consultant Gynaecologist, The Royal Marsden NHS Foundation Trust, London, UK

MEMBERSHIP ON ADVISORY / OVERSIGHT COMMITTEES

Dates	Committees
2017 –	Member, Project Steering Committee. ALDO Avoiding Late Diagnosis in Ovarian cancer. Cancer Vanguard project.
2016 –	Chair, Data Monitoring Committee: GEM3, A multi-centre double-blind placebo-controlled randomised trial of a combination of Methotrexate and Gefitinib versus Methotrexate alone as a treatment for ectopic pregnancy.
2016	Member, 'Be Clear on Cancer' campaign working group, Department of Health
2011 – 2015	Chair, Trial Steering Committee: A cluster randomised trial of STRATEGies to increase Cervical screening uptake at first invitation (STRATEGIC), University of Manchester
2009 –	Co-chair, International Cancer Benchmarking Partnership Module 4, Cancer Research UK, London
2009 – 2015	Member, Data Monitoring Committee: Comparison Arm for Protect (CAP) prostate cancer screening trial, University of Bristol
2009 – 2015	Member, Gynaecological Cancer Reference Group, National Cancer Intelligence Network, London
2007 –	Member, Network Site Specific Cancer Group for gynaecological cancers
2007 – 2014	Member, Data Monitoring Committee: Gynaecologic Cancer Intergroup trials ICON6 and ICON7, MRC Clinical Trials Unit at UCL, London
2009 – 2010	Member, National Awareness and Early Detection Initiative, Diagnostic Advisory Group
2008	Member, Cancer and Reproductive Health Study Group, 55 th RCOG Study Group
2008	Member, Gynaecological Cancer Reform Strategy Group, Department of Health
2007 – 2009	Member, Gynaecological Cancer Screening and Prevention Sub-committee, National Cancer Research Institute, London
2004 – 2008	Elected Council Member, British Gynaecological Cancer Society, London
2004 – 2009	Member, UCLH / IfWH Strategic Planning Board

PRIZES, AWARDS AND OTHER HONOURS

Dates	Detail of prize, award or honour	Awarding body
2014	Singapore Lecture and Medal	Royal College of Obstetrics and Gynaecology and Singapore Society
2013	46 th Dr Subodh Mitra Memorial Oration	Bengal Obstetric and Gynaecological Society, India
2013	Finalist, UCLH Celebrating Excellence Awards	University College London Hospitals NHS Foundation Trust, London, UK
2006	Asian Woman of the Year 2006	Asian Achievers Awards London, UK
1990	Mary George Prize, Best MD Obstetrics and Gynaecology	Christian Medical College, Vellore, India
1988	Dr A L Mudaliar Prize, Diploma examinations for Obstetrics and Gynaecology University	Madras University, India
1985	Jacob Chandy Medal for Best Outgoing Clinical Student	Christian Medical College, Vellore, India
1984	Victor Rambo Prize for Ophthalmology	
1984	R E S Muthiah Gold Medal in Ophthalmology	Madras University, India

RESEARCH GRANTS

Total grant funding of projects where principal investigator (PI) or Co-PI (GBP)	£ 30,732,991.80
Total industry funding to date (£)	£ 2,595,238.00

RESEARCH GRANTS – current

* Principal Investigator (PI) or Co-PI

Dates	Project title	Funding agency	Total award (GBP)
01/01/2017 – 31/01/2020	Long term impact of screening on ovarian cancer mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)*	NIHR Health Technology Assessment (HTA)	422,689.40
		Cancer Research UK (CRUK)	422,689.39
		The Eve Appeal	150,000

Dates	Project title	Funding agency	Total award (GBP)
01/07/2016 – 01/12/2017	Maintenance of UK FOCSS bioepository*	The Eve Appeal	49,856
18/08/2014 – 17/08/2018	Early Diagnosis Consortium Technology Studies	CRUK	127,525
01/10/2014 – 30/09/2019	ROCKETS – Refining Ovarian Cancer Test Accuracy Scores	NIHR HTA	1,000,037
01/01/2014 – 30/06/2017	Cardiometabolic disease prediction, causal analysis and drug development using high-resolution NMR metabolomics (The UCLEB consortium)	British Heart Foundation	795,445
01/04/2012 – 30/06/2017	International Cancer Benchmarking Partnership Module 4 – Pilot study England*	CRUK	134,926
01/09/2011 – 31/10/2018	PROMISE – Predicting Risk of Ovarian Malignancies, Improved Screening and Early detection	CRUK	1,620,000
		The Eve Appeal	1,640,000
01/07/2011 – 31/12/2017	Biomarker discovery and validation using the UKCTOCS biobank*	Abcodia UK	1,295,238

RESEARCH GRANTS – previous

* Principal Investigator (PI) or Co-PI

Dates	Project title	Funding agency	Total award (GBP)
03/11/2005 – 31/12/2015	UK Ovarian Cancer Population Study (UKOPS)*	The Eve Appeal	511,110
01/05/2013 – 30/04/2015	The lifetime effects, costs and cost-effectiveness of endometrial cancer screening	Cancer Research UK (CRUK)	64,947
27/03/2012 – 26/07/2014	Develop an effective strategy for early detection of ovarian cancer*	National Institutes of Health (NIH) / The University of Texas MD Anderson Cancer Center	68,506

Dates	Project title	Funding agency	Total award (GBP)
01/01/2001 – 11/08/2015	UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)*	Total	27,451,177
2000 – 2015	<i>Research costs</i>	MRC / CRUK	9,607,023
2003 – 2011	<i>Additional award for 13th UKCTOCS centre</i>	CRUK	453,422
2000 – 2011	<i>Treatment costs</i>	NIHR	16,915,154
2005 – 2012	<i>Research costs</i>	<i>The Eve Appeal</i>	475,578
01/01/2008 – 31/12/2015	Genetic Cancer Prediction through Population Screening (GCaPPS)	The Eve Appeal	561,523
2008 – 2011	Heritage in Hospitals: An investigation of the therapeutic and enrichment potential of object handling in hospitals and other healthcare organisations	Arts and Humanities Research Council	293,142
2008 – 2010	Discovery of novel serum markers based on aberrant post translational modification of O glyco-proteins and their application to early detection of cancer (OPTM)	EU FP7 – Research Funding 2007 – 2013 7 th Framework Programme	2,848,553
01/01/2005 – 31/12/2012	UK Familial Ovarian Cancer Screening Study (UK FOCSS) UCH centre grant*	NIHR	157,329
2005 – 2012	UK FOCSS Phase II Co-ordinating Centre	Total	3,126,163
2005 – 2011	<i>Main trial and serum bank</i>	CRUK	1,234,636
2006 – 2012	<i>Main trial and database</i>	<i>The Eve Appeal</i>	403,500
2007 – 2012	<i>Treatment costs</i>	NIHR	1,488,027
2000 – 2005	UK FOCSS Phase I	CRUK	504,150
		Department of Health	424,366
2007 – 2010	Validation of the novel multimarker assay for early detection of ovarian cancer	NIH	134,715
2005 – 2008	SELDI discovery of biomarkers for ovarian cancer	Ciphergen Biosystems Limited	1,300,000
1998 – 2002	A study of new methods of screening for cervical cancer	Imperial Cancer Research Fund	147,530
1998 – 2000	Optimising a multimodal ovarian cancer screening strategy*	JRB, St Bartholomew's Hospital	69,471

Dates	Project title	Funding agency	Total award (GBP)
1989 – 1990	Evaluation of plasma fructosamine as a screening test for gestational diabetes*	Fluid Research Fund, Christian Medical College, Vellore, India	INR 25,000

PUBLICATIONS – journal articles

1. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, Wang Z, Allen J, Keeman R, Eilber U, French JD, Qing Chen X, Fachal L, McCue K, McCart Reed AE, Ghoussaini M, Carroll JS, Jiang X, Finucane H, Adams M, Adank MA, Ahsan H, Aittomäki K, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Arun B, Auer PL, Bacot F, Barrdahl M, Baynes C, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Brinton L, Broberg P, Brock IW, Broeks A, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Butterbach K, Cai Q, Cai H, Caldés T, Canzian F, Carracedo A, Carter BD, Castelao JE, Chan TL, David Cheng TY, Seng Chia K, Choi JY, Christiansen H, Clarke CL; NBCS Collaborators, Collée M, Conroy DM, Cordina-Duverger E, Cornelissen S, Cox DG, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Elvira M, Engel C, Eriksson M, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gaborieau V, Gabrielson M, Gago-Dominguez M, Gao YT, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulas V, Giles GG, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeblerle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hamel N, Hankinson S, Harrington P, Hart SN, Hartikainen JM, Hartman M, Hein A, Heyworth J, Hicks B, Hillemanns P, Ho DN, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Hou MF, Hsiung CN, Huang G, Humphreys K, Ishiguro J, Ito H, Iwasaki M, Iwata H, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kasuga Y, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Kosma VM, Kristensen VN, Krüger U, Kwong A, Lambrechts D, Le Marchand L, Lee E, Lee MH, Lee JW, Neng Lee C, Lejbkowitz F, Li J, Lilyquist J, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Lophatananon A, Lubinski J, Luccarini C, Lux MP, Ma ESK, MaInnis RJ, Maishman T, Makalic E, Malone KE, Kostovska IM, Mannermaa A, Manoukian S, Manson JE, Margolin S, Mariapun S, Martinez ME, Matsuo K, Mavroudis D, McKay J, McLean C, Meijers-Heijboer H, Meindl A, Menéndez P, **Menon U**, Meyer J, Miao H, Miller N, Taib NAM, Muir K, Mulligan AM, Mulot C, Neuhausen SL, Nevanlinna H, Neven P, Nielsen SF, Noh DY, Nordestgaard BG, Norman A, Olopade OI, Olson JE, Olsson H, Olswold C, Orr N, Pankratz VS, Park SK, Park-Simon TW, Lloyd R, Perez JIA, Peterlongo P, Peto J, Phillips KA, Pinchev M, Plaseska-Karanfilska D, Prentice R, Presneau N, Prokofyeva D, Pugh E, Pylkäs K, Rack B, Radice P, Rahman N, Rennert G, Rennert HS, Rhenius V, Romero A, Romm J, Ruddy KJ, Rüdiger T, Rudolph A, Ruebner M, Rutgers EJT, Saloustros E, Sandler DP, Sangrajrang S, Sawyer EJ, Schmidt DF, Schmutzler RK,

- Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Scott RJ, Scott C, Seal S, Seynaeve C, Shah M, Sharma P, Shen CY, Sheng G, Sherman ME, Shrubsole MJ, Shu XO, Smeets A, Sohn C, Southey MC, Spinelli JJ, Stegmaier C, Stewart-Brown S, Stone J, Stram DO, Surowy H, Swerdlow A, Tamimi R, Taylor JA, Tengström M, Teo SH, Beth Terry M, Tessier DC, Thanasitthichai S, Thöne K, Tollenaar RAEM, Tomlinson I, Tong L, Torres D, Truong T, Tseng CC, Tsugane S, Ulmer HU, Ursin G, Untch M, Vachon C, van Asperen CJ, Van Den Berg D, van den Ouweland AMW, van der Kolk L, van der Luijt RB, Vincent D, Vollenweider J, Waisfisz Q, Wang-Gohrke S, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Wu AH, Xia L, Yamaji T, Yang XR, Har Yip C, Yoo KY, Yu JC, Zheng W, Zheng Y, Zhu B, Ziogas A, Ziv E; ABCTB Investigators; ConFab/AOCS Investigators, Lakhani SR, Antoniou AC, Droit A, Andrulis IL, Amos CI, Couch FJ, Pharoah PDP, Chang-Claude J, Hall P, Hunter DJ, Milne RL, García-Closas M, Schmidt MK, Chanock SJ, Dunning AM, Edwards SL, Bader GD, Chenevix-Trench G, Simard J, Kraft P, Easton DF. Association analysis identifies 65 new breast cancer risk loci. *Nature*. 2017 Oct 23. doi: 10.1038/nature24284. PMID: 29059683.
2. Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Toloczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf AD, Ryan A, Chudecka-Glaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubinski J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Eilber U, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, deFazio A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido Dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, **Menon U**, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncol*. 2017 Oct 12:e173290. doi: 10.1001/jamaoncol.2017.3290. PMID: 29049607.
 3. Yang WL, Gentry-Maharaj A, Simmons A, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu KH, Bowtell D, Jacobs I, Skates SJ, He WW, **Menon U***, Bast RC* Jr; AOCS Study Group. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. *Clin Cancer Res*. 2017 Oct 1;23(19):5912-5922. doi: 10.1158/1078-0432.CCR-17-0284. PMID: 29049607. * equal contribution
 4. Minlikeeva AN, Freudenheim JL, Eng KH, Cannioto RA, Friel G, Szender JB, Segal B, Odunsi K, Mayor P, Diergaarde B, Zsiros E, Kelemen LE, Köbel M, Steed H, deFazio A, Jordan SJ, Fasching PA, Beckmann MW, Risch HA, Rossing MA, Doherty JA, Chang-Claude J, Goodman MT, Dörk T, Edwards R, Modugno F, Ness RB, Matsuo K, Mizuno M, Karlan BY, Goode EL, Kjaer SK, Høgdall E, Schildkraut JM, Terry KL, Cramer DW, Bandera EV, Paddock LE, Kiemeny LA, Massuger LFAG, Sutphen R, Anton-Culver H, Ziogas A, **Menon U**, Gayther SA, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Kupryjanczyk J, Jensen A, Webb PM, Moysich KB; Ovarian Cancer Association Consortium; Australian

- Ovarian Cancer Study Group. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. *Cancer Epidemiol Biomarkers Prev*. 2017 Sep;26(9):1470-1473. doi: 10.1158/1055-9965.EPI-17-0367. PMID: 28864456.
5. Datta SS, Tripathi L, Varghese R, Logan J, Gessler S, Chatterjee S, Bhaumik J, **Menon U**. Pivotal role of families in doctor-patient communication in oncology: a qualitative study of patients, their relatives and cancer clinicians. *Eur J Cancer Care (Engl)*. 2017 Sep;26(5). doi: 10.1111/ecc.12543. PMID: 27430633.
 6. **Menon U**, McGuire AJ, Raikou M, Ryan A, Davies SK, Burnell M, Gentry-Maharaj A, Kalsi JK, Singh N, Amso NN, Cruickshank D, Dobbs S, Godfrey K, Herod J, Leeson S, Mould T, Murdoch J, Oram D, Scott I, Seif MW, Williamson K, Woolas R, Fallowfield L, Campbell S, Skates SJ, Parmar M, Jacobs IJ. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Br J Cancer*. 2017 Aug 22;117(5):619-627. doi: 10.1038/bjc.2017.222. Epub 2017 Jul 25. PubMed PMID: 28742794; PMCID: PMC5572177.
 7. Russell MR, Graham C, D'Amato A, Gentry-Maharaj A, Ryan A, Kalsi JK, Ainley C, Whetton AD, **Menon U**, Jacobs I, Graham RLJ. A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. *Br J Cancer*. 2017 Aug 22;117(5):666-674. doi: 10.1038/bjc.2017.199. PMCID: PMC5572165.
 8. Stott W, Campbell S, Franchini A, Blyuss O, Zaikin A, Ryan A, Jones C, Gentry-Maharaj A, Fletcher G, Kalsi J, Skates S, Parmar M, Amso N, Jacobs I, **Menon U**. Self-reported transvaginal ultrasound visualization of normal ovaries in postmenopausal women is not reliable: results of expert review of archived images in UKCTOCS. *Ultrasound Obstet Gynecol*. 2017 Aug 10. doi: 10.1002/uog.18836. PMID: 28796383.
 9. Manchanda R, Patel S, Antoniou AC, Levy-Lahad E, Turnbull C, Evans G, Hopper J, Macinnis RJ, **Menon U**, Jacobs I, Legood R. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. *Am J Obstet Gynecol*. 2017 Jul 6. pii: S0002-9378(17)30842-6. doi: 10.1016/j.ajog.2017.06.038. PMID: 28690137.
 10. Trembling PM, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, Burnell M, Jacobs I, **Menon U***, Rosenberg WM*. Risk of chronic liver disease in postmenopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *BMC Public Health*. 2017 Jun 28;17(1):603. doi: 10.1186/s12889-017-4518-y. PMCID: PMC5490218. * equal contribution
 11. Liu G, Lee S, Lee AW, Wu AH, Bandera EV, Jensen A, Anne Rossing M, Moysich KB, Chang-Claude J, Doherty J, Gentry-Maharaj A, Kiemeny L, Gayther SA, Modugno F, Massuger L, Goode EL, Fridley B, Terry KL, Cramer DW, Ramus SJ, Anton-Culver H, Ziogas A, Tyrer JP, Schildkraut JM, Kjaer SK, Webb PM, Ness RB, **Menon U**, Berchuck A, Pharoah PD, Risch H, Leigh Pearce C, Mukherjee B. Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. *Am J Epidemiol*. 2017 Jun 14. doi: 10.1093/aje/kwx243. PMID: 28633381.
 12. Dale CE, Fatemifar G, Palmer TM, White J, Prieto-Merino D, Zabaneh D, Engmann JEL, Shah T, Wong A, Warren HR, McLachlan S, Trompet S, Moldovan M, Morris RW, Sofat R, Kumari M, Hyppönen E, Jefferis BJ, Gaunt TR, Ben-Shlomo Y, Zhou A, Gentry-Maharaj A, Ryan A; UCLEB Consortium; METASTROKE Consortium, Mutsert R,

- Noordam R, Caulfield MJ, Jukema JW, Worrall BB, Munroe PB, **Menon U**, Power C, Kuh D, Lawlor DA, Humphries SE, Mook-Kanamori DO, Sattar N, Kivimaki M, Price JF, Davey Smith G, Dudbridge F, Hingorani AD, Holmes MV, Casas JP. Causal Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus: A Mendelian Randomization Analysis. *Circulation*. 2017 Jun 13;135(24):2373-2388. doi: 10.1161/CIRCULATIONAHA.116.026560. PMID: PMC5515354.
13. Gentry-Maharaj A, Karpinskyj C, Glazer C, Burnell M, Bailey K, Apostolidou S, Ryan A, Lanceley A, Fraser L, Jacobs I, Hunter MS, **Menon U**. Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening. *Climacteric*. 2017 Jun;20(3):240-247. doi: 10.1080/13697137.2017.1301919. Epub 2017 Mar 22. PMID: PMC5448394.
 14. Praestegaard C, Jensen A, Jensen SM, Nielsen TS, Webb PM, Nagle CM, DeFazio A; Australian Ovarian Cancer Study Group, Høgdall E, Rossing MA, Doherty JA, Wicklund KG, Goodman MT, Modugno F, Moysich K, Ness RB, Edwards R, Matsuo K, Hosono S, Goode EL, Winham SJ, Fridley BL, Cramer DW, Terry KL, Schildkraut JM, Berchuck A, Bandera EV, Paddock LE, Massuger LF, Wentzensen N, Pharoah P, Song H, Whittemore A, McGuire V, Sieh W, Rothstein J, Anton-Culver H, Ziogas A, **Menon U**, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pearce CL, Pike M, Lee AW, Sutphen R, Chang-Claude J, Risch HA, Kjaer SK; Ovarian Cancer Association Consortium. Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. *Int J Cancer*. 2017 Jun 1;140(11):2422-2435. doi: 10.1002/ijc.30600. PMID: PMC5489656.
 15. Manchanda R, Legood R, Antoniou AC, Pearce L, **Menon U**. Changing the Risk Threshold for Surgical Prevention of Ovarian Cancer. *BJOG*. 2017 May 26. doi: 10.1111/1471-0528.14763. PMID: 28548227.
 16. Rosenthal AN, Fraser LSM, Philpott S, Manchanda R, Burnell M, Badman P, Hadwin R, Rizzuto I, Benjamin E, Singh N, Evans DG, Eccles DM, Ryan A, Liston R, Dawnay A, Ford J, Gunu R, Mackay J, Skates SJ, **Menon U***, Jacobs IJ*; United Kingdom Familial Ovarian Cancer Screening Study collaborators. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. *J Clin Oncol*. 2017 May 1;35(13):1411-1420. doi: 10.1200/JCO.2016.69.9330. PMID: PMC5455461. * equal contribution
 17. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC Jr, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N; AOCS study group., Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KBM, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A,

Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dossus L, Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlersen B, Ekici AB, Ellis S, Elvira M; EMBRACE Study., Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilias G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, García MJ, Garcia-Barberan V, Gehrig A; GEMO Study Collaborators., Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harrington PA, Harris HR, Hauke J; HEBON Study., Hein A, Henderson A, Hildebrandt MAT, Hillemanns P, Hodgson S, Høgdall CK, Høgdall E, Hogervorst FBL, Holland H, Hooning MJ, Hosking K, Huang RY, Hulick PJ, Hung J, Hunter DJ, Huntsman DG, Huzarski T, Imyanitov EN, Isaacs C, Iversen ES, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jernetz M, Jensen A, Jensen UB, John EM, Johnatty S, Jones ME, Kannisto P, Karlan BY, Karnezis A, Kast K; KConFab Investigators., Kennedy CJ, Khusnutdinova E, Kiemeny LA, Kiiski JI, Kim SW, Kjaer SK, Köbel M, Kopperud RK, Kruse TA, Kupryjanczyk J, Kwong A, Laitman Y, Lambrechts D, Larrañaga N, Larson MC, Lazaro C, Le ND, Le Marchand L, Lee JW, Lele SB, Leminen A, Leroux D, Lester J, Lesueur F, Levine DA, Liang D, Liebrich C, Lilyquist J, Lipworth L, Lissowska J, Lu KH, Lubinński J, Luccarini C, Lundvall L, Mai PL, Mendoza-Fandiño G, Manoukian S, Massuger LFAG, May T, Mazoyer S, McAlpine JN, McGuire V, McLaughlin JR, McNeish I, Meijers-Heijboer H, Meindl A, **Menon U**, Mensenkamp AR, Merritt MA, Milne RL, Mitchell G, Modugno F, Moes-Sosnowska J, Moffitt M, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Nathanson KL, Nedergaard L, Ness RB, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Odunsi K, Olah E, Olopade OI, Olsson H, Olswold C, O'Malley DM, Ong KR, Onland-Moret NC; OPAL study group., Orr N, Orsulic S, Osorio A, Palli D, Papi L, Park-Simon TW, Paul J, Pearce CL, Pedersen IS, Peeters PHM, Peissel B, Peixoto A, Pejovic T, Pelttari LM, Permuth JB, Peterlongo P, Pezzani L, Pfeiler G, Phillips KA, Piedmonte M, Pike MC, Piskorz AM, Poblete SR, Pocza T, Poole EM, Poppe B, Porteous ME, Prieur F, Prokofyeva D, Pugh E, Pujana MA, Pujol P, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rhiem K, Rice P, Richardson A, Robson M, Rodriguez GC, Rodríguez-Antona C, Romm J, Rookus MA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Salvesen HB, Sandler DP, Schoemaker MJ, Senter L, Setiawan VW, Severi G, Sharma P, Shelford T, Siddiqui N, Side LE, Sieh W, Singer CF, Sobol H, Song H, Southey MC, Spurdle AB, Stadler Z, Steinemann D, Stoppa-Lyonnet D, Sucheston-Campbell LE, Sukiennicki G, Sutphen R, Sutter C, Swerdlow AJ, Szabo CI, Szafron L, Tan YY, Taylor JA, Tea MK, Teixeira MR, Teo SH, Terry KL, Thompson PJ, Thomsen LCV, Thull DL, Tihomirova L, Tinker AV, Tischkowitz M, Tognazzo S, Toland AE, Tone A, Trabert B, Travis RC, Trichopoulou A, Tung N, Tworoger SS, van Altena AM, Van Den Berg D, van der Hout AH, van der Luijt RB, Van Heetvelde M, Van Nieuwenhuysen E, van Rensburg EJ, Vanderstichele A, Varon-Mateeva R, Vega A, Edwards DV, Vergote I, Vierkant RA, Vijai J, Vratimos A, Walker L, Walsh C, Wand D, Wang-Gohrke S, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, Whittemore AS, Wijnen JT, Wilkens LR, Wolk A, Woo M, Wu X, Wu AH, Yang H, Yannoukakos D, Zogas A, Zorn KK, Narod SA, Easton DF, Amos CI, Schildkraut JM, Ramus SJ, Ottini L, Goodman MT, Park SK, Kelemen LE, Risch HA, Thomassen M, Offit K, Simard J, Schmutzler RK, Hazelett D, Monteiro AN, Couch FJ, Berchuck A, Chenevix-Trench G, Goode EL, Sellers TA, Gayther SA, Antoniou AC, Pharoah PDP. Identification

- of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet.* 2017 May;49(5):680-691. doi: 10.1038/ng.3826. PMID: 28346442.
18. Dixon SC, Nagle CM, Wentzensen N, Trabert B, Beeghly-Fadiel A, Schildkraut JM, Moysich KB, deFazio A; Australian Ovarian Cancer Study Group, Risch HA, Rossing MA, Doherty JA, Wicklund KG, Goodman MT, Modugno F, Ness RB, Edwards RP, Jensen A, Kjær SK, Høgdall E, Berchuck A, Cramer DW, Terry KL, Poole EM, Bandera EV, Paddock LE, Anton-Culver H, Ziogas A, **Menon U**, Gayther SA, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Pike MC, Webb PM. Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. *Br J Cancer.* 2017 Apr 25;116(9):1223-1228. doi: 10.1038/bjc.2017.68. Epub 2017 Mar 28. PMID: PMC5418444.
 19. Fallowfield L, Solis-Trapala I, **Menon U**, Langridge C, May S, Jacobs I, Jenkins V. The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT. *Br J Cancer.* 2017 Apr 11;116(8):1111-1117. doi: 10.1038/bjc.2017.72. Epub 2017 Mar 21. PMID: PMC5396121.
 20. Mariño IP*, Blyuss O*, Ryan A, Gentry-Maharaj A, Timms JF, Dawnay A, Kalsi J, Jacobs I, **Menon U***, Zaikin A*. Change-point of multiple biomarkers in women with ovarian cancer. *Biomedical Signal Processing and Control.* 2017 Mar 31; 33:169-77. * equal contribution.
 21. Gentry-Maharaj A, Glazer C, Burnell M, Ryan A, Berry H, Kalsi J, Woolas R, Skates SJ, Campbell S, Parmar M, Jacobs I, **Menon U**. Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *BMJ Open.* 2017 Mar 6;7(3):e011822. doi: 10.1136/bmjopen-2016-011822. Central PMID: PMC5353253.
 22. Dicks E, Song H, Ramus SJ, Oudenhove EV, Tyrer JP, Intermaggio MP, Kar S, Harrington P, Bowtell DD, Group AS, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Piskorz A, Goranova T, Kent E, Siddiqui N, Paul J, Crawford R, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Odunsi K, Whittemore AS, Bogdanova N, Dürst M, Hillemanns P, Karlan BY, Gentry-Maharaj A, **Menon U**, Tischkowitz M, Levine D, Brenton JD, Dörk T, Goode EL, Gayther SA, Pharoah DPP. Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. *Oncotarget.* 2017 Mar 3;8(31):50930-50940. doi: 10.18632/oncotarget.15871. eCollection 2017 Aug 1. PMID: PMC5584218.
 23. Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, Joseph JM, Mayor P, Abrams SI, Segal BH, Wallace PK, Soh KT, Zsiros E, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bjorge L, Bruegl A, Campbell IG, Campbell SP, Chenevix-Trench G, Cramer DW, Dansonka-Mieszkowska A, Dao F, Diergaard B, Doerk T, Doherty JA, du Bois A, Eccles D, Engelholm SA, Fasching PA, Gayther SA, Gentry-Maharaj A, Glasspool RM, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hillemanns P, Høgdall C, Høgdall EV, Huzarski T, Jensen A, Johnatty SE, Jung A, Karlan BY, Klapdor R, Kluz T, Konopka B, Kjær SK, Kupryjanczyk J, Lambrechts D, Lester J, Lubiński J, Levine DA, Lundvall L, McGuire V, McNeish IA, **Menon U**, Modugno F, Ness RB, Orsulic S, Paul J, Pearce CL, Pejovic T, Pharoah P, Ramus SJ, Rothstein J, Rossing MA, Rübner M, Schildkraut JM, Schmalfeldt B, Schwaab I, Siddiqui N, Sieh W, Sobiczewski P, Song H, Terry KL, Van Nieuwenhuysen E,

- Vanderstichele A, Vergote I, Walsh CS, Webb PM, Wentzensen N, Whittemore AS, Wu AH, Ziogas A, Odunsi K, Chang-Claude J, Goode EL, Moysich KB; Australian Ovarian Cancer Study. No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. *Cancer Epidemiol Biomarkers Prev*. 2017 Mar;26(3):420-424. doi: 10.1158/1055-9965.EPI-16-0631. PMID: PMC5500198.
24. Kar SP, Adler E, Tyrer J, Hazelett D, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bogdanova N, Brinton L, Butzow R, Campbell I, Carty K, Chang-Claude J, Cook LS, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Doherty JA, Dörk T, Dürst M, Eccles D, Fasching PA, Flanagan J, Gentry-Maharaj A, Glasspool R, Goode EL, Goodman MT, Gronwald J, Heitz F, Hildebrandt MA, Høgdall E, Høgdall CK, Huntsman DG, Jensen A, Karlan BY, Kelemen LE, Kiemenev LA, Kjaer SK, Kupryjanczyk J, Lambrechts D, Levine DA, Li Q, Lissowska J, Lu KH, Lubiński J, Massuger LF, McGuire V, McNeish I, **Menon U**, Modugno F, Monteiro AN, Moysich KB, Ness RB, Nevanlinna H, Paul J, Pearce CL, Pejovic T, Permuth JB, Phelan C, Pike MC, Poole EM, Ramus SJ, Risch HA, Rossing MA, Salvesen HB, Schildkraut JM, Sellers TA, Sherman M, Siddiqui N, Sieh W, Song H, Southey M, Terry KL, Tworoger SS, Walsh C, Wentzensen N, Whittemore AS, Wu AH, Yang H, Zheng W, Ziogas A, Freedman ML, Gayther SA, Pharoah PD, Lawrenson K. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. *Br J Cancer*. 2017 Feb 14;116(4):524-535. doi: 10.1038/bjc.2016.426. PMID: PMC5318969.
 25. Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM, Prytomanova OM, Jacobs IJ, Widschwendter M, **Menon U**, Timms JF. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. *Br J Cancer*. 2017 Feb 14;116(4):501-508. doi: 10.1038/bjc.2016.433. PMID: PMC5318971.
 26. Kiechl S, Schramek D, Widschwendter M, Fourkala EO, Zaikin A, Jones A, Jaeger B, Rack B, Janni W, Scholz C, Willeit J, Weger S, Mayr A, Teschendorff A, Rosenthal A, Fraser L, Philpott S, Dubeau L, Keshtgar M, Roylance R, Jacobs IJ, **Menon U**, Schett G, Penninger JM. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. *Oncotarget*. 2017 Jan 17;8(3):3811-3825. doi: 10.18632/oncotarget.14013. PMID: PMC5354797.
 27. Russell MR, D'Amato A, Graham C, Crosbie EJ, Gentry-Maharaj A, Ryan A, Kalsi JK, Fourkala EO, Dive C, Walker M, Whetton AD, **Menon U**, Jacobs I, Graham RL. Novel risk models for early detection and screening of ovarian cancer. *Oncotarget*. 2017 Jan 3;8(1):785-797. doi: 10.18632/oncotarget.13648. PMID: PMC5352196.
 28. Lee AW, Bomkamp A, Bandera EV, Jensen A, Ramus SJ, Goodman MT, Rossing MA, Modugno F, Moysich KB, Chang-Claude J, Rudolph A, Gentry-Maharaj A, Terry KL, Gayther SA, Cramer DW, Doherty JA, Schildkraut JM, Kjaer SK, Ness RB, **Menon U**, Berchuck A, Mukherjee B, Roman L, Pharoah PD, Chenevix-Trench G, Olson S, Hogdall E, Wu AH, Pike MC, Stram DO, Pearce CL; Ovarian Cancer Association Consortium.. A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. *Int J Cancer*. 2016 Dec 15;139(12):2646-2654. doi: 10.1002/ijc.30274. PMID: 27420401.
 29. Burnell M, Iyer R, Gentry-Maharaj A, Nordin A, Liston R, Manchanda R, Das N, Gornall R, Beardmore-Gray A, Hillaby K, Leeson S, Linder A, Lopes A, Meechan D, Mould T, Nevin J, Olaitan A, Rufford B, Shanbhag S, Thackeray A, Wood N, Reynolds K, Ryan A, **Menon U**. Benchmarking of surgical complications in gynaecological oncology:

prospective multicentre study. *BJOG*. 2016 Dec;123(13):2171-2180. doi: 10.1111/1471-0528.13994. PubMed PMID: 27006076

30. Southey MC, Goldgar DE, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, Foulkes WD, Dennis J, Michailidou K, van Rensburg EJ, Heikkinen T, Nevanlinna H, Hopper JL, Dörk T, Claes KB, Reis-Filho J, Teo ZL, Radice P, Catucci I, Peterlongo P, Tsimiklis H, Odefrey FA, Dowty JG, Schmidt MK, Broeks A, Hogervorst FB, Verhoef S, Carpenter J, Clarke C, Scott RJ, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Bolla MK, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Marme F, Burwinkel B, Yang R, Guénel P, Truong T, Menegaux F, Sanchez M, Bojesen S, Nielsen SF, Flyger H, Benitez J, Zamora MP, Perez JI, Menéndez P, Anton-Culver H, Neuhausen S, Ziogas A, Clarke CA, Brenner H, Arndt V, Stegmaier C, Brauch H, Brüning T, Ko YD, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova NV, Antonenkova NN, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Spurdle AB, Investigators K; Australian Ovarian Cancer Study Group., Wauters E, Smeets D, Beuselinck B, Floris G, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Olson JE, Vachon C, Pankratz VS, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Kristensen V, Alnæs GG, Zheng W, Hunter DJ, Lindstrom S, Hankinson SE, Kraft P, Andrulis I, Knight JA, Glendon G, Mulligan AM, Jukkola-Vuorinen A, Grip M, Kauppila S, Devilee P, Tollenaar RA, Seynaeve C, Hollestelle A, Garcia-Closas M, Figueroa J, Chanock SJ, Lissowska J, Czene K, Darabi H, Eriksson M, Eccles DM, Rafiq S, Tapper WJ, Gerty SM, Hooning MJ, Martens JW, Collée JM, Tilanus-Linthorst M, Hall P, Li J, Brand JS, Humphreys K, Cox A, Reed MW, Luccarini C, Baynes C, Dunning AM, Hamann U, Torres D, Ulmer HU, Rüdiger T, Jakubowska A, Lubinski J, Jaworska K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Swerdlow A, Ashworth A, Orr N, Jones M, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Simard J, Dumont M, Soucy P, Eeles R, Muir K, Wiklund F, Gronberg H, Schleutker J, Nordestgaard BG, Weischer M, Travis RC, Neal D, Donovan JL, Hamdy FC, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Schaid DJ, Kelley JL, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Butterbach K, Park J, Kaneva R, Batra J, Teixeira MR, Kote-Jarai Z, Olama AA, Benlloch S, Renner SP, Hartmann A, Hein A, Ruebner M, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambretchs S, Doherty JA, Rossing MA, Nickels S, Eilber U, Wang-Gohrke S, Odunsi K, Sucheston-Campbell LE, Friel G, Lurie G, Killeen JL, Wilkens LR, Goodman MT, Runnebaum I, Hillemanns PA, Pelttari LM, Butzow R, Modugno F, Edwards RP, Ness RB, Moysich KB, du Bois A, Heitz F, Harter P, Kommoss S, Karlan BY, Walsh C, Lester J, Jensen A, Kjaer SK, Høgdall E, Peissel B, Bonanni B, Bernard L, Goode EL, Fridley BL, Vierkant RA, Cunningham JM, Larson MC, Fogarty ZC, Kalli KR, Liang D, Lu KH, Hildebrandt MA, Wu X, Levine DA, Dao F, Bisogna M, Berchuck A, Iversen ES, Marks JR, Akushevich L, Cramer DW, Schildkraut J, Terry KL, Poole EM, Stampfer M, Tworoger SS, Bandera EV, Orlov I, Olson SH, Bjorge L, Salvesen HB, van Altena AM, Aben KK, Kiemeny LA, Massuger LF, Pejovic T, Bean Y, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Górski B, Gronwald J, Menkiszak J, Høgdall CK, Lundvall L, Nedergaard L, Engelholm SA, Dicks E, Tyrer J, Campbell I, McNeish I, Paul J, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Cai H, Shu XO, Teten RT, Sutphen R, McLaughlin JR, Narod SA, Phelan CM, Monteiro AN, Fenstermacher D, Lin HY, Permuth JB, Sellers TA, Chen YA, Tsai YY, Chen Z, Gentry-Maharaj A, Gayther SA, Ramus SJ, **Menon U**, Wu AH, Pearce CL, Van Den Berg D, Pike MC, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Moes-Sosnowska J,

- Kupryjanczyk J, Pharoah PD, Song H, Winship I, Chenevix-Trench G, Giles GG, Tavtigian SV, Easton DF, Milne RL. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *J Med Genet*. 2016 Dec;53(12):800-811. doi: 10.1136/jmedgenet-2016-103839. PMID: PMC5200636.
31. Pennington M, Gentry-Maharaj A, Karpinskyj C, Miners A, Taylor J, Manchanda R, Iyer R, Griffin M, Ryan A, Jacobs I, **Menon U***, Legood R*. Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *PLoS One*. 2016 Nov 9;11(11):e0165539. doi: 10.1371/journal.pone.0165539. PMID: PMC5102347. * equal contribution
 32. Lawrenson K, Kar S, McCue K, Kuchenbaecker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Bandera EV, Barile M, Barkardottir RB, Barrowdale D, Beckmann MW, Benitez J, Berchuck A, Bisogna M, Bjorge L, Blomqvist C, Blot W, Bogdanova N, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Børresen-Dale AL, Brauch H, Brennan P, Brenner H, Bruinsma F, Brunet J, Buhari SA, Burwinkel B, Butzow R, Buys SS, Cai Q, Caldes T, Campbell I, Cannioto R, Chang-Claude J, Chiquette J, Choi JY, Claes KB; GEMO Study Collaborators., Cook LS, Cox A, Cramer DW, Cross SS, Cybulski C, Czene K, Daly MB, Damiola F, Dansonka-Mieszkowska A, Darabi H, Dennis J, Devilee P, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dumont M, Ehrencrona H, Ejlertsen B, Ellis S; EMBRACE., Engel C, Lee E, Evans DG, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foretova L, Fostira F, Foulkes WD, Fridley BL, Friedman E, Frost D, Gambino G, Ganz PA, Garber J, García-Closas M, Gentry-Maharaj A, Ghossaini M, Giles GG, Glasspool R, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Goode EL, Goodman MT, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hallberg E, Hamann U, Hansen TV, Harrington PA, Hartman M, Hassan N, Healey S; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)., Heitz F, Herzog J, Høgdall E, Høgdall CK, Hogervorst FB, Hollestelle A, Hopper JL, Hulick PJ, Huzarski T, Imyanitov EN; KConFab Investigators.; Australian Ovarian Cancer Study Group., Isaacs C, Ito H, Jakubowska A, Janavicius R, Jensen A, John EM, Johnson N, Kabisch M, Kang D, Kapuscinski M, Karlan BY, Khan S, Kiemenev LA, Kjaer SK, Knight JA, Konstantopoulou I, Kosma VM, Kristensen V, Kupryjanczyk J, Kwong A, de la Hoya M, Laitman Y, Lambrechts D, Le N, De Leener K, Lester J, Levine DA, Li J, Lindblom A, Long J, Lophatananon A, Loud JT, Lu K, Lubinski J, Mannermaa A, Manoukian S, Le Marchand L, Margolin S, Marme F, Massuger LF, Matsuo K, Mazoyer S, McGuffog L, McLean C, McNeish I, Meindl A, **Menon U**, Mensenkamp AR, Milne RL, Montagna M, Moysich KB, Muir K, Mulligan AM, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Nord S, Nussbaum RL, Odunsi K, Offit K, Olah E, Olopade OI, Olson JE, Olswold C, O'Malley D, Orlov I, Orr N, Osorio A, Park SK, Pearce CL, Pejovic T, Peterlongo P, Pfeiler G, Phelan CM, Poole EM, Pylkäs K, Radice P, Rantala J, Rashid MU, Rennert G, Rhenius V, Rhiem K, Risch HA, Rodriguez G, Rossing MA, Rudolph A, Salvesen HB, Sangrajrang S, Sawyer EJ, Schildkraut JM, Schmidt MK, Schmutzler RK, Sellers TA, Seynaeve C, Shah M, Shen CY, Shu XO, Sieh W, Singer CF, Sinilnikova OM, Slager S, Song H, Soucy P, Southey MC, Stenmark-Askmal M, Stoppa-Lyonnet D, Sutter C, Swerdlow A, Tchatou S, Teixeira MR, Teo SH, Terry KL, Terry MB, Thomassen M, Tibiletti MG, Tihomirova L, Tognazzo S, Toland AE, Tomlinson I, Torres D, Truong T, Tseng CC, Tung N, Tworoger SS, Vachon C, van den Ouweland AM, van Doorn HC, van Rensburg EJ, Van't Veer LJ, Vanderstichele

- A, Vergote I, Vijai J, Wang Q, Wang-Gohrke S, Weitzel JN, Wentzensen N, Whittemore AS, Wildiers H, Winqvist R, Wu AH, Yannoukakos D, Yoon SY, Yu JC, Zheng W, Zheng Y, Khanna KK, Simard J, Monteiro AN, French JD, Couch FJ, Freedman ML, Easton DF, Dunning AM, Pharoah PD, Edwards SL, Chenevix-Trench G, Antoniou AC, Gayther SA. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nat Commun.* 2016 Sep 7;7:12675. doi: 10.1038/ncomms12675. PMID: 27594614.
33. Ong JS, Cuellar-Partida G, Lu Y, Ovarian Cancer Study A, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Anne Doherty J, Anne Rossing M, Chang-Claude J, Eilber U, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Høgdall E, Høgdall CK, Jensen A, Giles GG, Bruinsma F, Kjaer SK, Hildebrandt MA, Liang D, Lu KH, Wu X, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Stampfer M, Missmer S, Borge L, Salvesen HB, Kopperud RK, Bischof K, Aben KK, Kiemeny LA, Massuger LF, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Blake Gilks C, Gronwald J, Jakubowska A, Lubiński J, Kluz T, Song H, Tyrer JP, Wentzensen N, Brinton L, Trabert B, Lissowska J, McLaughlin JR, Narod SA, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Campbell I, Gayther SA, Gentry-Maharaj A, **Menon U**, Ramus SJ, Wu AH, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham JM, Fridley BL, Winham SJ, Bandera EV, Poole EM, Morgan TK, Risch HA, Goode EL, Schildkraut JM, Pearce CL, Berchuck A, Pharoah PD, Chenevix-Trench G, Gharahkhani P, Neale RE, Webb PM, MacGregor S. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. *Int J Epidemiol.* 2016 Sep 4. pii: dyw207. PMID: 27594614.
34. Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ; ABCTB Investigators., Kibel AS, Dansonka-Mieszkowska A, Michael A, Dieffenbach AK, Gentry-Maharaj A, Whittemore AS, Wolk A, Monteiro A, Peixoto A, Kierzek A, Cox A, Rudolph A, Gonzalez-Neira A, Wu AH, Lindblom A, Swerdlow A; AOCs Study Group & Australian Cancer Study (Ovarian Cancer).; APCB BioResource., Ziogas A, Ekici AB, Burwinkel B, Karlan BY, Nordestgaard BG, Blomqvist C, Phelan C, McLean C, Pearce CL, Vachon C, Cybulski C, Slavov C, Stegmaier C, Maier C, Ambrosone CB, Høgdall CK, Teerlink CC, Kang D, Tessier DC, Schaid DJ, Stram DO, Cramer DW, Neal DE, Eccles D, Flesch-Janys D, Edwards DR, Wokozorczyk D, Levine DA, Yannoukakos D, Sawyer EJ, Bandera EV, Poole EM, Goode EL, Khusnutdinova E, Høgdall E, Song F, Bruinsma F, Heitz F, Modugno F, Hamdy FC, Wiklund F, Giles GG, Olsson H, Wildiers H, Ulmer HU, Pandha H, Risch HA, Darabi H, Salvesen HB, Nevanlinna H, Gronberg H, Brenner H, Brauch H, Anton-Culver H, Song H, Lim HY, McNeish I, Campbell I, Vergote I, Gronwald J, Lubiński J, Stanford JL, Benítez J, Doherty JA, Permuth JB, Chang-Claude J, Donovan JL, Dennis J, Schildkraut JM, Schleutker J, Hopper JL, Kupryjanczyk J, Park JY, Figueroa J, Clements JA, Knight JA, Peto J, Cunningham JM, Pow-Sang J, Batra J, Czene K, Lu KH, Herkommer K, Khaw KT; kConFab Investigators., Matsuo K, Muir K, Offitt K, Chen K, Moysich KB, Aittomäki K, Odunsi K, Kiemeny LA, Massuger LF, Fitzgerald LM, Cook LS, Cannon-Albright L, Hooning MJ, Pike MC, Bolla MK, Luedeke M, Teixeira MR, Goodman MT, Schmidt MK, Riggan M, Aly M, Rossing MA, Beckmann MW, Moisse M, Sanderson M, Southey MC,

- Jones M, Lush M, Hildebrandt MA, Hou MF, Schoemaker MJ, Garcia-Closas M, Bogdanova N, Rahman N; NBCS Investigators., Le ND, Orr N, Wentzensen N, Pashayan N, Peterlongo P, Guénel P, Brennan P, Paulo P, Webb PM, Broberg P, Fasching PA, Devilee P, Wang Q, Cai Q, Li Q, Kaneva R, Butzow R, Kopperud RK, Schmutzler RK, Stephenson RA, MacInnis RJ, Hoover RN, Winqvist R, Ness R, Milne RL, Travis RC, Benlloch S, Olson SH, McDonnell SK, Tworoger SS, Maia S, Berndt S, Lee SC, Teo SH, Thibodeau SN, Bojesen SE, Gapstur SM, Kjær SK, Pejovic T, Tammela TL; GENICA Network.; PRACTICAL consortium., Dörk T, Brüning T, Wahlfors T, Key TJ, Edwards TL, **Menon U**, Hamann U, Mitev V, Kosma VM, Setiawan VW, Kristensen V, Arndt V, Vogel W, Zheng W, Sieh W, Blot WJ, Kluzniak W, Shu XO, Gao YT, Schumacher F, Freedman ML, Berchuck A, Dunning AM, Simard J, Haiman CA, Spurdle A, Sellers TA, Hunter DJ, Henderson BE, Kraft P, Chanock SJ, Couch FJ, Hall P, Gayther SA, Easton DF, Chenevix-Trench G, Eeles R, Pharoah PD, Lambrechts D. Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discov.* 2016 Sep;6(9):1052-67. doi: 10.1158/2159-8290.CD-15-1227. PMCID: PMC5010513.
35. Manchanda R, Legood R, Antoniou AC, Gordeev VS, **Menon U**. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis. *J Med Genet.* 2016 Sep;53(9):591-9. doi: 10.1136/jmedgenet-2016-103800. PMID: 27354448.
 36. Sundar S, Rick C, Dowling F, Au P, Snell K, Rai N, Champaneria R, Stobart H, Neal R, Davenport C, Mallett S, Sutton A, Kehoe S, Timmerman D, Bourne T, Van Calster B, Gentry-Maharaj A, **Menon U**, Deeks J; ROcKeTS study group. Refining Ovarian Cancer Test accuracy Scores (ROcKeTS): protocol for a prospective longitudinal test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer. *BMJ Open.* 2016 Aug 9;6(8):e010333. doi: 10.1136/bmjopen-2015-010333. PMCID: PMC4985790.
 37. Weller D, Vedsted P, Anandan C, Zalounina A, Fourkala EO, Desai R, Liston W, Jensen H, Barisic A, Gavin A, Grunfeld E, Lambe M, Law RJ, Malmberg M, Neal RD, Kalsi J, Turner D, White V, Bomb M, **Menon U**; ICBP Module 4 Working Group. An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation. *BMJ Open.* 2016 Jul 25;6(7):e009641. doi: 10.1136/bmjopen-2015-009641. PMCID: PMC4964239.
 38. Permuth JB, Pirie A, Ann Chen Y, Lin HY, Reid BM, Chen Z, Monteiro A, Dennis J, Mendoza-Fandino G; AOCS Study Group.; Australian Cancer Study (Ovarian Cancer)., Anton-Culver H, Bandera EV, Bisogna M, Brinton L, Brooks-Wilson A, Carney ME, Chenevix-Trench G, Cook LS, Cramer DW, Cunningham JM, Cybulski C, D'Aloisio AA, Anne Doherty J, Earp M, Edwards RP, Fridley BL, Gayther SA, Gentry-Maharaj A, Goodman MT, Gronwald J, Hogdall E, Iversen ES, Jakubowska A, Jensen A, Karlan BY, Kelemen LE, Kjaer SK, Kraft P, Le ND, Levine DA, Lissowska J, Lubinski J, Matsuo K, **Menon U**, Modugno R, Moysich KB, Nakanishi T, Ness RB, Olson S, Orlow I, Pearce CL, Pejovic T, Poole EM, Ramus SJ, Anne Rossing M, Sandler DP, Shu XO, Song H, Taylor JA, Teo SH, Terry KL, Thompson PJ, Tworoger SS, Webb PM, Wentzensen N, Wilkens LR, Winham S, Woo YL, Wu AH, Yang H, Zheng W, Ziogas A, Phelan CM, Schildkraut JM, Berchuck A, Goode EL, Dp Pharoah P, Sellers TA; Ovarian Cancer Association Consortium.. Exome genotyping arrays to identify rare and low frequency variants

- associated with epithelial ovarian cancer risk. *Hum Mol Genet.* 2016 Jul 4. pii: ddw196. PMID: 27378695.
39. Cuellar-Partida G, Lu Y, Dixon SC; Australian Ovarian Cancer Study., Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty JA, Rossing MA, Chang-Claude J, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Høgdall E, Høgdall C, Jensen A, Giles GG, Bruinsma F, Kjaer SK, Hildebrandt MA, Liang D, Lu KH, Wu X, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Stampfer M, Missmer S, Bjorge L, Salvesen HB, Kopperud RK, Bischof K, Aben KK, Kiemenev LA, Massuger LF, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Blake Gilks C, Gronwald J, Jakubowska A, Lubiński J, Kluz T, Song H, Tyrer JP, Wentzensen N, Brinton L, Trabert B, Lissowska J, McLaughlin JR, Narod SA, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Campbell I, Gayther SA, Gentry-Maharaj A, **Menon U**, Ramus SJ, Wu AH, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham JM, Fridley BL, Winham SJ, Bandera EV, Poole EM, Morgan TK, Goode EL, Schildkraut JM, Pearce CL, Berchuck A, Pharoah PD, Webb PM, Chenevix-Trench G, Risch HA, MacGregor S. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. *Hum Genet.* 2016 Jul;135(7):741-56. doi: 10.1007/s00439-016-1663-9. PMCID: PMC4976079.
 40. Manchanda R, Burnell M, Loggenberg K, Desai R, Wardle J, Sanderson SC, Gessler S, Side L, Balogun N, Kumar A, Dorkins H, Wallis Y, Chapman C, Tomlinson I, Taylor R, Jacobs C, Legood R, Raikou M, McGuire A, Beller U, **Menon U**, Jacobs I. Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. *J Med Genet.* 2016 Jul;53(7):472-80. doi: 10.1136/jmedgenet-2015-103740. PMID: 26993268.
 41. Smits S, Boivin J, **Menon U**, Brain K. The double-edged sword of ovarian cancer information for women at increased risk who have previously taken part in screening. *Ecanermedscience.* 2016 Jun 30;10:650. doi: 10.3332/ecancer.2016.650. PMCID: PMC4929978.
 42. Hampras SS, Sucheston-Campbell LE, Cannioto R, Chang-Claude J, Modugno F, Dörk T, Hillemanns P, Preus L, Knutson KL, Wallace PK, Hong CC, Friel G, Davis W, Nesline M, Pearce CL, Kelemen LE, Goodman MT, Bandera EV, Terry KL, Schoof N, Eng KH, Clay A, Singh PK, Joseph JM, Aben KK, Anton-Culver H, Antonenkova N, Baker H, Bean Y, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Butzow R, Campbell IG, Carty K, Cook LS, Cramer DW, Cybulski C, Dansonka-Mieszkowska A, Dennis J, Despierre E, Dicks E, Doherty JA, du Bois A, Dürst M, Easton D, Eccles D, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Gronwald J, Harrington P, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hogdall C, Hogdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Karlan BY, Kellar M, Kelley JL, Kiemenev LA, Klapdor R, Kolomeyevskaya N, Krakstad C, Kjaer SK, Kruszka B, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lissowska J, Liu S, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, McNeish I, **Menon U**, Moes-Sosnowska J, Narod SA, Nedergaard L, Nevanlinna H, Nickels S, Olson SH, Orlow I, Weber RP, Paul J, Pejovic T, Pelttari LM,

- Perkins B, Permuth-Wey J, Pike MC, Plisiecka-Halasa J, Poole EM, Risch HA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schernhammer E, Schmitt K, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Tangen IL, Teo SH, Thompson PJ, Timorek A, Tsai YY, Tworoger SS, Tyrer J, van Altena AM, Vergote I, Vierkant RA, Walsh C, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Wu AH, Wu X, Woo YL, Yang H, Zheng W, Ziogas A, Gayther SA, Ramus SJ, Sellers TA, Schildkraut JM, Phelan CM, Berchuck A, Chenevix-Trench G, Cunningham JM, Pharoah PP, Ness RB, Odunsi K, Goode EL, Moysich KB. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. *Oncotarget*. 2016 Jun 21. doi: 10.18632/oncotarget.10215. PMID: 27533245.
43. Russell MR, Walker MJ, Williamson AJ, Gentry-Maharaj A, Ryan A, Kalsi J, Skates S, D'Amato A, Dive C, Pernemalm M, Humphryes PC, Fourkala EO, Whetton AD, **Menon U**, Jacobs I, Graham RL. Protein Z: A putative novel biomarker for early detection of ovarian cancer. *Int J Cancer*. 2016 Jun 15;138(12):2984-92. doi: 10.1002/ijc.30020. PMID: PMC4840324.
44. Dixon SC, Nagle CM, Thrift AP, Pharoah PD, Pearce CL, Zheng W, Painter JN; AOCs Group & Australian Cancer Study (Ovarian Cancer)., Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Rudolph A, Moysich KB, Odunsi K, Goodman MT, Wilkens LR, Thompson PJ, Shvetsov YB, Dörk T, Park-Simon TW, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Modugno F, Ness RB, Edwards RP, Kelley JL, Heitz F, Karlan BY, Kjær SK, Høgdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Winham SJ, Giles GG, Bruinsma F, Milne RL, Southey MC, Hildebrandt MA, Wu X, Lu KH, Liang D, Levine DA, Bisogna M, Schildkraut JM, Berchuck A, Cramer DW, Terry KL, Bandera EV, Olson SH, Salvesen HB, Thomsen LC, Kopperud RK, Bjorge L, Kiemeny LA, Massuger LF, Pejovic T, Cook LS, Le ND, Swenerton KD, Brooks-Wilson A, Kelemen LE, Lubiński J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall CK, Lundvall L, Song H, Tyrer JP, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore AS, Sieh W, McGuire V, Rothstein JH, Narod SA, Phelan C, Risch HA, McLaughlin JR, Anton-Culver H, Ziogas A, **Menon U**, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pike MC, Tseng CC, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzylowska A, Spiewankiewicz B, Webb PM; Ovarian Cancer Association Consortium.. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. *Int J Epidemiol*. 2016 Jun;45(3):884-95. doi: 10.1093/ije/dyw158. PMID: 27401727.
45. Fourkala EO, Blyuss O, Field H, Gunu R, Ryan A, Barth J, Jacobs I, Zaikin A, Dawnay A, **Menon U**. Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS). *Steroids*. 2016 Jun;110:62-9. doi: 10.1016/j.steroids.2016.04.003. PMID: 27091764.
46. Bartlett TE, Chindera K, McDermott J, Breeze CE, Cooke WR, Jones A, Reisel D, Karegodar ST, Arora R, Beck S, **Menon U**, Dubeau L, Widschwendter M. Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution. *Nat Commun*. 2016 May 24;7:11620. doi:10.1038/ncomms11620. PMID: PMC4890182.

47. Lim A, Mesher D, Gentry-Maharaj A, Balogun N, Widschwendter M, Jacobs I, Sasieni P, **Menon U**. Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. *BJOG*. 2016 May;123(6):1012-20. doi: 10.1111/1471-0528.13447. PMID: PMC4855631.
48. Usset JL, Raghavan R, Tyrer JP, McGuire V, Sieh W, Webb P, Chang-Claude J, Rudolph A, Anton-Culver H, Berchuck A, Brinton L, Cunningham JM, DeFazio A, Doherty JA, Edwards RP, Gayther SA, Gentry-Maharaj A, Goodman MT, Høgdall E, Jensen A, Johnatty SE, Kiemenev LA, Kjaer SK, Larson MC, Lurie G, Massuger L, **Menon U**, Modugno F, Moysich KB, Ness RB, Pike MC, Ramus SJ, Rossing MA, Rothstein J, Song H, Thompson PJ, van den Berg DJ, Vierkant RA, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wilkens LR, Wu AH, Yang H, Pearce CL, Schildkraut JM, Pharoah P, Goode EL, Fridley BL; Ovarian Cancer Association Consortium and the Australian Cancer Study. Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. *Cancer Epidemiol Biomarkers Prev*. 2016 May;25(5):780-90. doi: 10.1158/1055-9965.EPI-15-1039. PMID: PMC4873330.
49. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A; Australian Ovarian Cancer Study Group, Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT, Beckmann L, Beckmann MW, Benitez J, Berger A, Berger R, Beuselinck B, Bisogna M, Bjorge L, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Brand JS, Brauch H; Breast Cancer Family Register, Brenner H, Brinton L, Brooks-Wilson A, Bruinsma F, Brunet J, Brüning T, Budzilowska A, Bunker CH, Burwinkel B, Butzow R, Buys SS, Caligo MA, Campbell I, Carter J, Chang-Claude J, Chanock SJ, Claes KB, Collée JM, Cook LS, Couch FJ, Cox A, Cramer D, Cross SS, Cunningham JM, Cybulski C, Czene K, Damiola F, Dansonka-Mieszkowska A, Darabi H, de la Hoya M, deFazio A, Dennis J, Devilee P, Dicks EM, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Silva Idos S, du Bois A, Dumont M, Dunning AM, Duran M, Easton DF, Eccles D, Edwards RP, Ehrencrona H, Ejlertsen B, Ekici AB, Ellis SD; EMBRACE, Engel C, Eriksson M, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Fontaine A, Fortuzzi S, Fostira F, Fridley BL, Friebel T, Friedman E, Friel G, Frost D, Garber J, García-Closas M, Gayther SA; GEMO Study Collaborators; GENICA Network, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goodman MT, Gore M, Greene MH, Grip M, Gronwald J, Gschwantler Kaulich D, Guénel P, Guzman SR, Haeberle L, Haiman CA, Hall P, Halverson SL, Hamann U, Hansen TV, Harter P, Hartikainen JM, Healey S; HEBON, Hein A, Heitz F, Henderson BE, Herzog J, T Hildebrandt MA, Høgdall CK, Høgdall E, Hogervorst FB, Hopper JL, Humphreys K, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska K, Jensen A, Jensen UB, Johnson N, Jukkola-Vuorinen A, Kabisch M, Karlan BY, Kataja V, Kauff N; KConFab Investigators, Kelemen LE, Kerin MJ, Kiemenev LA, Kjaer SK, Knight JA, Knol-Bout JP, Konstantopoulou I, Kosma VM, Krakstad C, Kristensen V, Kuchenbaecker KB, Kupryjanczyk J, Laitman Y, Lambrechts D, Lambrechts S, Larson MC, Lasa A, Laurent-Puig P, Lazaro C, Le ND, Le Marchand L, Leminen A, Lester J, Levine DA, Li J, Liang D, Lindblom A, Lindor N, Lissowska J, Long J, Lu KH, Lubinski J, Lundvall L, Lurie G, Mai PL,

- Mannermaa A, Margolin S, Mariette F, Marme F, Martens JW, Massuger LF, Maugard C, Mazoyer S, McGuffog L, McGuire V, McLean C, McNeish I, Meindl A, Menegaux F, Menéndez P, Menkiszak J, **Menon U**, Mensenkamp AR, Miller N, Milne RL, Modugno F, Montagna M, Moysich KB, Müller H, Mulligan AM, Muranen TA, Narod SA, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nielsen SF, Nordestgaard BG, Nussbaum RL, Odunsi K, Offit K, Olah E, Olopade OI, Olson JE, Olson SH, Oosterwijk JC, Orlow I, Orr N, Orsulic S, Osorio A, Ottini L, Paul J, Pearce CL, Pedersen IS, Peissel B, Pejovic T, Pelttari LM, Perkins J, Permuth-Wey J, Peterlongo P, Peto J, Phelan CM, Phillips KA, Piedmonte M, Pike MC, Platte R, Plisiecka-Halasa J, Poole EM, Poppe B, Pylkäs K, Radice P, Ramus SJ, Rebbeck TR, Reed MW, Rennert G, Risch HA, Robson M, Rodriguez GC, Romero A, Rossing MA, Rothstein JH, Rudolph A, Runnebaum I, Salani R, Salvesen HB, Sawyer EJ, Schildkraut JM, Schmidt MK, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schrauder MG, Schumacher F, Schwaab I, Scuvera G, Sellers TA, Severi G, Seynaeve CM, Shah M, Shrubsole M, Siddiqui N, Sieh W, Simard J, Singer CF, Sinilnikova OM, Smeets D, Sohn C, Soller M, Song H, Soucy P, Southey MC, Stegmaier C, Stoppa-Lyonnet D, Sucheston L; SWE-BCRA, Swerdlow A, Tangen IL, Tea MK, Teixeira MR, Terry KL, Terry MB, Thomassen M, Thompson PJ, Tihomirova L, Tischkowitz M, Toland AE, Tollenaar RA, Tomlinson I, Torres D, Truong T, Tsimiklis H, Tung N, Tworoger SS, Tyrer JP, Vachon CM, Van 't Veer LJ, van Altena AM, Van Asperen CJ, van den Berg D, van den Ouweland AM, van Doorn HC, Van Nieuwenhuysen E, van Rensburg EJ, Vergote I, Verhoef S, Vierkant RA, Vijai J, Vitonis AF, von Wachenfeldt A, Walsh C, Wang Q, Wang-Gohrke S, Wappenschmidt B, Weischer M, Weitzel JN, Weltens C, Wentzensen N, Whittemore AS, Wilkens LR, Winqvist R, Wu AH, Wu X, Yang HP, Zaffaroni D, Pilar Zamora M, Zheng W, Ziogas A, Chenevix-Trench G, Pharoah PD, Rookus MA, Hooning MJ, Goode EL. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecol Oncol*. 2016 May;141(2):386-401. doi: 10.1016/j.ygyno.2015.04.034. PMID: 26868067.
50. Dilley J, Manchanda R, Johnson M, Rosenthal AN, Gessler S, **Menon U**. Importance of serial CA125 measurements over an absolute cut-off value for the detection of asymptomatic ovarian cancer in high-risk patients. *Int J Gynaecol Obstet*. 2016 May;133(2):239-40. doi: 10.1016/j.ijgo.2015.09.013. PMID: 26868067.
51. Lee AW, Ness RB, Roman LD, Terry KL, Schildkraut JM, Chang-Claude J, Doherty JA, **Menon U**, Cramer DW, Gayther SA, Risch H, Gentry-Maharaj A, Goodman MT, Modugno F, Eilber U, Moysich KB, Berchuck A, Rossing MA, Jensen A, Wicklund KG, Cushing-Haugen KL, Hogdall E, Rudolph A, Thompson PJ, Wilkens LR, Kjaer SK, Carney ME, Stram DO, Ramus SJ, Wu AH, Pike MC, Pearce CL; Ovarian Cancer Association Consortium. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. *Obstet Gynecol*. 2016 May;127(5):828-36. doi:10.1097/AOG.0000000000001387. PMID: 27054934.
52. Præstegaard C, Kjaer SK, Nielsen TS, Jensen SM, Webb PM, Nagle CM, Høgdall E, Risch HA, Rossing MA, Doherty JA, Wicklund KG, Goodman MT, Modugno F, Moysich K, Ness RB, Edwards RP, Goode EL, Winham SJ, Fridley BL, Cramer DW, Terry KL, Schildkraut JM, Berchuck A, Bandera EV, Paddock L, Kiemeny LA, Massuger LF, Wentzensen N, Pharoah P, Song H, Whittemore AS, McGuire V, Sieh W, Rothstein J, Anton-Culver H, Ziogas A, **Menon U**, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pearce CL, Pike MC, Lee AW, Chang-Claude J, Jensen A; Ovarian Cancer Association Consortium. The association between socioeconomic status and tumour stage at diagnosis of ovarian

- cancer: A pooled analysis of 18 case-control studies. *Cancer Epidemiol.* 2016 Apr;41:71-9. doi: 10.1016/j.canep.2016.01.012. PMID: 26851750.
53. Jenkinson C, Elliott VL, Evans A, Oldfield L, Jenkins RE, O'Brien DP, Apostolidou S, Gentry-Maharaj A, Fourkala EO, Jacobs IJ, **Menon U**, Cox T, Campbell F, Pereira SP, Tuveson DA, Park BK, Greenhalf W, Sutton R, Timms JF, Neoptolemos JP, Costello E. Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. *Clin Cancer Res.* 2016 Apr 1;22(7):1734-43. doi: 10.1158/1078-0432.CCR-15-0879. PMID: PMC4820087.
 54. Jacobs IJ*, **Menon U***, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomized controlled trial. *Lancet.* 2016 Mar 5;387(10022):945-56. doi: 10.1016/S0140-6736(15)01224-6. PMID: PMC4779792. * equal contribution
 55. Winham SJ, Pirie A, Chen YA, Larson MC, Fogarty ZC, Earp MA, Anton-Culver H, Bandera EV, Cramer D, Doherty JA, Goodman MT, Gronwald J, Karlan BY, Kjaer SK, Levine DA, **Menon U**, Ness RB, Pearce CL, Pejovic T, Rossing MA, Wentzensen N, Bean YT, Bisogna M, Brinton LA, Carney ME, Cunningham JM, Cybulski C, deFazio A, Dicks EM, Edwards RP, Gayther SA, Gentry-Maharaj A, Gore M, Iversen ES, Jensen A, Johnatty SE, Lester J, Lin HY, Lissowska J, Lubinski J, Menkiszak J, Modugno F, Moysich KB, Orlov I, Pike MC, Ramus SJ, Song H, Terry KL, Thompson PJ, Tyrer JP, van den Berg DJ, Vierkant RA, Vitonis AF, Walsh C, Wilkens LR, Wu AH, Yang H, Ziogas A, Berchuck A; Georgia Chenevix-Trench on behalf of Australian Ovarian Cancer Study Group, Schildkraut JM, Permuth-Wey J, Phelan CM, Pharoah PD, Fridley BL, Sellers TA, Goode EL. Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. *Cancer Epidemiol Biomarkers Prev.* 2016 Mar;25(3):446-54. doi: 10.1158/1055-9965.EPI-15-0240. PMID: PMC4779669.
 56. Manchanda R, **Menon U**. Opportunistic bilateral salpingectomy (OBS) for the prevention of ovarian cancer should be offered in the context of a clinical trial: FOR: There is lack of clarity on a number of key issues. *BJOG.* 2016 Feb;123(3):463. doi: 10.1111/1471-0528.13741. PMID: 26810679.
 57. Sharma A, Burnell M, Gentry-Maharaj A, Campbell S, Amso NN, Seif MW, Fletcher G, Brunell C, Turner G, Rangar R, Ryan A, Jacobs I, **Menon U**. Quality assurance and its impact on ovarian visualization rates in the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Ultrasound Obstet Gynecol.* 2016 Feb;47(2):228-35. doi: 10.1002/uog.14929. PMID: PMC4755159.
 58. Pharoah PD, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, Alsop K; Australian Ovarian Cancer Study Group, Bogdanova N, Cicek MS, Cunningham JM, Fridley BL, Gentry-Maharaj A, Hillemanns P, Lele S, Lester J, McGuire V, Moysich KB, Poblete S, Sieh W, Sucheston-Campbell L, Widschwendter M; Ovarian Cancer Association Consortium, Whittemore AS, Dörk T, **Menon U**, Odunsi K, Goode EL, Karlan BY, Bowtell DD, Gayther SA, Ramus SJ. PPM1D Mosaic Truncating Variants in Ovarian

- Cancer Cases May Be Treatment-Related Somatic Mutations. *J Natl Cancer Inst.* 2016 Jan 27;108(3). pii: djv347. doi: 10.1093/jnci/djv347. PMID: 26823519.
59. Manchanda R, Chandrasekaran D, Saridogan E, Burnell M, Crawford R, Brockbank E, Kalsi J, Jurkovic D, **Menon U**. Should Opportunistic Bilateral Salpingectomy (OBS) for Prevention of Ovarian Cancer Be Incorporated Into Routine Care or Offered in the Context of a Clinical Trial? *Int J Gynecol Cancer.* 2016 Jan;26(1):31-3. doi: 10.1097/IGC.0000000000000567. PMID: 26658362.
 60. Barclay M, Gildea C, Poole J, Hirschowitz L, **Menon U**, Nordin A. Factors Affecting Short-term Mortality in Women With Ovarian, Tubal, or Primary Peritoneal Cancer: Population-Based Cohort Analysis of English National Cancer Registration Data. *Int J Gynecol Cancer.* 2016 Jan;26(1):56-65. doi: 10.1097/IGC.0000000000000562. PMID: 26509852.
 61. Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D; EMBRACE, McGuffog L, Ellis S, Feng B, Buys SS, Hopper JL, Southey MC, Tesoriero A; kConFab Investigators, James PA, Bruinsma F, Campbell IG; Australia Ovarian Cancer Study Group, Broeks A, Schmidt MK, Hogervorst FB; HEBON, Beckman MW, Fasching PA, Fletcher O, Johnson N, Sawyer EJ, Riboli E, Banerjee S, **Menon U**, Tomlinson I, Burwinkel B, Hamann U, Marme F, Rudolph A, Janavicius R, Tihomirova L, Tung N, Garber J, Cramer D, Terry KL, Poole EM, Tworoger SS, Dorfling CM, van Rensburg EJ, Godwin AK, Guénel P, Truong T; GEMO Study Collaborators, Stoppa-Lyonnet D, Damiola F, Mazoyer S, Sinilnikova OM, Isaacs C, Maugard C, Bojesen SE, Flyger H, Gerdes AM, Hansen TV, Jensen A, Kjaer SK, Hogdall C, Hogdall E, Pedersen IS, Thomassen M, Benitez J, González-Neira A, Osorio A, Hoya Mde L, Segura PP, Diez O, Lazaro C, Brunet J, Anton-Culver H, Eunjung L, John EM, Neuhausen SL, Ding YC, Castillo D, Weitzel JN, Ganz PA, Nussbaum RL, Chan SB, Karlan BY, Lester J, Wu A, Gayther S, Ramus SJ, Sieh W, Whittermore AS, Monteiro AN, Phelan CM, Terry MB, Piedmonte M, Offit K, Robson M, Levine D, Moysich KB, Cannioto R, Olson SH, Daly MB, Nathanson KL, Domchek SM, Lu KH, Liang D, Hildebrandt MA, Ness R, Modugno F, Pearce L, Goodman MT, Thompson PJ, Brenner H, Butterbach K, Meindl A, Hahnen E, Wappenschmidt B, Brauch H, Brüning T, Blomqvist C, Khan S, Nevanlinna H, Pelttari LM, Aittomäki K, Butzow R, Bogdanova NV, Dörk T, Lindblom A, Margolin S, Rantala J, Kosma VM, Mannermaa A, Lambrechts D, Neven P, Claes KB, Maerken TV, Chang-Claude J, Flesch-Janys D, Heitz F, Varon-Mateeva R, Peterlongo P, Radice P, Viel A, Barile M, Peissel B, Manoukian S, Montagna M, Oliani C, Peixoto A, Teixeira MR, Collavoli A, Hallberg E, Olson JE, Goode EL, Hart SN, Shimelis H, Cunningham JM, Giles GG, Milne RL, Healey S, Tucker K, Haiman CA, Henderson BE, Goldberg MS, Tischkowitz M, Simard J, Soucy P, Eccles DM, Le N, Borresen-Dale AL, Kristensen V, Salvesen HB, Bjorge L, Bandera EV, Risch H, Zheng W, Beeghly-Fadiel A, Cai H, Pylkäs K, Tollenaar RA, Ouweland AM, Andrulis IL, Knight JA; OCGN, Narod S, Devilee P, Winqvist R, Figueroa J, Greene MH, Mai PL, Loud JT, García-Closas M, Schoemaker MJ, Czene K, Darabi H, McNeish I, Siddiqui N, Glasspool R, Kwong A, Park SK, Teo SH, Yoon SY, Matsuo K, Hosono S, Woo YL, Gao YT, Foretova L, Singer CF, Rappaport-Furhauser C, Friedman E, Laitman Y, Rennert G, Imyanitov EN, Hulick PJ, Olopade OI, Senter L, Olah E, Doherty JA, Schildkraut J, Koppert LB, Kiemenev LA, Massuger LF, Cook LS, Pejovic T, Li J, Borg A, Öfverholm A, Rossing MA, Wentzensen N, Henriksson K, Cox A, Cross SS, Pasini BJ, Shah M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Gronwald J, Agnarsson BA, Kupryjanczyk J, Moes-Sosnowska J, Fostira F, Konstantopoulou I, Slager S, Jones M;

- PRostate cancer Association group To Investigate Cancer Associated aLterations in the genome, Antoniou AC, Berchuck A, Swerdlow A, Chenevix-Trench G, Dunning AM, Pharoah PD, Hall P, Easton DF, Couch FJ, Spurdle AB, Goldgar DE. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *J Natl Cancer Inst.* 2015 Nov 19;108(2). pii: djv315. doi: 10.1093/jnci/djv315. PMID: 26586665.
62. Lee AW, Templeman C, Stram DA, Beesley J, Tyrer J, Berchuck A, Pharoah PP, Chenevix-Trench G, Pearce CL; **Ovarian Cancer Association Consortium**. Evidence of a genetic link between endometriosis and ovarian cancer. *Fertil Steril.* 2016 Jan;105(1):35-43.e10. doi: 10.1016/j.fertnstert.2015.09.023. PMID: 26477498.
 63. Johnatty SE, Tyrer JP, Kar S, Beesley J, Lu Y, Gao B, Fasching PA, Hein A, Ekici AB, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Rossing MA, Doherty JA, Chang-Claude J, Modugno F, Ness RB, Moysich KB, Levine DA, Kiemeny LA, Massuger LF, Gronwald J, Lubiński J, Jakubowska A, Cybulski C, Brinton L, Lissowska J, Wentzensen N, Song H, Rhenius V, Campbell I, Eccles D, Sieh W, Whittemore AS, McGuire V, Rothstein JH, Sutphen R, Anton-Culver H, Ziogas A, Gayther SA, Gentry-Maharaj A, **Menon U**, Ramus SJ, Pearce CL, Pike MC, Stram DO, Wu AH, Kupryjanczyk J, Dansonka-Mieszkowska A, Rzepecka IK, Spiewankiewicz B, Goodman MT, Wilkens LR, Carney ME, Thompson PJ, Heitz F, du Bois A, Schwaab I, Harter P, Pisterer J, Hillemanns P; AGO Study Group, Karlan BY, Walsh C, Lester J, Orsulic S, Winham SJ, Earp M, Larson MC, Fogarty ZC, Høgdall E, Jensen A, Kjaer SK, Fridley BL, Cunningham JM, Vierkant RA, Schildkraut JM, Iversen ES, Terry KL, Cramer DW, Bandera EV, Orlow I, Pejovic T, Bean Y, Høgdall C, Lundvall L, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Sellers T, Kennedy C, Chiew YE, Berchuck A, MacGregor S, Pharoah PD, Goode EL, deFazio A, Webb PM, Chenevix-Trench G; Australian Ovarian Cancer Study Group. Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. *Clin Cancer Res.* 2015 Dec 1;21(23):5264-76. doi: 10.1158/1078-0432.CCR-15-0632. PMCID: PMC4624261.
 64. Chandrasekaran D, **Menon U**, Evans G, Crawford R, Saridogan E, Jacobs C, Tischkowitz M, Brockbank E, Kalsi J, Jurkovic D, Manchanda R. Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK. *Fam Cancer.* 2015 Dec;14(4):521-30. doi: 10.1007/s10689-015-9823-y. PMID: 26178205.
 65. Amankwah EK, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Aben KK, Anton-Culver H, Antonenkova N, Bruinsma F, Bandera EV, Bean YT, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bunker CH, Butzow R, Campbell IG, Carty K, Chen Z, Chen YA, Chang-Claude J, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka-Mieszkowska A, du Bois A, Despierre E, Dicks E, Doherty JA, Dörk T, Dürst M, Easton DF, Eccles DM, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harrington P, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hillemanns P, Hogdall CK, Hogdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Karlan BY, Jim H, Kellar M, Kiemeny LA, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lim BK, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, McNeish I, **Menon U**, Milne RL, Modugno F, Moysich KB, Ness RB, Nevanlinna H,

- Eilber U, Odunsi K, Olson SH, Orlow I, Orsulic S, Weber RP, Paul J, Pearce CL, Pejovic T, Pelttari LM, Permuth-Wey J, Pike MC, Poole EM, Risch HA, Rosen B, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schernhammer E, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Spiewankiewicz B, Sucheston-Campbell L, Teo SH, Terry KL, Thompson PJ, Thomsen L, Tangen IL, Tworoger SS, van Altena AM, Vierkant RA, Vergote I, Walsh CS, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Wu AH, Wu X, Woo YL, Yang H, Zheng W, Ziogas A, Kelemen LE, Berchuck A; Georgia Chenevix-Trench on behalf of the AOCs management group, Schildkraut JM, Ramus SJ, Goode EL, Monteiro AN, Gayther SA, Narod SA, Pharoah PD, Sellers TA, Phelan CM. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. *Genet Epidemiol.* 2015 Dec;39(8):689-97. doi: 10.1002/gepi.21921. PMID: PMC4721602.
66. Manchanda R, Legood R, Pearce L, **Menon U**. Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women. *Gynecol Oncol.* 2015 Dec;139(3):487-94. doi: 10.1016/j.ygyno.2015.10.001. PMID: 26436478.
67. Lawrenson K, Iversen ES, Tyrer J, Weber RP, Concannon P, Hazelett DJ, Li Q, Marks JR, Berchuck A, Lee JM, Aben KK, Anton-Culver H, Antonenkova N; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group, Bandera EV, Bean Y, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Butzow R, Campbell IG, Carty K, Chang-Claude J, Chenevix-Trench G, Chen A, Chen Z, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Plisiecka-Halasa J, Dennis J, Dicks E, Doherty JA, Dörk T, du Bois A, Eccles D, Easton DT, Edwards RP, Eilber U, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Goode EL, Goodman MT, Gronwald J, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hillemanns P, Hogdall E, Hogdall C, Hosono S, Jakubowska A, Paul J, Jensen A, Karlan BY, Kjaer SK, Kelemen LE, Kellar M, Kelley JL, Kiemeny LA, Krakstad C, Lambrechts D, Lambrechts S, Le ND, Lee AW, Cannioto R, Leminen A, Lester J, Levine DA, Liang D, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Nevanlinna H, McNeish I, **Menon U**, Modugno F, Moysich KB, Narod SA, Nedergaard L, Ness RB, Noor Azmi MA, Odunsi K, Olson SH, Orlow I, Orsulic S, Pearce CL, Pejovic T, Pelttari LM, Permuth-Wey J, Phelan CM, Pike MC, Poole EM, Ramus SJ, Risch HA, Rosen B, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Budzilowska A, Sellers TA, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Sucheston L, Tangen IL, Teo SH, Terry KL, Thompson PJ, Timorek A, Tworoger SS, Nieuwenhuysen EV, Vergote I, Vierkant RA, Wang-Gohrke S, Walsh C, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Woo YL, Wu X, Wu AH, Yang H, Zheng W, Ziogas A, Coetzee GA, Freedman ML, Monteiro AN, Moes-Sosnowska J, Kupryjanczyk J, Pharoah PD, Gayther SA, Schildkraut JM. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. *Carcinogenesis.* 2015 Nov;36(11):1341-53. doi: 10.1093/carcin/bgv138. PMID: PMC4635670.
68. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, **Menon U**, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott

- CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. *Nat Rev Cancer*. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. PMID: 26493647.
69. Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, Fraser L, Gentry-Maharaj A, Hayward J, Philpott S, Anderson C, Edlund CK, Conti D, Harrington P, Barrowdale D, Bowtell DD, Alsop K, Mitchell G; AOCs Study Group, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Sieh W, McGuire V, Lester J, Bogdanova N, Dürst M, Hillemanns P; Ovarian Cancer Association Consortium, Odunsi K, Whittemore AS, Karlan BY, Dörk T, Goode EL, **Menon U**, Jacobs IJ, Antoniou AC, Pharoah PD, Gayther SA. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. *J Natl Cancer Inst*. 2015 Aug 27;107(11). pii: djv214. doi: 10.1093/jnci/djv214. PMID: 26315354.
 70. Lu Y, Cuellar-Partida G, Painter JN, Nyholt DR; Australian Ovarian Cancer Study; International Endogene Consortium (IEC), Morris AP, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty JA, Rossing MA, Wicklund KG, Chang-Claude J, Eilber U, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Høgdall E, Jensen A, Giles GG, Bruinsma F, Kjaer SK, Hildebrandt MA, Liang D, Lu KH, Wu X, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Missmer S, Bjorge L, Salvesen HB, Kopperud RK, Bischof K, Aben KK, Kiemeny LA, Massuger LF, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Gilks CB, Gronwald J, Jakubowska A, Lubiński J, Gawełko J, Song H, Tyrer JP, Wentzensen N, Brinton L, Trabert B, Lissowska J, McLaughlin JR, Narod SA, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Gayther SA, Gentry-Maharaj A, **Menon U**, Ramus SJ, Wu AH, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham JM, Fridley BL, Winham SJ, Bandera EV, Poole EM, Morgan TK, Risch HA, Goode EL, Schildkraut JM, Webb PM, Pearce CL, Berchuck A, Pharoah PD, Montgomery GW, Zondervan KT, Chenevix-Trench G, MacGregor S. Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. *Hum Mol Genet*. 2015 Oct 15;24(20):5955-64. doi: 10.1093/hmg/ddv306. PMC4581608.
 71. Kar SP, Tyrer JP, Li Q, Lawrenson K, Aben KK, Anton-Culver H, Antonenkova N, Chenevix-Trench G; Australian Cancer Study; Australian Ovarian Cancer Study Group, Baker H, Bandera EV, Bean YT, Beckmann MW, Berchuck A, Bisogna M, Bjørge L, Bogdanova N, Brinton L, Brooks-Wilson A, Butzow R, Campbell I, Carty K, Chang-Claude J, Chen YA, Chen Z, Cook LS, Cramer D, Cunningham JM, Cybulski C, Dansonka-Mieszkowska A, Dennis J, Dicks E, Doherty JA, Dörk T, du Bois A, Dürst M, Eccles D, Easton DF, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Goode EL, Goodman MT, Gronwald J, Harrington P, Harter P, Hein A, Heitz F, Hildebrandt MA, Hillemanns P, Hogdall E, Hogdall CK, Hosono S, Iversen ES, Jakubowska A, Paul J, Jensen A, Ji BT, Karlan BY, Kjaer SK, Kelemen LE, Kellar M, Kelley J, Kiemeny LA, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger L, Matsuo K, McGuire V, McLaughlin JR, McNeish IA, **Menon U**, Modugno F, Moysich KB, Narod SA, Nedergaard L, Ness RB, Nevanlinna H,

- Odunsi K, Olson SH, Orlow I, Orsulic S, Weber RP, Pearce CL, Pejovic T, Pelttari LM, Permuth-Wey J, Phelan CM, Pike MC, Poole EM, Ramus SJ, Risch HA, Rosen B, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schildkraut JM, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Sucheston-Campbell LE, Tangen IL, Teo SH, Terry KL, Thompson PJ, Timorek A, Tsai YY, Tworoger SS, van Altena AM, Van Nieuwenhuysen E, Vergote I, Vierkant RA, Wang-Gohrke S, Walsh C, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Woo YL, Wu X, Wu A, Yang H, Zheng W, Ziogas A, Sellers TA, Monteiro AN, Freedman ML, Gayther SA, Pharoah PD. Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. *Cancer Epidemiol Biomarkers Prev.* 2015 Oct;24(10):1574-84. doi: 10.1158/1055-9965.EPI-14-1270. PMID: PMC4592449.
72. Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, Dubeau L, Cline M, Pan Y, Yi PC, Gareth Evans D, Jacobs IJ, **Menon U**, Wood CE, Dougall WC. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF- κ B Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. *EBioMedicine.* 2015 Sep 9;2(10):1331-9. doi: 10.1016/j.ebiom.2015.08.037. PMID: PMC4634624.
73. Jenkins V, Fallowfield L, Langridge C, Barrett J, Ryan A, Jacobs I, Kilkerr J, **Menon U**, Farewell V. Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening. *Int J Gynecol Cancer.* 2015 Oct;25(8):1519-25. doi: 10.1097/IGC.0000000000000507. PMID: PMC4582418.
74. Lawrenson K, Li Q, Kar S, Seo JH, Tyrer J, Spindler TJ, Lee J, Chen Y, Karst A, Drapkin R, Aben KK, Anton-Culver H, Antonenkova N; Australian Ovarian Cancer Study Group, Baker H, Bandera EV, Bean Y, Beckmann MW, Berchuck A, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Butzow R, Campbell IG, Carty K, Chang-Claude J, Chenevix-Trench G, Chen A, Chen Z, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka-Mieszkowska A, Dennis J, Dicks E, Doherty JA, Dörk T, du Bois A, Dürst M, Eccles D, Easton DT, Edwards RP, Eilber U, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Goode EL, Goodman MT, Grownwald J, Harrington P, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hillemanns P, Hogdall E, Hogdall C, Hosono S, Iversen ES, Jakubowska A, James P, Jensen A, Ji BT, Karlan BY, Kruger Kjaer S, Kelemen LE, Kellar M, Kelley JL, Kiemeny LA, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Nevanlinna H, McNeish I, **Menon U**, Modugno F, Moysich KB, Narod SA, Nedergaard L, Ness RB, Azmi MA, Odunsi K, Olson SH, Orlow I, Orsulic S, Weber RP, Pearce CL, Pejovic T, Pelttari LM, Permuth-Wey J, Phelan CM, Pike MC, Poole EM, Ramus SJ, Risch HA, Rosen B, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schildkraut JM, Schwaab I, Sellers TA, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Sucheston L, Tangen IL, Teo SH, Terry KL, Thompson PJ, Timorek A, Tsai YY, Tworoger SS, van Altena AM, Van Nieuwenhuysen E, Vergote I, Vierkant RA, Wang-Gohrke S, Walsh C, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Woo YL, Wu X, Wu AH, Yang H, Zheng W, Ziogas A, Monteiro A, Pharoah PD, Gayther SA, Freedman ML. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade

- serous ovarian cancer. *Nat Commun.* 2015 Sep 22;6:8234. doi: 10.1038/ncomms9234. PMID: PMC4580986.
75. Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, Edlund CK, Conti D, Harrington P, Fraser L, Philpott S, Anderson C, Rosenthal A, Gentry-Maharaj A, Bowtell DD, Alsop K, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Høgdall E, Høgdall CK, Jensen A, Kjaer SK, Lubiński J, Huzarski T, Jakubowska A, Gronwald J, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Odunsi K, Goode EL, **Menon U**, Jacobs IJ, Gayther SA, Pharoah PD. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. *J Clin Oncol.* 2015 Sep 10;33(26):2901-7. doi: 10.1200/JCO.2015.61.2408. PMID: PMC4554751.
 76. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; **ICON7 trial investigators**. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. *Lancet Oncol.* 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. PMID: PMC4648090.
 77. Kelemen LE, Lawrenson K, Tyrer J, Li Q, Lee JM, Seo JH, Phelan CM, Beesley J, Chen X, Spindler TJ, Aben KK, Anton-Culver H, Antonenkova N; Australian Cancer Study; Australian Ovarian Cancer Study Group; **Ovarian Cancer Association Consortium**. Genome-wide significant risk associations for mucinous ovarian carcinoma. *Nat Genet.* 2015 Aug;47(8):888-97. doi: 10.1038/ng.3336. PMID: PMC4520768.
 78. Thomas DS, Fourkala EO, Apostolidou S, Gunu R, Ryan A, Jacobs I, **Menon U**, Alderton W, Gentry-Maharaj A, Timms JF. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. *Br J Cancer.* 2015 Jul 14;113(2):268-74. doi: 10.1038/bjc.2015.202. PMID: PMC4506388.
 79. Coetzee SG, Shen HC, Hazelett DJ, Lawrenson K, Kuchenbaecker K, Tyrer J, Rhie SK, Levanon K, Karst A, Drapkin R, Ramus SJ; Ovarian Cancer Association Consortium, The Consortium of Investigators of Modifiers of BRCA1/2, Couch FJ, Offit K, Chenevix-Trench G, Monteiro AN, Antoniou A, Freedman M, Coetzee GA, Pharoah PD, Noushmehr H, Gayther SA; **Ovarian Cancer Association Consortium** The Consortium of Investigators of Modifiers of BRCA1/2. Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Hum Mol Genet.* 2015 Jul 1;24(13):3595-607. doi: 10.1093/hmg/ddv101. PMID: PMC4459387.
 80. Key TJ, Appleby PN, Reeves GK, Travis RC, Brinton LA, Helzlsouer KJ, Dorgan JF, Gapstur SM, Gaudet MM, Kaaks R, Riboli E, Rinaldi S, Manjer J, Hallmans G, Giles GG, Le Marchand L, Kolonel LN, Henderson BE, Tworoger SS, Hankinson SE, Zeleniuch-Jacquotte A, Koenig K, Krogh V, Sieri S, Muti P, Ziegler RG, Schairer C, Fuhrman BJ, Barrett-Connor E, Laughlin GA, Grant EJ, Cologne J, Ohishi W, Hida A, Cauley JA, Fourkala EO, **Menon U**, Rohan TE, Strickler HD, Gunter MJ; Endogenous Hormones and Breast Cancer Collaborative Group. Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies. *Steroids.* 2015 Jul;99(Pt A):49-55. doi: 10.1016/j.steroids.2014.09.001. PMID: PMC4502556.
 81. **Menon U**, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S,

- Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. *J Clin Oncol*. 2015 Jun 20;33(18):2062-71. doi: 10.1200/JCO.2014.59.4945. PMID: PMC4463475.
82. Davis SJ, Sheppard KE, Anglesio MS, George J, Traficante N, Fereday S, Intermaggio MP, **Menon U**, Gentry-Maharaj A, Lubinski J, Gronwald J, Pearce CL, Pike MC, Wu A, Kommos S, Pfisterer J, du Bois A, Hilpert F, Ramus SJ, Bowtell DD, Huntsman DG, Pearson RB, Simpson KJ, Campbell IG, Goringe KL. Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. *Mol Cancer Ther*. 2015 Jun;14(6):1495-503. doi: 10.1158/1535-7163.MCT-15-0039. PMID: 25852062.
 83. Nouretdinov I, Devetyarov D, Vovk V, Burford B, Camuzeaux S, Gentry-Maharaj A, Tiss A, Smith C, Luo ZY, Chervonenkis A, Hallett R, Waterfield M, Cramer R, Timms JF, Jacobs I, **Menon U**, Gammerman A. Multiprobabilistic prediction in early medical diagnoses. *Annals of Mathematics and Artificial Intelligence*. 2015 Jun; 74(1-2):203-222. Web of Science ISI:000355747600011
 84. Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, Lee AW, **Menon U**, Fasching PA, McAlpine JN, Doherty JA, Modugno F, Schildkraut JM, Rossing MA, Huntsman DG, Wu AH, Berchuck A, Pike MC, Pharoah PD. Population distribution of lifetime risk of ovarian cancer in the United States. *Cancer Epidemiol Biomarkers Prev*. 2015 Apr;24(4):671-6. doi: 10.1158/1055-9965.EPI-14-1128. PMID: 25623732.
 85. Gentry-Maharaj A, Karpinskyj C, Glazer C, Burnell M, Ryan A, Fraser L, Lanceley A, Jacobs I, Hunter MS, **Menon U**. Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy: a nested United Kingdom Collaborative Trial of Ovarian Cancer Screening cohort study. *Menopause*. 2015 Apr;22(4):384-90. doi: 10.1097/GME.0000000000000330. PMID: PMC4470524.
 86. Bailey K, Ryan A, Apostolidou S, Fourkala E, Burnell M, Gentry-Maharaj A, Kalsi J, Parmar M, Jacobs I, Pikhart H, **Menon U**. Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *BMC Public Health*. 2015 Mar 17;15:253. doi: 10.1186/s12889-015-1609-5. PMID: PMC4367890.
 87. Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Spiewankiewicz B, Myers EJ; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Ekici AB, Hein A, Vergote I, Van Nieuwenhuysen E, Lambrechts D, Wicklund KG, Eilber U, Wang-Gohrke S, Chang-Claude J, Rudolph A, Sucheston-Campbell L, Odunsi K, Moysich KB, Shvetsov YB, Thompson PJ, Goodman MT, Wilkens LR, Dörk T, Hillemanns P, Dürst M, Runnebaum IB, Bogdanova N, Pelttari LM, Nevanlinna H, Leminen A, Edwards RP, Kelley JL, Harter P, Schwaab I, Heitz F, du Bois A, Orsulic S, Lester J, Walsh C, Karlan BY, Hogdall E, Kjaer SK, Jensen A, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Southey MC, Giles GG, Bruinsma F, Wu X, Hildebrandt MA, Lu K, Liang D, Bisogna M, Levine DA, Weber RP, Schildkraut JM, Iversen ES, Berchuck A, Terry KL, Cramer DW, Tworoger SS, Poole EM, Olson SH, Orlow I, Bandera EV, Bjorge L, Tangen IL, Salvesen HB, Krakstad C, Massuger LF, Kiemeny LA, Aben KK, van Altena AM, Bean Y, Pejovic T, Kellar M, Le ND, Cook LS, Kelemen LE,

- Brooks-Wilson A, Lubinski J, Gronwald J, Cybulski C, Jakubowska A, Wentzensen N, Brinton LA, Lissowska J, Yang H, Nedergaard L, Lundvall L, Hogdall C, Song H, Campbell IG, Eccles D, Glasspool R, Siddiqui N, Carty K, Paul J, McNeish IA, Sieh W, McGuire V, Rothstein JH, Whittmore AS, McLaughlin JR, Risch HA, Phelan CM, Anton-Culver H, Ziogas A, **Menon U**, Ramus SJ, Gentry-Maharaj A, Harrington P, Pike MC, Modugno F, Rossing MA, Ness RB, Pharoah PD, Stram DO, Wu AH, Pearce CL. Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. *Gynecol Oncol*. 2015 Mar;136(3):542-8. doi: 10.1016/j.ygyno.2014.12.017. PMID: 25528498.
88. Iyer R, Gentry-Maharaj A, Nordin A, Burnell M, Liston R, Manchanda R, Das N, Desai R, Gornall R, Beardmore-Gray A, Nevin J, Hillaby K, Leeson S, Linder A, Lopes A, Meehan D, Mould T, Varkey S, Olaitan A, Rufford B, Ryan A, Shanbhag S, Thackeray A, Wood N, Reynolds K, **Menon U**. Predictors of complications in gynaecological oncological surgery: a prospective multicentre study (UKGOSOC-UK gynaecological oncology surgical outcomes and complications). *Br J Cancer*. 2015 Feb 3;112(3):475-84. doi: 10.1038/bjc.2014.630. PMCID: PMC4453652.
89. O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, Fourkala EO, Camuzeaux S, Blyuss O, Gunu R, Dawnay A, Zaikin A, Smith RC, Jacobs IJ, **Menon U**, Costello E, Pereira SP, Timms JF. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. *Clin Cancer Res*. 2015 Feb 1;21(3):622-31. doi: 10.1158/1078-0432.CCR-14-0365. PMCID: PMC4181906.
90. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Gerdes AM, Ejertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S; EMBRACE, Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM; GEMO Study Collaborators, Damiola F, Mazoyer S, Stoppa-Lyonnet D, Claes K, De Leeneer K, Kirk J, Rodriguez GC, Piedmonte M, O'Malley DM, de la Hoya M, Caldes T, Aittomäki K, Nevanlinna H, Collée JM, Rookus MA, Oosterwijk JC; Breast Cancer Family Registry, Tihomirova L, Tung N, Hamann U, Isaccs C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB; HEBON, Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira MR; KConFab Investigators, Pankratz VS, Wang X, Lindor N, Szabo CI, Kauff N, Vijai J, Aghajanian CA, Pfeiler G, Berger A, Singer CF, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Tchatchou S, Andrulis IL, Glendon G, Toland AE, Jensen UB, Kruse TA, Thomassen M, Bojesen A, Zidan J, Friedman E, Laitman Y, Soller M, Liljegren A, Arver B, Einbeigi Z, Stenmark-Askmal M, Olopade OI, Nussbaum RL, Rebbeck TR, Nathanson KL, Domchek SM, Lu KH, Karlan BY, Walsh C, Lester J; Australian Cancer Study (Ovarian Cancer Investigators); Australian Ovarian Cancer Study Group, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, Chang-Claude J, Wang-Gohrke S, Eilber U, Moysich KB, Odunsi K, Sucheston L, Lele S, Wilkens LR, Goodman MT, Thompson PJ, Shvetsov YB, Runnebaum

- IB, Dürst M, Hillemanns P, Dörk T, Antonenkova N, Bogdanova N, Leminen A, Pelttari LM, Butzow R, Modugno F, Kelley JL, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Matsuo K, Hosono S, Orsulic S, Jensen A, Kjaer SK, Hogdall E, Hasmad HN, Azmi MA, Teo SH, Woo YL, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Bruinsma F, Giles GG, Liang D, Hildebrandt MA, Wu X, Levine DA, Bisogna M, Berchuck A, Iversen ES, Schildkraut JM, Concannon P, Weber RP, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, Olson SH, Krakstad C, Salvesen HB, Tangen IL, Bjorge L, van Altena AM, Aben KK, Kiemeny LA, Massuger LF, Kellar M, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Cybulski C, Yang H, Lissowska J, Brinton LA, Wentzensen N, Hogdall C, Lundvall L, Nedergaard L, Baker H, Song H, Eccles D, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Ji BT, Zheng W, Shu XO, Gao YT, Rosen B, Risch HA, McLaughlin JR, Narod SA, Monteiro AN, Chen A, Lin HY, Permuth-Wey J, Sellers TA, Tsai YY, Chen Z, Ziogas A, Anton-Culver H, Gentry-Maharaj A, **Menon U**, Harrington P, Lee AW, Wu AH, Pearce CL, Coetzee G, Pike MC, Dansonka-Mieszkowska A, Timorek A, Rzepecka IK, Kupryjanczyk J, Freedman M, Noushmehr H, Easton DF, Offit K, Couch FJ, Gayther S, Pharoah PP, Antoniou AC, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1 and BRCA2. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nat Genet.* 2015 Feb;47(2):164-71. doi: 10.1038/ng.3185. PMID: PMC4445140.
91. Jenkinson C, Elliott V, **Menon U**, Apostolidou S, Fourkala OE, Gentry-Maharaj A, Pereira SP, Jacobs I, Cox TF, Greenhalf W, Timms JF, Sutton R, Neoptolemos JP, Costello E. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. *J Proteomics.* 2015 Jan 15;113:400-2. PubMed PMID: 25316052.
92. Blyuss O, Gentry-Maharaj A, Fourkala EO, Ryan A, Zaikin A, **Menon U**, Jacobs I, Timms JF. Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset. *Biomed Res Int.* 2015;2015:681416. doi: 10.1155/2015/681416. PMID: PMC4706857.
93. Jim HS, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Chen Z, Chen AY, Permuth-Wey J, Aben KK, Anton-Culver H, Antonenkova N, Bruinsma F, Bandera EV, Bean YT, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bunker CH, Butzow R, Campbell IG, Carty K, Chang-Claude J, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka-Mieszkowska A, du Bois A, Despierre E, Sieh W, Doherty JA, Dörk T, Dürst M, Easton DF, Eccles DM, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hillemanns P, Hogdall CK, Hogdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Karlan BY, Kellar M, Kiemeny LA, Krakstad C, Kjaer SK, Kupryjanczyk J, Vierkant RA, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lim BK, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, McNeish I, **Menon U**, Milne RL, Modugno F, Thomsen L, Moysich KB, Ness RB, Nevanlinna H, Eilber U, Odunsi K, Olson SH, Orlow I, Orsulic S, Palmieri Weber R, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Schernhammer E, Risch HA, Rosen B, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Song H, Southey MC, Spiewankiewicz B, Sucheston-Campbell L, Teo SH, Terry KL, Thompson PJ, Tangen IL,

- Tworoger SS, van Altena AM, Vergote I, Walsh CS, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Wu AH, Wu X, Woo YL, Yang H, Zheng W, Ziogas A, Amankwah E, Berchuck A; Georgia Chenevix-Trench on behalf of the AOCs management group 95,96, Schildkraut JM, Kelemen LE, Ramus SJ, Monteiro AN, Goode EL, Narod SA, Gayther SA, Pharoah PD, Sellers TA, Phelan CM. Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). *J Genet Genome Res.* 2015;2(2). pii: 017. PMID: PMC4722961.
94. Chornokur G, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Amankwah EK, Qu X, Tsai YY, Jim HS, Chen Z, Chen AY, Permuth-Wey J, Aben KK, Anton-Culver H, Antonenkova N, Bruinsma F, Bandera EV, Bean YT, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bunker CH, Butzow R, Campbell IG, Carty K, Chang-Claude J, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka-Mieszkowska A, du Bois A, Despierre E, Dicks E, Doherty JA, Dörk T, Dürst M, Easton DF, Eccles DM, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gao YT, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harrington P, Harter P, Hein A, Heitz F, Hildebrandt MA, Hillemanns P, Hogdall CK, Hogdall E, Hosono S, Jakubowska A, Jensen A, Ji BT, Karlan BY, Kelemen LE, Kellar M, Kiemeny LA, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lim BK, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, McNeish I, **Menon U**, Milne RL, Modugno F, Moysich KB, Ness RB, Nevanlinna H, Eilber U, Odunsi K, Olson SH, Orlow I, Orsulic S, Weber RP, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Risch HA, Rosen B, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schernhammer E, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Spiewankiewicz B, Sucheston L, Teo SH, Terry KL, Thompson PJ, Thomsen L, Tangen IL, Tworoger SS, van Altena AM, Vierkant RA, Vergote I, Walsh CS, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Wu AH, Wu X, Woo YL, Yang H, Zheng W, Ziogas A, Hasmad HN, Berchuck A; Georgia Chenevix-Trench; AOCs management group, Iversen ES, Schildkraut JM, Ramus SJ, Goode EL, Monteiro AN, Gayther SA, Narod SA, Pharoah PD, Sellers TA, Phelan CM. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. *PLoS One.* 2015 Jun 19;10(6):e0128106. doi: 10.1371/journal.pone.0128106. PMID: PMC4474865.
95. Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, **Menon U**, Jacobs I. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing. *J Natl Cancer Inst.* 2014 Nov 30;107(1):380. doi: 10.1093/jnci/dju380. PMID: PMC4301704.
96. Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, McGuire A, Beller U, **Menon U**, Jacobs I. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. *J Natl Cancer Inst.* 2014 Nov 30;107(1):379. doi: 10.1093/jnci/dju379. Print 2015 Jan. PMID: PMC4301703.
97. Köbel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi K, **Menon U**, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall C, Kalli KR, Fridley

- BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L; AOCs Study Group, Goode EL, Kjær SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, Kelemen LE. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. *Br J Cancer*. 2014 Dec 9;111(12):2297-307. doi: 10.1038/bjc.2014.567. PMID: PMC4264456.
98. **Menon U**, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. *BJOG*. 2014 Dec;121 Suppl 7:35-9. doi: 10.1111/1471-0528.13211. PMID: 25488086.
 99. Timms JF, Arslan-Low E, Kabir M, Worthington J, Camuzeaux S, Sinclair J, Szaub J, Afrough B, Podust VN, Fourkala EO, Cubizolles M, Kronenberg F, Fung ET, Gentry-Maharaj A, **Menon U**, Jacobs I. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. *Proteomics Clin Appl*. 2014 Dec;8(11-12):982-93. doi: 10.1002/prca.201400063. PMID: 25290619.
 100. Lu Y, Ek WE, Whiteman D, Vaughan TL, Spurdle AB, Easton DF, Pharoah PD, Thompson DJ, Dunning AM, Hayward NK, Chenevix-Trench G; Q-MEGA and AMFS Investigators; ANECS-SEARCH; **UKOPS-SEARCH**; BEACON Consortium, Macgregor S. Most common 'sporadic' cancers have a significant germline genetic component. *Hum Mol Genet*. 2014 Nov 15;23(22):6112-8. doi: 10.1093/hmg/ddu312. PMID: PMC4271103.
 101. Witt J, Elwyn G, Wood F, Rogers MT, **Menon U**, Brain K. Adapting the coping in deliberation (CODE) framework: a multi-method approach in the context of familial ovarian cancer risk management. *Patient Educ Couns*. 2014 Nov;97(2):200-10. doi: 10.1016/j.pec.2014.07.004. PMID: 25064250.
 102. Kelemen LE, Terry KL, Goodman MT, Webb PM, Bandera EV, McGuire V, Rossing MA, Wang Q, Dicks E, Tyrer JP, Song H, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Timorek A, **Menon U**, Gentry-Maharaj A, Gayther SA, Ramus SJ, Narod SA, Risch HA, McLaughlin JR, Siddiqui N, Glasspool R, Paul J, Carty K, Gronwald J, Lubiński J, Jakubowska A, Cybulski C, Kiemenev LA, Massuger LF, van Altena AM, Aben KK, Olson SH, Orlow I, Cramer DW, Levine DA, Bisogna M, Giles GG, Southey MC, Bruinsma F, Kjaer SK, Høgdall E, Jensen A, Høgdall CK, Lundvall L, Engelholm SA, Heitz F, du Bois A, Harter P, Schwaab I, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Thompson PJ, Lurie G, Wilkens LR, Lambrechts D, Van Nieuwenhuysen E, Lambrechts S, Vergote I, Beesley J; AOCs Study Group/ACS Investigators, Fasching PA, Beckmann MW, Hein A, Ekici AB, Doherty JA, Wu AH, Pearce CL, Pike MC, Stram D, Chang-Claude J, Rudolph A, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Bogdanova N, Antonenkova N, Odunsi K, Edwards RP, Kelley JL, Modugno F, Ness RB, Karlan BY, Walsh C, Lester J, Orsulic S, Fridley BL, Vierkant RA, Cunningham JM, Wu X, Lu K, Liang D, Hildebrandt MA, Weber RP, Iversen ES, Tworoger SS, Poole EM, Salvesen HB, Krakstad C, Borge L, Tangen IL, Pejovic T, Bean Y, Kellar M, Wentzensen N, Brinton LA, Lissowska J, Garcia-Closas M, Campbell IG, Eccles D, Whittemore AS, Sieh W, Rothstein JH, Anton-Culver H, Ziogas A, Phelan CM, Moysich KB, Goode EL, Schildkraut JM, Berchuck A, Pharoah PD, Sellers TA, Brooks-Wilson A, Cook LS, Le ND. Consortium analysis of gene and gene-folate

- interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. *Mol Nutr Food Res*. 2014 Oct;58(10):2023-35. doi: 10.1002/mnfr.201400068. PMID: PMC4197821.
103. Fourkala EO, Burnell M, Cox C, Ryan A, Salter LC, Gentry-Maharaj A, Parmar M, Jacobs I, **Menon U**. Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *BMJ Open*. 2014 Sep 24;4(9):e005400. doi: 10.1136/bmjopen-2014-005400. PMID: PMC4185339.
 104. Barrett J, Jenkins V, Farewell V, **Menon U**, Jacobs I, Kilkerr J, Ryan A, Langridge C, Fallowfield L; UKCTOCS trialists. Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS). *BJOG*. 2014 Aug;121(9):1071-9. doi: 10.1111/1471-0528.12870. PMID: 24865441.
 105. Block MS, Charbonneau B, Vierkant RA, Fogarty Z, Bamlet WR, Pharoah PD; Georgia Chenevix-Trench; for AOCSS; /ACS Group, Rossing MA, Cramer D, Pearce CL, Schildkraut J, **Menon U**, Kjaer SK, Levine DA, Gronwald J, Culver HA, Whittemore AS, Karlan BY, Lambrechts D, Wentzensen N, Kupryjanczyk J, Chang-Claude J, Bandera EV, Hogdall E, Heitz F, Kaye SB, Fasching PA, Campbell I, Goodman MT, Pejovic T, Bean YT, Hays LE, Lurie G, Eccles D, Hein A, Beckmann MW, Ekici AB, Paul J, Brown R, Flanagan JM, Harter P, du Bois A, Schwaab I, Hogdall CK, Lundvall L, Olson SH, Orlow I, Paddock LE, Rudolph A, Eilber U, Dansonka-Mieszkowska A, Rzepecka IK, Ziolkowska-Seta I, Brinton LA, Yang H, Garcia-Closas M, Despierre E, Lambrechts S, Vergote I, Walsh CS, Lester J, Sieh W, McGuire V, Rothstein JH, Ziogas A, Lubiński J, Cybulski C, Menkiszak J, Jensen A, Gayther SA, Ramus SJ, Gentry-Maharaj A, Berchuck A, Wu AH, Pike MC, Van Den Berg D, Terry KL, Vitonis AF, Ramirez SM, Rider DN, Knutson KL, Sellers TA, Phelan CM, Doherty JA, Johnatty SE, deFazio A, Song H, Tyrer J, Kalli KR, Fridley BL, Cunningham JM, Goode EL. Variation in NF- κ B signaling pathways and survival in invasive epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev*. 2014 Jul;23(7):1421-7. doi: 10.1158/1055-9965.EPI-13-0962. PMID: PMC4082406.
 106. Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JA, Lane JA, Avery KN, Down L, Walsh E, Davis M, Ben-Shlomo Y, Oliver SE, Evans S, Brindle P, Williams NJ, Hughes LJ, Hill EM, Davies C, Ng SY, Neal DE, Hamdy FC, Martin RM; **CAP trial group**. Design and preliminary recruitment results of the Cluster randomised trial of PSA testing for Prostate cancer (CAP). *Br J Cancer*. 2014 Jun 10;110(12):2829-36. doi: 10.1038/bjc.2014.242. PMID: PMC4056057.
 107. Fraser L, Burnell M, Salter LC, Fourkala EO, Kalsi J, Ryan A, Gessler S, Gidron Y, Steptoe A, **Menon U**. Identifying hopelessness in population research: a validation study of two brief measures of hopelessness. *BMJ Open*. 2014 May 30;4(5):e005093. doi: 10.1136/bmjopen-2014-005093. PMID: PMC4039863.
 108. Earp MA, Kelemen LE, Magliocco AM, Swenerton KD, Chenevix-Trench G; Australian Cancer Study; Australian Ovarian Cancer Study Group, Lu Y, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Despierre E, Vergote I, Lambrechts S, Doherty JA, Rossing MA, Chang-Claude J, Rudolph A, Friel G, Moysich KB, Odunsi K, Sucheston-Campbell L, Lurie G, Goodman MT, Carney ME, Thompson PJ, Runnebaum IB, Dürst M, Hillemanns P, Dörk T, Antonenkova N, Bogdanova N, Leminen A, Nevanlinna H, Pelttari LM, Butzow R, Bunker CH, Modugno F, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Karlan BY, Walsh C, Lester J, Jensen A, Kjær SK, Høgdall CK,

- Høgdall E, Lundvall L, Sellers TA, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Giles GG, Baglietto L, Severi G, Southey MC, Liang D, Wu X, Lu K, Hildebrandt MA, Levine DA, Bisogna M, Schildkraut JM, Iversen ES, Weber RP, Berchuck A, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Chandran U, Orlow I, Olson SH, Wik E, Salvesen HB, Bjorge L, Halle MK, van Altena AM, Aben KK, Kiemenev LA, Massuger LF, Pejovic T, Bean YT, Cybulski C, Gronwald J, Lubinski J, Wentzensen N, Brinton LA, Lissowska J, Garcia-Closas M, Dicks E, Dennis J, Easton DF, Song H, Tyrer JP, Pharoah PD, Eccles D, Campbell IG, Whittemore AS, McGuire V, Sieh W, Rothstein JH, Flanagan JM, Paul J, Brown R, Phelan CM, Risch HA, McLaughlin JR, Narod SA, Ziogas A, Anton-Culver H, Gentry-Maharaj A, **Menon U**, Gayther SA, Ramus SJ, Wu AH, Pearce CL, Pike MC, Dansonka-Mieszkowska A, Rzepecka IK, Szafron LM, Kupryjanczyk J, Cook LS, Le ND, Brooks-Wilson A; Ovarian Cancer Association Consortium. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. *Hum Genet.* 2014 May;133(5):481-97. doi: 10.1007/s00439-013-1383-3. PMID: PMC4063682.
109. Pedersen JW, Gentry-Maharaj A, Nøstdal A, Fourkala EO, Dawnay A, Burnell M, Zaikin A, Burchell J, Papadimitriou JT, Clausen H, Jacobs I, **Menon U***, Wandall HH*. Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. *Int J Cancer.* 2014 May 1;134(9):2180-88. PMID: PMC4234004. (* joint last and corresponding)
110. Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, Maurer MJ, Goergen KM, Fridley BL, Cunningham JM, Rider DN, Preston C, Hartmann LC, Lawrenson K, Wang C, Tyrer J, Song H, deFazio A, Johnatty SE, Doherty JA, Phelan CM, Sellers TA, Ramirez SM, Vitonis AF, Terry KL, Van Den Berg D, Pike MC, Wu AH, Berchuck A, Gentry-Maharaj A, Ramus SJ, Diergaard B, Shen H, Jensen A, Menkiszak J, Cybulski C, Lubinski J, Ziogas A, Rothstein JH, McGuire V, Sieh W, Lester J, Walsh C, Vergote I, Lambrechts S, Despierre E, Garcia-Closas M, Yang H, Brinton LA, Spiewankiewicz B, Rzepecka IK, Dansonka-Mieszkowska A, Seibold P, Rudolph A, Paddock LE, Orlow I, Lundvall L, Olson SH, Hogdall CK, Schwaab I, du Bois A, Harter P, Flanagan JM, Brown R, Paul J, Ekici AB, Beckmann MW, Hein A, Eccles D, Lurie G, Hays LE, Bean YT, Pejovic T, Goodman MT, Campbell I, Fasching PA, Konecny G, Kaye SB, Heitz F, Hogdall E, Bandera EV, Chang-Claude J, Kupryjanczyk J, Wentzensen N, Lambrechts D, Karlan BY, Whittemore AS, Culver HA, Gronwald J, Levine DA, Kjaer SK, **Menon U**, Schildkraut JM, Pearce CL, Cramer DW, Rossing MA, Chenevix-Trench G; AOCs group; ACS, Pharoah PD, Gayther SA, Ness RB, Odunsi K, Sucheston LE, Knutson KL, Goode EL. Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. *Cancer Immunol Res.* 2014 Apr;2(4):332-40. doi: 10.1158/2326-6066.CIR-13-0136. PMID: PMC4000890.
111. Gentry-Maharaj A, Taylor H, Kalsi J, Ryan A, Burnell M, Sharma A, Apostolidou S, Campbell S, Jacobs I, **Menon U**. Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *BMJ Open.* 2014 Mar 3;4(3):e004421. doi: 10.1136/bmjopen-2013-004421. PMID: PMC3939665.
112. Paddon HL, Thomson LJ, **Menon U**, Lanceley AE, Chatterjee HJ. Mixed methods evaluation of well-being benefits derived from a heritage-in-health intervention with hospital patients. *Arts Health.* 2014 Feb;6(1):24-58. PMID: PMC4285724.

113. Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, Rider DN, Sellers TA, Tworoger SS, Poole E, Risch HA, Salvesen HB, Kiemeny LA, Baglietto L, Giles GG, Severi G, Trabert B, Wentzensen N, Chenevix-Trench G; for AOCs/ACS group, Whittemore AS, Sieh W, Chang-Claude J, Bandera EV, Orlow I, Terry K, Goodman MT, Thompson PJ, Cook LS, Rossing MA, Ness RB, Narod SA, Kupryjanczyk J, Lu K, Butzow R, Dörk T, Pejovic T, Campbell I, Le ND, Bunker CH, Bogdanova N, Runnebaum IB, Eccles D, Paul J, Wu AH, Gayther SA, Hogdall E, Heitz F, Kaye SB, Karlan BY, Anton-Culver H, Gronwald J, Hogdall CK, Lambrechts D, Fasching PA, **Menon U**, Schildkraut J, Pearce CL, Levine DA, Kjaer SK, Cramer D, Flanagan JM, Phelan CM, Brown R, Massuger LF, Song H, Doherty JA, Krakstad C, Liang D, Odunsi K, Berchuck A, Jensen A, Lubinski J, Nevanlinna H, Bean YT, Lurie G, Ziogas A, Walsh C, Despierre E, Brinton L, Hein A, Rudolph A, Dansonka-Mieszkowska A, Olson SH, Harter P, Tyrer J, Vitonis AF, Brooks-Wilson A, Aben KK, Pike MC, Ramus SJ, Wik E, Cybulski C, Lin J, Sucheston L, Edwards R, McGuire V, Lester J, du Bois A, Lundvall L, Wang-Gohrke S, Szafron LM, Lambrechts S, Yang H, Beckmann MW, Pelttari LM, Van Altena AM, van den Berg D, Halle MK, Gentry-Maharaj A, Schwaab I, Chandran U, Menkiszak J, Ekici AB, Wilkens LR, Leminen A, Modugno F, Friel G, Rothstein JH, Vergote I, Garcia-Closas M, Hildebrandt MA, Sobiczewski P, Kelemen LE, Pharoah PD, Moysich K, Knutson KL, Cunningham JM, Fridley BL, Goode EL. Risk of ovarian cancer and the NF- κ B pathway: genetic association with IL1A and TNFSF10. *Cancer Res.* 2014 Feb 1;74(3):852-61. doi: 10.1158/0008-5472.CAN-13-1051. PMID: PMC3946482.
114. Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ; Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer), Risch HA, Rossing MA, Doherty JA, Goodman MT, Lurie G, Kjær SK, Hogdall E, Jensen A, Cramer DW, Terry KL, Vitonis A, Bandera EV, Olson S, King MG, Chandran U, Anton-Culver H, Ziogas A, **Menon U**, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pearce CL, Pike MC, Berchuck A, Schildkraut JM, Wentzensen N; Ovarian Cancer Association Consortium. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. *J Natl Cancer Inst.* 2014 Feb;106(2):djt431. doi: 10.1093/jnci/djt431. PMID: PMC3924755.
115. Anjum S, Fourkala EO, Zikan M, Wong A, Gentry-Maharaj A, Jones A, Hardy R, Cibula D, Kuh D, Jacobs IJ, Teschendorff AE, **Menon U**, Widschwendter M. A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. *Genome Med.* 2014 Jun 27;6(6):47. doi: 10.1186/gm567. PMID: PMC4110671.
116. Gentry-Maharaj A, Fourkala EO, Burnell M, Ryan A, Apostolidou S, Habib M, Sharma A, Parmar M, Jacobs I, **Menon U**. Concordance of National Cancer Registration with self-reported breast, bowel and lung cancer in England and Wales: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. *Br J Cancer.* 2013 Nov 26;109(11):2875-9. PMID: 24129231
117. Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, Intermaggio MP, Edlund CK, Ramus SJ, Gayther SA, Dubeau L, Fourkala EO, Zaikin A, **Menon U**, Jacobs IJ. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. *Lancet Oncol.* 2013 Nov;14(12):1226-32.

118. Low EL, Simon AE, Waller J, Wardle J, **Menon U**. Experience of symptoms indicative of gynaecological cancers in UK women. *Br J Cancer*. 2013 Aug 20;109(4):882-7.
119. Köbel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GL, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich K, Edwards R, Modugno F, Bunker C, Wozniak EL, Benjamin E, Gayther SA, Gentry-Maharaj A, **Menon U**, Gilks CB, Huntsman DG, Ramus SJ, Goode EL; Ovarian Tumor Tissue Analysis consortium. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. *Cancer Epidemiol Biomarkers Prev*. 2013 Oct;22(10):1677-86.
120. Iyer R, Gentry-Maharaj A, Nordin A, Liston R, Burnell M, Das N, Desai R, Gornall R, Beardmore-Gray A, Hillaby K, Leeson S, Linder A, Lopes A, Meechan D, Mould T, Nevin J, Olaitan A, Rufford B, Ryan A, Shanbhag S, Thackeray A, Wood N, Reynolds K, **Menon U**. Patient-reporting improves estimates of postoperative complication rates: a prospective cohort study in gynaecological oncology. *Br J Cancer*. 2013 Jul 11. PMID:23846170
121. Burford B, Gentry-Maharaj A, Graham R, Allen D, Pedersen JW, Nudelman AS, Blixt O, Fourkala EO, Bueti D, Dawnay A, Ford J, Desai R, David L, Trinder P, Acres B, Schwientek T, Gammerman A, Reis CA, Silva L, Osório H, Hallett R, Wandall HH, Mandel U, Hollingsworth MA, Jacobs I, Fentiman I, Clausen H*, Taylor-Papadimitriou J*, **Menon U***, Burchell JM*. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. *Br J Cancer*. 2013 May 28;108(10):2045-55.doi: 10.1038/bjc.2013.214. PMID:23652307 * equal contribution
122. Low EL, Waller J, **Menon U**, Jones A, Reid F, Simon AE. Ovarian cancer symptom awareness and anticipated time to help-seeking for symptoms among UK women. *J Fam Plann Reprod Health Care*. 2013 Jul;39(3):163-71. doi: 10.1136/jfprhc-2012-100473.
123. Ander E, Thomson L, Blair K, Noble G, **Menon U**, Lanceley A, Chatterjee H. Using museum objects to improve wellbeing in mental health service users and neurological rehabilitation clients. *The British Journal of Occupational Therapy*, May 2013 Vol 76 (5); p208-217.
124. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, Lawrenson K, Stutz MD, Lu Y, Karevan R, Woods N, Johnston RL, French JD, Chen X, Weischer M, Nielsen SF, Maranian MJ, Ghoussaini M, Ahmed S, Baynes C, Bolla MK, Wang Q, Dennis J, McGuffog L, Barrowdale D, Lee A, Healey S, Lush M, Tessier DC, Vincent D, Bacot F; Australian Cancer Study; Australian Ovarian Cancer Study; Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab); Gene Environment Interaction and Breast Cancer (GENICA); Swedish Breast Cancer Study (SWE-BRCA); Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); Epidemiological study of BRCA1 & BRCA2 Mutation Carriers (EMBRACE); Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO), Vergote I, Lambrechts S, Despierre E, Risch HA, González-Neira A, Rossing MA, Pita G, Doherty JA, Alvarez N, Larson MC, Fridley BL, Schoof N, Chang-Claude J, Cicek MS, Peto J, Kalli KR, Broeks A, Armasu SM, Schmidt MK, Braaf LM, Winterhoff B, Nevanlinna H, Konecny GE, Lambrechts D, Rogmann L, Guénel P, Teoman A, Milne RL, Garcia JJ, Cox A, Shridhar V, Burwinkel B, Marme F, Hein R, Sawyer EJ, Haiman CA, Wang-Gohrke S,

Andrulis IL, Moysich KB, Hopper JL, Odunsi K, Lindblom A, Giles GG, Brenner H, Simard J, Lurie G, Fasching PA, Carney ME, Radice P, Wilkens LR, Swerdlow A, Goodman MT, Brauch H, Garcia-Closas M, Hillemanns P, Winqvist R, Dürst M, Devilee P, Runnebaum I, Jakubowska A, Lubinski J, Mannermaa A, Butzow R, Bogdanova NV, Dörk T, Pelttari LM, Zheng W, Leminen A, Anton-Culver H, Bunker CH, Kristensen V, Ness RB, Muir K, Edwards R, Meindl A, Heitz F, Matsuo K, du Bois A, Wu AH, Harter P, Teo SH, Schwaab I, Shu XO, Blot W, Hosono S, Kang D, Nakanishi T, Hartman M, Yatabe Y, Hamann U, Karlan BY, Sangrajrang S, Kjaer SK, Gaborieau V, Jensen A, Eccles D, Høgdall E, Shen CY, Brown J, Woo YL, Shah M, Azmi MA, Luben R, Omar SZ, Czene K, Vierkant RA, Nordestgaard BG, Flyger H, Vachon C, Olson JE, Wang X, Levine DA, Rudolph A, Weber RP, Flesch-Janys D, Iversen E, Nickels S, Schildkraut JM, Silva Idos S, Cramer DW, Gibson L, Terry KL, Fletcher O, Vitonis AF, van der Schoot CE, Poole EM, Hogervorst FB, Tworoger SS, Liu J, Bandera EV, Li J, Olson SH, Humphreys K, Orlow I, Blomqvist C, Rodriguez-Rodriguez L, Aittomäki K, Salvesen HB, Muranen TA, Wik E, Brouwers B, Krakstad C, Wauters E, Halle MK, Wildiers H, Kiemeny LA, Mulot C, Aben KK, Laurent-Puig P, Altena AM, Truong T, Massuger LF, Benitez J, Pejovic T, Perez JJ, Hoatlin M, Zamora MP, Cook LS, Balasubramanian SP, Kelemen LE, Schneeweiss A, Le ND, Sohn C, Brooks-Wilson A, Tomlinson I, Kerin MJ, Miller N, Cybulski C, Henderson BE, Menkiszak J, Schumacher F, Wentzensen N, Le Marchand L, Yang HP, Mulligan AM, Glendon G, Engelholm SA, Knight JA, Høgdall CK, Apicella C, Gore M, Tsimiklis H, Song H, Southey MC, Jager A, den Ouweland AM, Brown R, Martens JW, Flanagan JM, Kriege M, Paul J, Margolin S, Siddiqui N, Severi G, Whittemore AS, Baglietto L, McGuire V, Stegmaier C, Sieh W, Müller H, Arndt V, Labrèche F, Gao YT, Goldberg MS, Yang G, Dumont M, McLaughlin JR, Hartmann A, Ekici AB, Beckmann MW, Phelan CM, Lux MP, Permutth-Wey J, Peissel B, Sellers TA, Ficarazzi F, Barile M, Ziogas A, Ashworth A, Gentry-Maharaj A, Jones M, Ramus SJ, Orr N, **Menon U**, Pearce CL, Brüning T, Pike MC, Ko YD, Lissowska J, Figueroa J, Kupryjanczyk J, Chanock SJ, Dansonka-Mieszkowska A, Jukkola-Vuorinen A, Rzepecka IK, Pylkäs K, Bidzinski M, Kauppila S, Hollestelle A, Seynaeve C, Tollenaar RA, Durda K, Jaworska K, Hartikainen JM, Kosma VM, Kataja V, Antonenkova NN, Long J, Shrubsole M, Deming-Halverson S, Lophatananon A, Siriwanarangsana P, Stewart-Brown S, Ditsch N, Lichtner P, Schmutzler RK, Ito H, Iwata H, Tajima K, Tseng CC, Stram DO, van den Berg D, Yip CH, Ikram MK, Teh YC, Cai H, Lu W, Signorello LB, Cai Q, Noh DY, Yoo KY, Miao H, Iau PT, Teo YY, McKay J, Shapiro C, Ademuyiwa F, Fountzilas G, Hsiung CN, Yu JC, Hou MF, Healey CS, Luccarini C, Peock S, Stoppa-Lyonnet D, Peterlongo P, Rebbeck TR, Piedmonte M, Singer CF, Friedman E, Thomassen M, Offit K, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Garber J, Narod SA, Weitzel JN, Montagna M, Olah E, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Ilyanov EN, Tihomirova L, Arun BK, Campbell I, Mensenkamp AR, van Asperen CJ, van Roozendaal KE, Meijers-Heijboer H, Collée JM, Oosterwijk JC, Hooning MJ, Rookus MA, van der Luijt RB, Os TA, Evans DG, Frost D, Fineberg E, Barwell J, Walker L, Kennedy MJ, Platte R, Davidson R, Ellis SD, Cole T, Bressac-de Paillerets B, Buecher B, Damiola F, Faivre L, Frenay M, Sinilnikova OM, Caron O, Giraud S, Mazoyer S, Bonadona V, Caux-Moncoutier V, Toloczko-Grabarek A, Gronwald J, Byrski T, Spurdle AB, Bonanni B, Zaffaroni D, Giannini G, Bernard L, Dolcetti R, Manoukian S, Arnold N, Engel C, Deissler H, Rhiem K, Niederacher D, Plendl H, Sutter C, Wappenschmidt B, Borg A, Melin B, Rantala J, Soller M, Nathanson KL, Domchek SM, Rodriguez GC, Salani R, Kaulich DG, Tea MK, Paluch SS, Laitman Y, Skytte AB, Kruse TA, Jensen UB, Robson

- M, Gerdes AM, Ejlertsen B, Foretova L, Savage SA, Lester J, Soucy P, Kuchenbaecker KB, Olswold C, Cunningham JM, Slager S, Pankratz VS, Dicks E, Lakhani SR, Couch FJ, Hall P, Monteiro AN, Gayther SA, Pharoah PD, Reddel RR, Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench G, Dunning AM. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nat Genet.* 2013 Apr;45(4):371-84.
125. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, Larson MC, Song H, Tessier DC, Bacot F, Vincent D, Cunningham JM, Dennis J, Dicks E; stralian Cancer Study; Australian Ovarian Cancer Study Group, Aben KK, Anton-Culver H, Antonenkova N, Armasu SM, Baglietto L, Bandera EV, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brenton JD, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Campbell I, Carney ME, Carvalho RS, Chang-Claude J, Chen YA, Chen Z, Chow WH, Cicek MS, Coetzee G, Cook LS, Cramer DW, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher D, Flanagan J, Gao YT, Garcia-Closas M, Gentry-Maharaj A, Giles G, Gjyshi A, Gore M, Gronwald J, Guo Q, Halle MK, Harter P, Hein A, Heitz F, Hillemanns P, Hoatlin M, Høgdall E, Høgdall CK, Hosono S, Jakubowska A, Jensen A, Kalli KR, Karlan BY, Kelemen LE, Kiemeny LA, Kjaer SK, Konecny GE, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee N, Lee J, Leminen A, Lim BK, Lissowska J, Lubiński J, Lundvall L, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, **Menon U**, Modugno F, Moysich KB, Nakanishi T, Narod SA, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson S, Orlow I, Paul J, Pejovic T, Pelttari LM, Permut-Wey J, Pike MC, Poole EM, Qu X, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum I, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shen H, Shridhar V, Shu XO, Sieh W, Southey MC, Spellman P, Tajima K, Teo SH, Terry KL, Thompson PJ, Timorek A, Tworoger SS, van Altena AM, van den Berg D, Vergote I, Vierkant RA, Vitonis AF, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wik E, Winterhoff B, Woo YL, Wu AH, Yang HP, Zheng W, Ziogas A, Zulkifli F, Goodman MT, Hall P, Easton DF, Pearce CL, Berchuck A, Chenevix-Trench G, Iversen E, Monteiro AN, Gayther SA, Schildkraut JM, Sellers TA. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nat Genet.* 2013 Apr;45(4):362-70.
126. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Köbel M; PRACTICAL Consortium, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Ling Woo Y, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Palmieri Weber R, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Anne Rossing M, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Zawiah Omar S, Olson SH, Odunsi K, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, **Menon U**, McLaughlin JR, McGuire V, Matsuo K, Mat Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubiński J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Krüger Kjaer S, Kiemeny LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, Jakubowska A, Iversen E, Hosono S, Høgdall CK, Høgdall E,

- Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle MK, Hall P, Gronwald J, Gore M, Goodman MT, Giles GG, Gentry-Maharaj A, Garcia-Closas M, Flanagan JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Easton DF, Dürst M, du Bois A, Dörk T, Doherty JA, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer DW, Cook LS, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker CH, Brueggmann D, Brown R, Brooks-Wilson A, Brinton LA, Bogdanova N, Block MS, Benjamin E, Beesley J, Beckmann MW, Bandera EV, Baglietto L, Bacot F, Armasu SM, Antonenkova N, Anton-Culver H, Aben KK, Liang D, Wu X, Lu K, Hildebrandt MA; stralian Ovarian Cancer Study Group; stralian Cancer Study, Schildkraut JM, Sellers TA, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, Goode EL, Leigh Pearce C. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nat Commun.* 2013 Mar 27;4:1628
127. Permut-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Ann Chen Y, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM; stralian Cancer Study; stralian Ovarian Cancer Study, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA; Consortium of Investigators of Modifiers of BRCA1/2, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Górski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Høgdall CK, Høgdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeny LA, Kikkawa F, Konecny GE, Krakstad C, Krüger Kjaer S, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Kiong Lim B, Lin J, Lissowska J, Lu KH, Lubiński J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, **Menon U**, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlov I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Anne Rossing M, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shridhar V, Shu XO, Shvetsov YB, Sieh W, Song H, Southey MC, Spiewankiewicz B, Stram D, Sutphen R, Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, Vergote I, Vierkant RA, Vincent D, Vitonis AF, Wang-Gohrke S, Palmieri Weber R, Wentzensen N, Whittemore AS, Wik E, Wilkens LR, Winterhoff B, Ling Woo Y, Wu AH, Xiang YB, Yang HP, Zheng W, Ziogas A, Zulkifli F, Phelan CM, Iversen E, Schildkraut JM, Berchuck A, Fridley BL, Goode EL, Pharoah PD, Monteiro AN, Sellers TA, Gayther SA. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nat Commun.* 2013 Mar 27;4:1627
128. Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, Rossing MA, Terry KL, Wu AH; The Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group, Risch HA, Yu H, Doherty JA, Chang-Claude J, Hein R, Nickels S, Wang-Gohrke S, Goodman MT, Carney ME, Matsuno RK, Lurie G, Moysich K, Kjaer SK, Jensen A, Hogdall E, Goode EL, Fridley BL, Vierkant RA, Larson MC, Schildkraut J, Hoyo C, Moorman P, Weber RP, Cramer DW, Vitonis AF, Bandera EV, Olson SH, Rodriguez-

- Rodriguez L, King M, Brinton LA, Yang H, Garcia-Closas M, Lissowska J, Anton-Culver H, Ziogas A, Gayther SA, Ramus SJ, **Menon U**, Gentry-Maharaj A, Webb PM; the Ovarian Cancer Association Consortium. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. *Endocr Relat Cancer*. 2013 Mar 22;20(2):251-262.
129. White KL, Vierkant RA, Fogarty Z, Charbonneau B, Block MS, Pharoah PD, Chenevix-Trench G, Rossing MA, Cramer DW, Pearce L, Schildkraut JM, **Menon U**, Kruger Kjær S, Levine DA, Gronwald J, Anton-Culver H, Whittemore AS, Karlan BY, Lambrechts D, Wentzensen N, Kupryjanczyk J, Chang-Claude J, Bandera EV, Hogdall EV, Heitz F, Kaye S, Fasching PA, Campbell IG, Goodman MT, Pejovic T, Bean YT, Lurie G, Eccles D, Hein A, Beckmann MW, Ekici AB, Paul J, Brown R, Flanagan JM, Harter P, du Bois A, Schwaab I, Hogdall CK, Lundvall L, Olson SH, Orlow I, Paddock LE, Rudolph A, Eilber U, Dansonka-Mieszkowska A, Rzepecka IK, Ziolkowska-Seta I, Brinton LA, Yang HP, Garcia-Closas M, Despierre E, Lambrechts S, Vergote I, Walsh C, Lester J, Sieh W, McGuire V, Rothstein JH, Ziogas A, Lubinski J, Cybulski C, Menkiszak J, Jensen A, Gayther SA, Ramus SJ, Gentry-Maharaj A, Berchuck A, Wu AH, Pike MC, Van Den Berg D, Terry KL, Vitonis AF, Doherty JA, Johnatty SE, Defazio A, Song H, Tyrer J, Sellers TA, Phelan CM, Kalli KR, Cunningham JM, Fridley BL, Goode EL. Analysis of Over 10,000 Cases Finds No Association between Previously-Reported Candidate Polymorphisms and Ovarian Cancer Outcome. *Cancer Epidemiol Biomarkers Prev*. 2013 Mar 19.
130. Pearce CL, Rossing MA, Lee AW, Ness RB, Webb PM, Chenevix-Trench G, Jordan SJ, Stram DA, Chang-Claude J, Hein R, Nickels S, Lurie G, Thompson PJ, Carney ME, Goodman MT, Moysich KB, Hogdall EV, Jensen A, Goode EL, Fridley BL, Cunningham JM, Vierkant RA, Weber RP, Ziogas A, Anton-Culver H, Gayther SA, Gentry-Maharaj A, **Menon U**, Ramus SJ, Brinton LA, Wentzensen N, Lissowska J, Garcia-Closas M, Massuger L, Kiemenev LA, van Altena AM, Aben KK, Berchuck A, Doherty JA, Iversen E, McGuire V, Moorman PG, Pharoah PD, Pike MC, Risch HA, Sieh W, Stram DO, Terry KL, Whittemore AS, Wu A, Schildkraut JM, Kjaer SK. Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. *Cancer Epidemiol Biomarkers Prev*. 2013 Mar 5.
131. Faber MT, Kjær SK, Dehlendorff C, Chang-Claude J, Andersen KK, Høgdall E, Webb PM, Jordan SJ; The Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group, Rossing MA, Doherty JA, Lurie G, Thompson PJ, Carney ME, Goodman MT, Ness RB, Modugno F, Edwards RP, Bunker CH, Goode EL, Fridley BL, Vierkant RA, Larson MC, Schildkraut J, Cramer DW, Terry KL, Vitonis AF, Bandera EV, Olson SH, King M, Chandran U, Kiemenev LA, Massuger LF, van Altena AM, Vermeulen SH, Brinton L, Wentzensen N, Lissowska J, Yang HP, Moysich KB, Odunsi K, Kasza K, Odunsi-Akanji O, Song H, Pharaoh P, Shah M, Whittemore AS, McGuire V, Sieh W, Sutphen R, **Menon U**, Gayther SA, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Pike MC, Risch HA, Jensen A; On behalf of the Ovarian Cancer Association Consortium. Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. *Cancer Causes Control*. 2013 Mar 2.
132. Chen K, Gentry-Maharaj A, Burnell M, Steentoft C, Marcos-Silva L, Mandel U, Jacobs I, Dawnay A, **Menon U***, Blixt O*. (*joint last author) Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. *J Proteome Res*. 2013 Mar 1;12(3):1408-18.

133. Gentry-Maharaj A, Sharma A, Burnell M, Ryan A, Amso NN, Seif MW, Turner G, Brunell C, Fletcher G, Rangar R, Fallowfield L, Campbell S, Jacobs I, **Menon U**. Acceptance of transvaginal sonography by postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. *Ultrasound Obstet Gynecol*. 2013 Jan;41(1):73-9.
134. Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, Hadwin R, Cafferty FH, Benjamin E, Singh N, Evans DG, Eccles DM, Skates SJ, Mackay J, **Menon U**, Jacobs IJ. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. *J Clin Oncol*. 2013 Jan 1;31(1):49-57.
135. Brain KE, Lifford KJ, Fraser L, Rosenthal AN, Rogers MT, Lancaster D, Phelps C, Watson EK, Clements A, **Menon U**. Psychological outcomes of familial ovarian cancer screening: no evidence of long-term harm. *Gynecol Oncol*. 2012 Dec;127(3):556-63.
136. Pedersen JW, Gentry-Maharaj A, Fourkala EO, Dawnay A, Burnell M, Zaikin A, Pedersen AE, Jacobs I, **Menon U***, Wandall HH*. Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer. *Br J Cancer*. 2012 Nov 20. doi: 10.1038/bjc.2012.517. (* joint last and corresponding)
137. Thomson LJ, Ander EE, **Menon U**, Lanceley A, Chatterjee HJ. Enhancing cancerpatient well-being with a nonpharmacological, heritage-focused intervention. *Journal of Pain Symptom Manage*. 2012 Nov;44(5):731-40.
138. Thomson L, Ander E, **Menon U**, Lanceley A, Chatterjee H. Quantitative evidence for wellbeing benefits from a heritage-in-health intervention with hospital patients. *International Journal of Art Therapy*, 2012, Vol.17(2), p.63-79
139. Hamajima N, Hirose K, Tajima K, Rohan T, Friedenreich CM, Calle EE, Gapstur SM, Patel AV, Coates RJ, Liff JM, Talamini R, Chantarakul N, Koetsawang S, Rachawat D, Marcou Y, Kakouri E, Duffy SW, Morabia A, Schuman L, Stewart W, Szklo M, Coogan PF, Palmer JR, Rosenberg L, Band P, Coldman AJ, Gallagher RP, Hislop TG, Yang P, Cummings SR, Canfell K, Sitas F, Chao P, Lissowska J, Horn-Ross PL, John EM, Kolonel LM, Nomura AMY, Ghiasvand R, Hu J, Johnson KC, Mao Y, Beral V, Bull D, Callaghan K, Crossley B, Goodill A, Green J, Hermon C, Key T, Lindgard I, Liu B, Pirie K, Reeves G, Collins R, Doll R, Peto R, Bishop T, Fentiman IS, De Sanjose S, Gonzalez CA, Lee N, Marchbanks P, Ory HW, Peterson HB, Wingo P, Ebeling K, Kunde D, Nishan P, Hopper JL, Eliassen H, Hankinson S, Gajalakshmi V, Martin N, Pardthaisong T, Silpisornkosol S, Theetranont C, Boosiri B, Chutivongse S, Jimakorn P, Virutamasen P, Wongsrichanalai C, Neugut A, Santella R, Baines CJ, Kreiger N, Miller AB, Wall C, Tjonneland A, Jorgensen T, Stahlberg C, Pedersen AT, Flesch-Janys D, Hakansson N, Cauley J, Heuch I, Adami HO, Persson I, Weiderpass E, Magnusson C, Chang-Claude J, Kaaks R, McCredie M, Paul C, Skegg DCG, Spears GFS, Iwasaki M, Tsugane S, Anderson G, Daling JR, Hampton J, Hutchinson WB, Li CI, Malone K, Mandelson M, Newcomb P, Noonan EA, Ray RM, Stanford JL, Tang MTC, Thomas DB, Weiss NS, White E, Izquierdo A, Viladiu P, Fourkala EO, Jacobs I, **Menon U**, Ryan A, Cuevas HR, Ontiveros P, Palet A, Salazar SB, Aristizabal N, Cuadros A, Tryggvadottir L, Tulinius H, Riboli E, Andrieu N, Bachelot A, Le MG, Bremond A, Gairard B, Lansac J, Piana L, Renaud R, Clavel-Chapelon F, Fournier A, Touillaud M, Mesrine S, Chabbert-Buffet N, Boutron-Ruault MC, Wolk A, Torres-Mejia G, Franceschi S, Romieu I, Boyle P, Lubin F, Modan B, Ron E, Wax Y, Friedman GD, Hiatt RA, Levi F, Kosmelj K, Primic-Zakelj M, Ravnihar B, Stare J, Ekblom A, Erlandsson G, Beeson WL, Fraser G, Peto J, Hanson RL, Leske MC, Mahoney MC, Nasca PC, Varma AO, Weinstein

- AL, Hartman ML, Olsson H, Goldbohm RA, van den Brandt PA, Palli D, Teitelbaum S, Apelo RA, Baens J, de la Cruz JR, Javier B, Lacaya LB, Ngelangel CA, La Vecchia C, Negri E, Marubini E, Ferraroni M, Pike MC, Gerber M, Richardson S, Segala C, Gatei D, Kenya P, Kungu A, Mati JG, Brinton LA, Freedman M, Hoover R, Schairer C, Ziegler R, Banks E, Spirtas R, Lee HP, Rookus MA, van Leeuwen FE, Schoenberg JA, Graff-Iversen S, Selmer R, Jones L, McPherson K, Neil A, Vessey M, Yeates D, Mabuchi K, Preston D, Hannaford P, Kay C, McCann SE, Rosero-Bixby L, Gao YT, Jin F, Yuan J-M, Wei HY, Yun T, Zhiheng C, Berry G, Cooper Booth J, Jelichovsky T, MacLennan R, Shearman R, Hadjisavvas A, Kyriacou K, Loisdou M, Zhou X, Wang Q-S, Kawai M, Minami Y, Tsuji I, Lund E, Kumle M, Stalsberg H, Shu XO, Zheng W, Monninkhof EM, Onland-Moret NC, Peeters PHM, Katsouyanni K, Trichopoulou A, Trichopoulos D, Tzonou A, Baltzell KA, Dabancens A, Martinez L, Molina R, Salas O, Alexander FE, Anderson K, Folsom AR, Gammon MD, Hulka BS, Millikan R, Chilvers CED, Lumachi F, Bain C, Schofield F, Siskind V, Rebbeck TR, Bernstein LR, Enger S, Haile RW, Paganini-Hill A, Ross RK, Ursin G, Wu AH, Yu MC, Ewertz M, Clarke EA, Bergkvist L, Anderson GL, Gass M, O'Sullivan MJ, Kalache A, Farley TMM, Holck S, Meirik O, Fukao A Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. *Lancet Oncol.* 2012 Nov;13(11):1141-51. doi: 10.1016/S1470-2045(12)70425-4. Epub 2012 Oct 17
140. Sharma A, Apostolidou S, Burnell M, Campbell S, Habib M, Gentry-Maharaj A, Amso N, Seif MW, Fletcher G, Singh N, Benjamin E, Brunell C, Turner G, Rangar R, Godfrey K, Oram D, Herod J, Williamson K, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Fourkala EO, Ryan A, Parmar M, Jacobs I, **Menon U**. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). *Ultrasound Obstet Gynecol.* 2012 Sep;40(3):338-44.
 141. Manchanda R, Saridogan E, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, Side L, Gessler S, Jacobs I, **Menon U**. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). *Arch Gynecol Obstet.* 2012 Dec;286(6):1555-62. doi: 10.1007/s00404-012-2492-2. Epub 2012 Aug 4.
 142. Manchanda R, Silvano A, Abdelraheim A, Burnell M, Johnson M, Saridogan E, Rosenthal AN, Brunell C, Aslam N, Vashisht A, Pandis G, Jacobs I, **Menon U**, Benjamin E. Diathermy-induced injury may affect detection of occult tubal lesions at risk-reducing salpingo-oophorectomy. *Int J Gynecol Cancer.* 2012 Jun;22(5):881-8.
 143. Devetyarov D, Nouretdinov I, Burford B, Camuzeaux S, Gentry-Maharaj A, Tiss A, Smith C, Luo Z, Chervonenkis A, Hallett R, Vovk V, Waterfield M, Cramer R, Timms J, Sinclair J, **Menon U**, Jacobs I, Gammerman A. Conformal predictors in early diagnostics of ovarian and breast cancers. *Progress in artificial intelligence*, Volume 1, Number 3 (June 2012), 245 257.
 144. Fourkala EO, Gentry-Maharaj A, Burnell M, Ryan A, Manchanda R, Dawnay A, Jacobs I, Widschwendter M, **Menon U**. Histological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. *Br J Cancer.* 2012 May 17. doi: 10.1038/bjc.2012.155.
 145. Manchanda R, Burnell M, Abdelraheim A, Johnson M, Sharma A, Benjamin E, Brunell C, Saridogan E, Gessler S, Oram D, Side L, Rosenthal A, Jacobs I, **Menon U**. Factors

- influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis. *BJOG*. 2012 Apr;119(5):527-536. doi: 10.1111/j.1471-0528.2011.03257.
146. Thomson, L.J., Ander, E.E., **Menon, U.**, Lanceley, A. & Chatterjee, H.J. (In Review). Quantitative evidence for wellbeing benefits from a heritage-in-health intervention with hospital patients. *International Journal of Art Therapy* 2012.
 147. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, **Menon U**, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A, on behalf of the Ovarian Cancer Association Consortium. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncol* 21 Feb 2012.
 148. Fridley BL, Jenkins GD, Tsai YY, Song H, Bolton KL, Fenstermacher D, Tyrer J, Ramus SJ, Cunningham JM, Vierkant RA, Chen Z, Chen YA, Iversen E, **Menon U**, Gentry-Maharaj A, Schildkraut J, Sutphen R, Gayther SA, Hartmann LC, Pharoah PD, Sellers TA, Goode EL. Gene Set Analysis of Survival Following Ovarian Cancer Implicates Macrolide Binding and Intracellular Signaling Genes. *Gene Set Analysis of Survival Following Ovarian Cancer Implicates Macrolide Binding and Intracellular Signaling Genes*. *Cancer Epidemiol Biomarkers Prev* 02 Feb 2012.
 149. Lim AW, Mesher D, Gentry-Maharaj A, Balogun N, Jacobs I, **Menon U***, Sasieni P*. (joint) Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes. *J Natl Cancer Inst*. 2012 Jan 18;104(2):114-24.
 150. Vaes E, Manchanda R, Autier P, Nir R, Nir D, Bleiberg H, Robert A, **Menon U**. Differential diagnosis of adnexal masses: sequential use of the risk of malignancy index and HistoScanning, a novel computer-aided diagnostic tool. *Ultrasound Obstet Gynecol*. 2012 Jan;39(1):91-8.
 151. Thomson, L.J., Ander, E.E., **Menon, U.**, Lanceley, A. and Chatterjee, H.J. Enhancing cancer patient well-being with a nonpharmacological, heritage-focused intervention. *Journal of Pain and Symptom Management*, 44(5), Nov 2012, 731-740.
 152. Ander, E.E., Thomson, L.J., Noble, G., Lanceley, A., **Menon, U.** and Chatterjee, H.J. Heritage, health and wellbeing: Assessing the impact of a heritage focused intervention on health and wellbeing. *International Journal of Heritage Studies*, 19(3), May 2013, 229-242.
 153. Sengupta SB, Vadaparampil ST, **Menon U**. Preimplantation genetic diagnosis for hereditary cancers. *Adv Exp Med Biol* 732:103-113 2012.
 154. Thomson, L.J., Ander, E.A., **Menon, U.**, Lanceley, A. & Chatterjee, H.J. Evaluating the therapeutic effects of museum object handling with hospital patients: A review and initial trial of wellbeing measures. *Journal of Applied Arts and Health*, 2(1), 37-56. 2011.
 155. Fourkala EO, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J, Gunu R, Soromani C, Hasenbrink G, Jacobs I, Dawnay A, Widschwendter M, Lichtenberg-Fraté H, **Menon U**. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. *Endocr Relat Cancer* 23 Dec 2011.

156. Lanceley A, Noble G, Johnson M, Balogun N, Chatterjee H, **Menon U**. Investigating the Therapeutic Potential of a Heritage-Object Focused Intervention: a Qualitative Study. *J Health Psychol* 21 Nov 2011.
157. Timms JF, **Menon U**, Devetyarov D, Tiss A, Camuzeaux S, McCurrie K, Nouretdinov I, Burford B, Smith C, Gentry-Maharaj A, et al. Hallett R, Ford J, Luo Z, Vovk V, Gammerman A, Cramer R, Jacobs I. Early Detection of Ovarian Cancer in Samples Pre-Diagnosis Using CA125 and MALDI-MS Peaks. *Cancer Genomics Proteomics* 8(6):289-305 Nov 2011.
158. Manchanda R, Drapkin R, Jacobs I, **Menon U**. The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. *Gynecol Oncol*. 2012 Feb;124(2):185-91. doi: 10.1016/j.ygyno.2011.10.017. Epub 2011 Oct 20.
159. Hunter M, Gentry-Maharaj A, Ryan A, Burnell M, Lanceley A, Fraser L, Jacobs I, **Menon U**. Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10418 British women aged 54-65. *BJOG* 19 Oct 2011.
160. Lifford KJ, Fraser L, Rosenthal AN, Rogers MT, Lancaster D, Phelps C, Watson EK, Clements A, Iredale R, Jacobs I, **Menon U***, Brain KE*. (joint). Withdrawal from familial ovarian cancer screening for surgery: Findings from a psychological evaluation study (PsyFOCS). *Gynecol Oncol* 13 Oct 2011.
161. Beesley J, Pickett HA, Johnatty SE, Dunning AM, Chen X, Li J, Michailidou K, Lu Y, Rider DN, Palmieri RT, Stutz MD, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Chang-Claude J, Nickels S, Vrieling A, Flesch-Janys D, Wang-Gohrke S, Eilber U, Bogdanova N, Antonenkova N, Runnebaum IB, Dörk T, Goodman MT, Lurie G, Wilkens LR, Matsuno RK, Kiemeny LA, Aben KK, Mares T, Massuger LF, Fridley BL, Vierkant RA, Bandera EV, Olson SH, Orlov I, Rodriguez-Rodriguez L, Cook LS, Le ND, Brooks-Wilson A, Kelemen LE, Campbell I, Gayther SA, Ramus SJ, Gentry-Maharaj A, **Menon U**, Ahmed S, Baynes C, Pharoah PD, Investigators K; Australian Ovarian Cancer Study Group; ABCTB Investigators, Muir K, Lophatananon A, Chaiwerawattana A, Wiangnon S, Macgregor S, Easton DF, Reddel RR, Goode EL, Chenevix-Trench G; on behalf of the Ovarian Cancer Association Consortium. Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. *PLoS One*. 2011;6(9):e24987.
162. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, **Menon U**, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. *Nat Rev Cancer*. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144.
163. Simon AE, Wardle J, Grimmett C, Power E, Corker E, **Menon U**, Matheson L, Waller J. Ovarian and cervical cancer awareness: development of two validated measurement tools. *J Fam Plann Reprod Health Care*. 2011 Sep 20.
164. Sharma A, Gentry-Maharaj A, Burnell M, Fourkala EO, Campbell S, Amso N, Seif M, Ryan A, Parmar M, Jacobs I, **Menon U**, Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian

- Cancer Screening (UKCTOCS): a prospective cohort study. *BJOG*. 2012 Jan;119(2):207-19.
165. Vaes E, Manchanda R, Autier P, Nir R, Nir D, Bleiberg H, Robert A, **Menon U**. Differential diagnosis of adnexal masses: A sequential use of the Risk of Malignancy Index and a novel computer aided diagnostic tool. *Ultrasound Obstet Gynecol* 21 Jun 2011.
 166. Terry KL, Vitonis AF, Hernandez D, Lurie G, Song H, Ramus SJ, Titus-Ernstoff L, Carney ME, Wilkens LR, Gentry-Maharaj A, **Menon U**, Gayther SA, Pharoah PD, Goodman MT, Cramer DW, Birrer MJ. A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies. *Int J Mol Epidemiol Genet*. 2010 Jul 26;1(4):272-7.
 167. Permeth-Wey J, Chen Z, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Chanock SJ, Cramer DW, Cunningham JM, et al. Fenstermacher D, Fridley BL, Garcia-Closas M, Gayther SA, Gentry-Maharaj A, Gonzalez Bosquet J, Iversen E, Jim H, McLaughlin J, **Menon U**, Narod SA, Phelan CM, Ramus SJ, Risch H, Song H, Sutphen R, Terry KL, Tyrer J, Vierkant RA, Wentzensen N, Lancaster JM, Cheng JQ, Berchuck A, Pharoah PD, Schildkraut JM, Goode EL, Sellers TA. MicroRNA Processing and Binding Site Polymorphisms are not Replicated in the Ovarian Cancer Association Consortium. *Cancer Epidemiol Biomarkers Prev* 02 Jun 2011.
 168. Amankwah EK, Kelemen LE, Wang Q, Song H, Chenevix-Trench G, Beesley J, Webb PM, Pearce CL, Wu AH, Pike MC, Stram DO, Chang-Claude J, Wang-Gohrke S, Ness RB, Goode EL, Cunningham JM, Fridley BL, Vierkant RA, Tworoger SS, Whittemore AS, McGuire V, Sieh W, Gayther SA, Gentry-Maharaj A, **Menon U**, Ramus SJ, Rossing MA, Doherty JA, Goodman MT, Carney ME, Lurie G, Wilkens LR, Kjaer SK, Hogdall EV, Cramer DW, Terry KL, Garcia-Closas M, Yang HP, Lissowska J, Anton-Culver HA, Ziogas A, Schildkraut J, Berchuck A, Pharoah PD. Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 23 Mar 2011.
 169. Pearce CL, Doherty JA, Van Den Berg DJ, Moysich K, Hsu C, Cushing-Haugen KL, Conti DV, Ramus SJ, Gentry-Maharaj A, **Menon U**, Gayther SA, Pharoah PD, Song H, Kjaer SK, Hogdall E, Hogdall C, Whittemore AS, McGuire V, Sieh W, Gronwald J, Medrek K, Jakubowska A, Lubinski J, Chenevix-Trench G, AOCs/ACS Study Group, Beesley J, Webb PM, Berchuck A, Schildkraut JM, Iversen ES, Moorman PG, Edlund CK, Stram DO, Pike MC, Ness RB, Rossing MA, Wu AH. Genetic Variation in Insulin-like Growth Factor 2 May Play a Role in Ovarian Cancer Risk. *Hum Mol Genet* 21 Mar 2011.
 170. Manchanda R, Abdelraheim A, Johnson M, Rosenthal A, Benjamin E, Brunell C, Burnell M, Side L, Gessler S, Saridogan E, Oram D, Jacobs I, **Menon U**. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. *BJOG*. 2011 Mar 10. doi: 10.1111/j.1471-0528.2011.02920.
 171. Amankwah EK, Wang Q, Schildkraut JM, Tsai YY, Ramus SJ, Fridley BL, Beesley J, Johnatty SE, Webb PM, Chenevix-Trench G, et al. Australian Ovarian Cancer Study Group, Dale LC, Lambrechts D, Amant F, Despierre E, Vergote I, Gayther SA, Gentry-Maharaj A, **Menon U**, Chang-Claude J, Wang-Gohrke S, Anton-Culver H, Ziogas A, Dörk T, Dürst M, Antonenkova N, Bogdanova N, Brown R, Flanagan JM, Kaye SB, Paul J, Bützow R, Nevanlinna H, Campbell I, Eccles DM, Karlan BY, Gross J, Walsh C, Pharoah PD, Song H, Krüger Kjær S, Høgdall E, Høgdall C, Lundvall L, Nedergaard L, Kiemenev LA, Massuger LF, van Altena AM, Vermeulen SH, Le ND, Brooks-Wilson A, Cook LS,

- Phelan CM, Cunningham JM, Vachon CM, Vierkant RA, Iversen ES, Berchuck A, Goode EL, Sellers TA, Kelemen LE. Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the ovarian cancer association consortium. *PLoS One* 6(5):e19642 01 January 2011.
172. Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver HA, Antonenkova N, Antoniou AC, Bcfr Investigators SG, Beattie MS, et al. Beckmann M, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Bützow R, Caldes T, Caligo MA, Campbell IG, Chang-Claude J, Chen A, Chenevix-Trench G, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, Dork T, Durst M, Eccles D, Ekici AB, Embrace Investigators SG, Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Gemo Study Collaborators SG, Gentry-Maharaj A, Godwin AK, Goode E, Goodman MT, Gross J, Hansen TV, Harnett PR, Hebon Investigators SG, Heikkinen T, Hein R, Hogdall CK, Hogdall EV, Iversen E, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Kconfab Investigators SG, Kelemen LE, Kiemeny LA, Kjaer SK, Lambrechts D, Lapolla JP, Lazaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger L, McLaughlin JR, **Menon U**, Montagna M, Moysich KB, Narod S, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna HA, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut J, Sellers TA, Singer CF, Song H, Stram DO, Sutphen R, Swe-BrcA Investigators SG, Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. *Clin Cancer Res* 09 Mar 2011.
173. Burnell M, Gentry-Maharaj A, Ryan A, Apostolidou S, Habib M, Kalsi J, Skates S, Parmar M, Seif MW, Amso NN, et al. Godfrey K, Oram D, Herod J, Williamson K, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruikshank D, Campbell S, Fallowfield L, Jacobs I, **Menon U**. Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. *Trials* 12(1):61 01 Mar 2011.
174. Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A, Ryan A, Seif MW, Amso NN, Turner G, Brunell C, Fletcher G, Rangar R, Ford K, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Scott I, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Skates SJ, Fallowfield L, Parmar M, Campbell S, **Menon U**. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. *Lancet Oncol.* 2011 Jan;12(1):38-48.
175. Ander, E., Thomson, L., Lanceley, A., **Menon, U.**, Noble, G. and Chatterjee, H.J. (2011) Generic Wellbeing Outcomes: Towards a conceptual framework for wellbeing outcomes in museums. *Museum Management and Curatorship.* 26(3), 237-259.
176. Tiss A*, Timms JF*, Smith C, Devetyarov D, Gentry-Maharaj A, Camuzeaux S, Burford B, Nouretdinov I, Ford J, Luo Z, Jacobs I, **Menon U**, Gammerman A and Cramer R. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum MALDI-TOF MS profiling. *Int J Gynecological Cancer* 2010 Dec 20(9): 1518-1524.
177. Balogun N, Gentry-Maharaj A, Wozniak EL, Lim A, Ryan A, Ramus SJ, Ford J, Burnell M, Widschwendter M, Gessler SF, Gayther SA, Jacobs IJ, Menon U. Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking

- study. *J Clin Epidemiol*. 2011 May;64(5):525-30. doi: 10.1016/j.jclinepi.2010.07.008. Epub 2010 Nov 13. PubMed PMID: 21074968.
178. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, et al. Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemenev LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, Dörk T, Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, Lu K, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, Gentry-Maharaj A, **Menon U**, Wu AH, Stram DO, Pike MC, The Wellcome Trust Case-Control Consortium, Beesley J, Webb PM, The Australian Cancer Study (Ovarian Cancer), The Australian Ovarian Cancer Study Group, the Ovarian Cancer Association Consortium (OCAC), Chen X, Ekici AB, Thiel FC, Beckmann MW, Yang H, Wentzensen N, Lissowska J, Fasching PA, Despierre E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, Dürst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA, Pharoah PD. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nat Genet* 19 September 2010.
 179. Greimel E, Nordin A, Lancelley A, Creutzberg CL, van de Poll-Franse LV, Radisic VB, Galalae R, Schmalz C, Barlow E, Jensen PT, et al. Waldenström AC, Bergmark K, Chie WC, Kuljanic K, Costantini A, Singer S, Koensgen D, **Menon U**, Daghofer F, on behalf of the EORTC Quality of Life Group. Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). *Eur J Cancer* 17 September 2010.
 180. Lose F, Nagle CM, O'Mara T, Batra J, Bolton KL, Song H, Ramus SJ, Gentry-Maharaj A, **Menon U**, Gayther SA, et al. Pharoah PD, Kedda MA, Spurdle AB. Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. *Gynaecol Oncol* 8 September 2010.
 181. Near AM, Wu AH, Templeman C, Van Den Berg DJ, Doherty JA, Rossing MA, Goode EL, Cunningham JM, Vierkant RA, Fridley BL, Chenevix-Trench G, Webb PM; the Australian Cancer Study (Ovarian Cancer) (ACS).; the Australian Ovarian Cancer Study Group (AOCS), Kjær SK, Hogdall E, Gayther SA, Ramus SJ, **Menon U**, Gentry-Maharaj A, Schildkraut JM, Moorman PG, Palmieri RT, Ness RB, Moysich K, Cramer DW, Terry KL, Vitonis AF, Pike MC, Berchuck A, Pearce CL; on behalf of the Ovarian Cancer Association Consortium. Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. *Fertil Steril*. 2010 Aug 16.
 182. Tiss A, Smith C, **Menon U**, Jacobs I, Timms JF, Cramer R. A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. *Proteomics* 21 July 2010.
 183. Fallowfield L, Fleissig A, Barrett J, **Menon U**, Jacobs I, Kilkerr J, Farewell V. Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey

- of 21 715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening. *Br J Cancer*. 2010 Aug 10; 103(4):451-61.
184. Notaridou M, Quaye L, Dafou D, Jones C, Song H, Høgdall E, Kjaer SK, Christensen L, Høgdall C, Blaakaer J, McGuire V, Wu AH, Van Den Berg DJ, Pike MC, Gentry-Maharaj A, Wozniak E, Sher T, Jacobs IJ, Tyrer J, Schildkraut JM, Moorman PG, Iversen ES, Jakubowska A, Medrek K, Lubiński J, Ness RB, Moysich KB, Lurie G, Wilkens LR, Carney ME, Wang-Gohrke S, Doherty JA, Rossing MA, Beckmann W, Thiel FC, Ekici AB, Chen X, Beesley J, Gronwald J, Fasching PA, Chang-Claude J, Goodman MT, Chenevix-Trench G, Berchuck A, Pearce CL, Whittemore AS, **Menon U**, Pharoah PD, Gayther SA, Ramus SJ; The Australian Ovarian Cancer Study Group/Australian Cancer Study (Ovarian Cancer); on behalf of the Ovarian Cancer Association Consortium. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. *Int J Cancer*. 2010 Jul 15.
 185. Johnatty SE, Beesley J, Chen X, Macgregor S, Duffy DL, Spurdle AB, deFazio A, Gava N, Webb PM, Rossing MA, Doherty JA, Goodman MT, Lurie G, Thompson PJ, Wilkens LR, Ness RB, Moysich KB, Chang-Claude J, Wang-Gohrke S, Cramer DW, Terry KL, Hankinson SE, Tworoger SS, Garcia-Closas M, Yang H, Lissowska J, Chanock SJ, Pharoah PD, Song H, Whittemore AS, Pearce CL, Stram DO, Wu AH, Pike MC, Gayther SA, Ramus SJ, **Menon U**, Gentry-Maharaj A, Anton-Culver H, Ziogas A, Hogdall E, Kjaer SK, Hogdall C, Berchuck A, Schildkraut JM, Iversen ES, Moorman PG, Phelan CM, Sellers TA, Cunningham JM, Vierkant RA, Rider DN, Goode EL, Haviv I, Chenevix-Trench G; Ovarian Cancer Association Consortium; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer). Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". *PLoS Genet*. 2010 Jul 8;6(7):e1001016.
 186. Kelemen LE, Goodman MT, McGuire V, Rossing MA, Webb PM; Australian Cancer Study (Ovarian Cancer) Study Group, Köbel M, Anton-Culver H, Beesley J, Berchuck A, Brar S, Carney ME, Chang-Claude J, Chenevix-Trench G; Australian Ovarian Cancer Study Group, Cramer DW, Cunningham JM, Dicioccio RA, Doherty JA, Easton DF, Fredericksen ZS, Fridley BL, Gates MA, Gayther SA, Gentry-Maharaj A, Høgdall E, Kjaer SK, Lurie G, **Menon U**, Moorman PG, Moysich K, Ness RB, Palmieri RT, Pearce CL, Pharoah PD, Ramus SJ, Song H, Stram DO, Tworoger SS, Van Den Berg D, Vierkant RA, Wang-Gohrke S, Whittemore AS, Wilkens LR, Wu AH, Schildkraut JM, Sellers TA, Goode EL; Ovarian Cancer Association Consortium. Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. *Cancer Epidemiol Biomarkers Prev*. 2010 Jul;19(7):1822-30. Epub 2010 Jun 22.
 187. Lurie G, Wilkens LR, Thompson PJ, Carney ME, Palmieri RT, Pharoah PD, Song H, Hogdall E, Kjaer SK, Dicioccio RA, McGuire V, Whittemore AS, Gayther SA, Gentry-Maharaj A, **Menon U**, Ramus SJ, Goodman MT; on behalf of the Ovarian Cancer Association Consortium. Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: Pooled analysis in five studies within the Ovarian Cancer Association Consortium. *Int J Cancer*. 2010 Apr 19.
 188. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, **Menon U**, Lu K, Badgwell D, Bast RC Jr, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. *J Clin Oncol*. 2010 May 1;28(13):2159-66.

189. Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, **Menon U**, Hulman G, Desai M, Ho L, Terry G, Williams A, Sasieni P, Cuzick J. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. *Br J Cancer*. 2010 Apr 27;102(9):1405-10.
190. Pichert G, Jacobs C, Jacobs I, **Menon U**, Manchanda R, Johnson M, Hamed H, Firth C, Evison M, Tutt A, de Silva L, Langman C, Izatt L. Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers. *Fam Cancer*. 2010 Mar 19. (3):313-9.
191. Teschendorff AE, **Menon U**, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, Campan M, Noushmehr H, Bell CG, Maxwell AP, Savage DA, Mueller-Holzner E, Marth C, Kocjan G, Gayther SA, Jones A, Beck S, Wagner W, Laird PW, Jacobs IJ, Widschwendter M. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. *Genome Res*. 2010 Apr;20(4):440-6.
192. Timms, JF, Cramer R, Camuzeaux S, Tiss A, Smith C, Burford B, Nouretdinov I, Devetyarov D, Gentry-Maharaj A, Ford J, Luo Z, Gammerman A, **Menon U** and Jacobs I. Peptides Generated Ex Vivo from Serum Proteins by Tumor-Specific Exopeptidases Are Not Useful Biomarkers in Ovarian Cancer. *Clinical Chemistry* 56: 262-271; 10.1373/clinchem.2009.133363. 1 February 2010.
193. Doherty JA, Rossing MA, Cushing-Haugen KL, Chen C, Van Den Berg DJ, Wu AH, Pike MC, Ness RB, Moysich K, Chenevix-Trench G, Beesley J, Webb PM, Chang-Claude J, Wang-Gohrke S, Goodman MT, Lurie G, Thompson PJ, Carney ME, Hogdall E, Kjaer SK, Hogdall C, Goode EL, Cunningham JM, Fridley BL, Vierkant RA, Berchuck A, Moorman PG, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Yang HP, Garcia-Closas M, Chanock S, Lissowska J, Song H, Pharoah PD, Shah M, Perkins B, McGuire V, Whittemore AS, Di Cioccio RA, Gentry-Maharaj A, **Menon U**, Gayther SA, Ramus SJ, Ziogas A, Brewster W, Anton-Culver H; Australian Ovarian Cancer Study Management Group; Australian Cancer Study (Ovarian Cancer), Pearce CL; Ovarian Cancer Association Consortium (OCAC). ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. *Cancer Epidemiol Biomarkers Prev*. 2010 Jan;19(1):245-50.
194. Gammerman A, Vovk V, Burford B, Nouretdinov I, Luo Z, Chervonenkis A, Waterfield M, Cramer R, Tempst P, Villanueva J, Kabir M, Camuzeaux S, Timms J, **Menon U** and Jacobs I. Serum proteomic abnormality predating screen detection of ovarian cancer. *The Computer Journal* advance access April 15, 2008; published 2009 52: 326-333.
195. Teschendorff AE, **Menon U**, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, Jones A, Lechner M, Beck S, Jacobs IJ, Widschwendter M. An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer. *PLoS One*. *PLoS One*. 2009; 4(12): e8274. Published online 2009 December 18. doi: 10.1371/journal.pone.0008274.
196. Pearce CL, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, **Menon U**, Gayther SA, Anderson AR, Edlund CK, Wu AH, Chen X, Beesley J, Webb PM, Holt SK, Chen C, Doherty JA, Rossing MA, Whittemore AS, McGuire V, DiCioccio RA, Goodman MT, Lurie G, Carney ME, Wilkens LR, Ness RB, Moysich KB, Edwards R, Jennison E, Kjaer SK, Hogdall E, Hogdall CK, Goode EL, Sellers TA, Vierkant RA, Cunningham JM, Schildkraut JM, Berchuck A, Moorman PG, Iversen ES, Cramer DW, Terry KL, Vitonis AF, Titus-Ernstoff L, Song H, Pharoah PDP, Spurdle AB, Anton-Culver H, Ziogas A, Brewster W, Galitovskiy V, Chenevix-Trench G, Ovarian Canc Assoc Consortium. Validating genetic risk associations for ovarian cancer through the International Ovarian Cancer

- Association Consortium (vol 100, pg 412, 2009). BRIT J CANCER 101(10):1805-1805 10 Nov 2009.
197. Cunningham JM, Vierkant RA, Sellers TA, Phelan C, Rider DN, Liebow M, Schildkraut J, Berchuck A, Couch FJ, Wang X, Fridley BL; Ovarian Cancer Association Consortium, Gentry-Maharaj A, **Menon U**, Hogdall E, Kjaer S, Whittemore A, DiCioccio R, Song H, Gayther SA, Ramus SJ, Pharaoh PD, Goode EL. Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. *Br J Cancer*. 2009 Oct 20;101(8):1461-8. Epub 2009 Sep 8. PubMed PMID: 19738611; PubMed Central PMCID: PMC2768434.
 198. Song HL, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dork T, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen ZH, Cunningham JM, Dicks E, Doherty JA, Durst M, Ekici AB, Fenstermacher D, Fridley BL, Giles G, Gore ME, De Vivo I, Hillemanns P, Hogdall C, Hogdall E, Iversen ES, Jacobs IJ, Jakubowska A, Li D, Lissowska J, Lubinski J, Lurie G, McGuire V, McLaughlin J, Medrek K, Moorman PG, Moysich K, Narod S, Phelan C, Pye C, Risch H, Runnebaum IB, Severi G, Southey M, Stram DO, Thiel FC, Terry KL, Tsai YY, Tworoger SS, Van Den Berg DJ, Vierkant RA, Wang-Gohrke S, Webb PM, Wilkens LR, Wu AH, Yang HN, Brewster W, Ziogas A, Houlston R, Tomlinson I, Whittemore AS, Rossing MA, Ponder BAJ, Pearce CL, Ness RB, **Menon U**, Kjaer SK, Gronwald J, Garcia-Closas M, Fasching PA, Easton DF, Chenevix-Trench G, Berchuck A, Pharaoh PDP, Gayther SA, Australian Canc Ovarian Study, Australian Ovarian Canc Study Grp, Ovarian Canc Assoc Consortium. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *NAT GENET* 41(9):996-U60 Sep 2009
 199. Widschwendter M, Apostolidou S, Jones AA, Fourkala EO, Arora R, Pearce CL, Frasco MA, Ayhan A, Zikan M, Cibula D, Iyibozkurt CA, Yavuz E, Hauser-Kronberger C, Dubeau L, **Menon U**, Jacobs IJ. HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. *Int J Cancer*. 2009 May 28. 125(9):2214-8.
 200. M Widschwendter M, Lichtenberg-Frate H, Hasenbrink G, Schwarzer S, Dawnay A, Lam A, **Menon U**, Apostolidou S, Raum E, Stegmaier C, Jacobs IJ, Brenner H. Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. *Br J Cancer*. 2009 Jul 7;101(1):160-5.
 201. Fourkala EO, Hauser-Kronberger C, Apostolidou S, Burnell M, Jones A, Grall J, Reitsamer R, Fiegl H, Jacobs I, **Menon U**, Widschwendter M. DNA methylation of polycomb group target genes in cores taken from breast cancer centre and periphery. *Breast Cancer Res Treat*. 120(2):345-55. Epub 2009 Apr 8.
 202. Song H, Ramus SJ, Kjaer SK, DiCioccio RA, Chenevix-Trench G, Pearce CL, Hogdall E, Whittemore AS, McGuire V, Hogdall C, Blaakaer J, Wu AH, Van Den Berg DJ, Stram DO, **Menon U**, Gentry-Maharaj A, Jacobs IJ, Webb PM, Beesley J, Chen X; Australian Cancer (Ovarian) Study; Australian Ovarian Cancer Study Group, Rossing MA, Doherty JA, Chang-Claude J, Wang-Gohrke S, Goodman MT, Lurie G, Thompson PJ, Carney ME, Ness RB, Moysich K, Goode EL, Vierkant RA, Cunningham JM, Anderson S, Schildkraut JM, Berchuck A, Iversen ES, Moorman PG, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Anton-Culver H, Ziogas A, Brewster WR, Ponder BA, Easton DF, Gayther SA, Pharaoh PD; Ovarian Cancer Association Consortium (OCAC). Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. *Hum Mol Genet*. 2009 Jun 15;18(12):2297-304.

203. Quaye L, Dafou D, Ramus SJ, Song H, Gentry-Maharaj A, Notaridou M, Hogdall E, Kjaer SK, Christensen L, Hogdall C, Easton DF, Jacobs I, **Menon U**, Pharoah PD, Gayther SA. Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. *Hum Mol Genet.* 2009 May 15;18(10):1869-78. Epub 2009 Mar 6. Erratum in: *Hum Mol Genet.* 2009 Aug 1;18(15):2928.
204. Quaye L, Song H, Ramus SJ, Gentry-Maharaj A, Høgdall E, DiCioccio RA, McGuire V, Wu AH, Van Den Berg DJ, Pike MC, Wozniak E, Doherty JA, Rossing MA, Ness RB, Moysich KB, Høgdall C, Blaakaer J; Ovarian Cancer Association Consortium, Easton DF, Ponder BA, Jacobs IJ, **Menon U**, Whittemore AS, Krüger-Kjaer S, Pearce CL, Pharoah PD, Gayther SA. Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. *Br J Cancer.* 2009 Mar 24;100(6): 993-1001.
205. **Menon U**, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Lancet Oncol.* 2009 Apr;10(4):327-40.
206. Pearce CL, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, **Menon U**, Gayther SA, Anderson AR, Edlund CK, Wu AH, Chen X, Beesley J, Webb PM, Holt SK, Chen C, Doherty JA, Rossing MA, Whittemore AS, McGuire V, DiCioccio RA, Goodman MT, Lurie G, Carney ME, Wilkens LR, Ness RB, Moysich KB, Edwards R, Jennison E, Kjaer SK, Hogdall E, Hogdall CK, Goode EL, Sellers TA, Vierkant RA, Cunningham JC, Schildkraut JM, Berchuck A, Moorman PG, Iversen ES, Cramer DW, Terry KL, Vitonis AF, Titus-Ernstoff L, Song H, Pharoah PD, Spurdle AB, Anton-Culver H, Ziogas A, Brewster W, Galitovskiy V, Chenevix-Trench G; Australian Cancer Study; Australian Ovarian Cancer Study Group. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. *Br J Cancer.* 2009 Jan 27;100(2):412-20.
207. Palmieri RT, Wilson MA, Iversen ES, Clyde MA, Calingaert B, Moorman PG, Poole C, Anderson AR, Anderson S, Anton-Culver H, Beesley J, Hogdall E, Brewster W, Carney ME, Chen X, Chenevix-Trench G, Chang-Claude J, Cunningham JM, Docioccio RA, Doherty JA, Easton DF, Edlund CK, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Kjaer SK, Hogdall CK, Hopkins MP, Jenison EL, Blaakaer J, Lurie G, McGuire V, **Menon U**, Moysich KB, Ness RB, Pearce CL, Pharoah PD, Pike MC, Ramus SJ, Rossing MA, Song H, Terada KY, Vandenberg D, Vierkant RA, Wang-Gohrke S, Webb PM, Whittemore AS, Wu AH, Ziogas A, Berchuck A, Schildkraut JM; Ovarian Cancer Association Consortium; Australian Cancer Study (Ovarian Cancer Group); Australian Ovarian Cancer Study Group. Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. *Cancer Epidemiol Biomarkers Prev.* 2008 Dec;17(12):3567-72.
208. **Menon U**, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, Lewis S, Lopez A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Skates S, Parmar M, Jacobs I. Recruitment to multicentre trials--lessons

- from UKCTOCS: descriptive study. *BMJ*. 2008 Nov 13;337:a2079. doi: 10.1136/bmj.a2079.
209. Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, **Menon U**, Stegmaier C, Jacobs IJ, Brenner H. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. *PLoS ONE*. 2008 Jul 16;3(7):e2656.
 210. Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, Pearce CL, **Menon U**, Gentry-Maharaj A, Gayther SA, Dicioccio RA, McGuire V, Whittemore AS, Song H, Easton DF, Pharoah PD, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Terry KL, Cramer DW, Tworoger SS, Hankinson SE, Berchuck A, Moorman PG, Schildkraut JM, Cunningham JM, Liebow M, Kjaer SK, Hogdall E, Hogdall C, Blaakaer J, Ness RB, Moysich KB, Edwards RP, Carney ME, Lurie G, Goodman MT, Wang-Gohrke S, Kropp S, Chang-Claude J; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer), Webb PM, Chen X, Beesley J, Chenevix-Trench G, Goode EL; Ovarian Cancer Association Consortium. Consortium analysis of 7 candidate SNPs for ovarian cancer. *Int J Cancer*. 2008 Jul 15;123(2):380-8.
 211. Lanceley A, Savage J, **Menon U**, Jacobs I (2008). Influences on multidisciplinary team decision-making. *Int J Gynecol Cancer*. *Int J Gynecol Cancer*. 2008 Mar-Apr;18(2):215-22
 212. Singh N, Ayhan A, **Menon U**, Chin Aleong JA, Faruqi AZ, Gayther SA, Jacobs IJ. Grading of serous ovarian carcinoma: further evidence of a lack of agreement between conventional grading systems. *Histopathology*. 2008 Feb;52(3):393-5.
 213. Gammerman A, Vovk V, Burford B, Nouretdinov I, Luo ZY, Chervonenkis A, Waterfield M, Cramer R, Tempst P, Villanueva J, Kabir M, Camuzeaux S, Timms J, **Menon U**, Jacobs I. Serum proteomic abnormality predating screen detection of ovarian cancer. *COMPUT J* 2008.
 214. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, **Menon U**, Lu K, Badgwell D, Bast RC, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. *Cancer Biomark* 4(3):175-175 2008
 215. Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, **Menon U**, Stegmaier C, Jacobs IJ, Brenner H. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. *PloS One* 3(7):e2656 2008
 216. Tiss A, Smith C, Camuzeaux S, Kabir M, Gayther S, **Menon U**, Waterfield M, Timms J, Jacobs I, Cramer R. Serum peptide profiling using MALDI mass spectrometry: avoiding the pitfalls of coated magnetic beads using well-established ZipTip technology. *Proteomics* 7(suppl 1):77-89 1 Sep 2007
 217. Lanceley A, Ndebele N, Johnson M, **Menon U**, Noble G, Chatterjee H. In another vein: The potential of 'object handling' for women facing a gynaecological cancer diagnosis. *Psycho-oncol* 16(9):S115-S116 Sep 2007
 218. **Menon U**, Joyce Harper, Aarti Sharma, Lindsay Fraser, Matthew Burnell, Karim ElMasry, Charles Rodeck, Ian J Jacobs. Questionnaire survey of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast ovarian cancer. *Hum Reprod*. 2007 Jun;22(6):1573-7.
 219. **Menon U**, Matthew Burnell, Aarti Sharma, Aleksandra Gentry-Maharaj, Lindsay Fraser, Andy Ryan, Mahesh Parmar, Myra Hunter, Ian J Jacobs for the UKCTOCS group (2007). Decline in use of hormone therapy amongst postmenopausal women in the UK. *Menopause*. 2007 May-Jun;14(3 Pt 1):462-7

220. Timms JF, Arslan-Low E, Gentry-Maharaj A, Luo Z, T'Jampens D, Podust VN, Ford J, Fung ET, Gammerman A, Jacobs I, **Menon U**. Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. *Clin Chem* 53(4):645-656 Apr 2007
221. Rufford BD, Jacobs IJ, **Menon U** (2007). Feasibility of screening for ovarian cancer using symptoms as selection criteria. *BJOG*. Jan;114(1):59-64.
222. Alexander-Sefre F, Chee N, Spencer C, **Menon U**, Shepherd JH. Surgical morbidity associated with radical trachelectomy and radical hysterectomy. *Gynecol Oncol* 101(3):450-454 Jun 2006
223. Sharma A, Beveridge H, Fallowfield L, Jacobs I, **Menon U**. (2006) Postmenopausal women undergoing transvaginal ultrasound screening prefer not to have chaperones. *BJOG*. 113(8); 954-7.
224. **Menon U**, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RCJ, Oram D, Jacobs IJ. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. *J Clin Oncol* 23(31):7919-7926 1 Nov 2005
225. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, **Menon U**, Jacobs I, Lu K. (2005) New tumor markers: CA125 and beyond. *Int J Gynecol Cancer* (2005). Nov-Dec;15 Suppl 3:274-81.
226. Mehra G, Weekes AR, Jacobs IJ, Visvanathan D, **Menon U**, Jeyarajah AR. Laparoscopic extraperitoneal paraaortic lymphadenectomy: a study of its applications in gynecological malignancies. *Gynecol Oncol* 93(1):189-193 Apr 2004
227. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, **Menon U**, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P. Management of women who test positive for high-risk types of human papillomavirus: the HART study. *Lancet* 362(9399):1871-1876 6 Dec 2003
228. Skates SJ, **Menon U**, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ (2003). Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal Women. *J Clin Oncol* May 15; 21(10 Suppl):206-10.
229. Pauler DK, **Menon U**, Symecko HL, Skates SJ, Jacobs IJ. Factors Influencing Serum CA125II Levels in Healthy Postmenopausal Women. *Cancer Epidemiology, Biomarkers and Prevention* 10(5):489-493 1 Jan 2001
230. **Menon U**, Riley SC, Thomas J, Bose C, Dawnay A, Evans LW, Groome NP, Jacobs IJ. Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. *BJOG* 107(9):1069-1074 Sep 2000.
231. **Menon U**, Talaat A, Rosenthal AN, Macdonald ND, Jeyarajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. *BJOG* 107(2):165-169 Feb 2000
232. Macdonald, N.D., **Menon U**., Jacobs,I.J. (2000). Registration of cancers in England and Wales. *British Journal of Cancer* 83(2), 279-279. ISSN: 0007-0920
233. MacDonald N, Sibley K, Rosenthal A, **Menon U**, Jayarajah A, Oram D, Jacobs I. A comparison of National Cancer Registry and direct follow-up in the ascertainment of ovarian cancer. *Br J Cancer* 80(11):1826-1827 Aug 1999
234. **Menon U**, Talaat A, Jeyarajah AR, Rosenthal AN, MacDonald ND, Skates SJ, Sibley K, Oram DH, Jacobs IJ. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. *Br J Cancer* 80(10):1644-1647 Jul 1999

235. Jacobs IJ, Skates SJ, MacDonald N, **Menon U**, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH. Screening for ovarian cancer: a pilot randomised controlled trial. *Lancet* 353(9160):1207-1210 10 Apr 1999
236. **Menon U**, Ranjan M, Jasper P, Oommen A. Evaluation of plasma fructosamine as a screening test for gestational diabetes. *Aust N Z J Obstet Gynaecol* 31(1):25-26 Feb 1991

PUBLICATIONS – editorials/reviews

1. Dilley J, Gentry-Maharaj A, **Menon U**. Gynecological surveillance in high risk women. *Minerva Ginecol.* 2016 Oct;68(5):497-508. Epub 2016 Mar 1. Review. PubMed PMID: 26930388.
2. **Menon U**, Griffin M, Gentry-Maharaj A. Ovarian cancer screening-Current status, future directions. *Gynecol Oncol.* 2014 Feb;132(2):490-495.
3. Kalsi J, Manchanda R, **Menon U**. Screening for gynecologic cancers. *Expert Review of Obstetrics & Gynecology* March 2013, Vol. 8, No. 2, Pages 143-160.
4. Manchanda R, Drapkin R, **Menon U**. There is a need for routine peritoneal cytology at RRSO. *Gynecol Oncol.* 2013 Jan;128(1):149-50.
5. Sengupta SB, Vadaparampil ST, Menon U. Preimplantation genetic diagnosis for hereditary cancers. *Adv Exp Med Biol* 732:103-113 2012.
6. Jacobs I, **Menon U**. Can ovarian cancer screening save lives? The question remains unanswered. *Obstet Gynecol* 118(6):1209-1211 Dec 2011.
7. **Menon U**, Gentry-Maharaj A, Jacobs I. Ovarian cancer screening and mortality. *JAMA* 306(14):1544 12 Oct 2011.
8. **Menon U**. Ovarian cancer screening has no effect on disease-specific mortality. *Evid Based Med.* 2011 Sep 26.
9. Jacobs I, **Menon U**. The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. *Cancer Prev Res (Phila)* 4(3):299-302 Mar 2011.
10. Hamilton W, **Menon U**. Ovarian cancer. *BMJ.* 2009 Nov 18;339:b4650. doi: 10.1136/bmj.b4650.
11. Manchanda R, **Menon U**, Michaelson-Cohen R, Beller U, Jacobs I. Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. *Curr Opin Obstet Gynecol.* 2009 Feb;21(1):31-8.
12. **Menon U**. Ovarian cancer: challenges of early detection. *Nat Clin Pract Oncol.* 2007 Sep;4(9):498-9.
13. Widschwendter M, **Menon U**. (2006) Circulating methylated DNA: a new generation of tumor markers. *Clin Cancer Res.* Dec 15;12(24):7205-8.
14. Sharma A, **Menon U** (2006). Screening for Gynaecological Cancers *European Journal of Surgical Oncology Eur J Surg Oncol.* Oct;32(8):818-24, ISSN: 0748-7983.
15. Rosenthal AN, **Menon U**, Jacobs IJ (2006). Screening for Ovarian Cancer. *Clin Obstet Gynecol.* Sep;49(3):433-447.
16. Sharma A, **Menon U** (2006). The value of ovarian cancer screening. *Br J Hosp Med.* 67(6):314-7.
17. Crosbie E, **Menon U** (2005). Epithelial ovarian cancer and induction of ovulation. *Reviews in Gynaecological Practice* 5 131-8.

18. Jacobs IJ, **Menon U**. (2004). Progress challenges in screening for early detection of ovarian cancer. *Mol Cell Proteomics*. 2004 Feb 5.
19. **Menon U** (2004). Ovarian cancer screening. *CMAJ*. 2004;171(4):323-4.
20. S Lewis, **U Menon** (2003). Screening for Ovarian Cancer. Expert review for Anti cancer Therapy. 2003 Feb;3(1):55-62.
21. Alexander-Sefre F, **Menon U**, Jacobs IJ (2002). Ovarian cancer screening. *Hosp Med*. Apr; 63 (4):210-3.
22. **Menon U**, Jacobs IJ (2001). Ovarian cancer screening in the general population– an update. *Current opinion in Obstetrics and Gynaecology*. 13(1); 61-4.
23. **Menon U**, Jacobs IJ (2001). Ovarian cancer screening in the general population– current status. *International Journal Gynecological Cancer*. 11(S1):3-6.
24. Rufford B, **Menon U**, Jacobs IJ (2001). Ovarian Cancer Screening. In the Proceedings of the 2nd World Congress on Controversies in Obstetrics, Gynaecology and Infertility (Paris, France, September 2001).
25. **Menon U**, Jacobs IJ (2000). Recent developments in ovarian cancer screening. *Current opinion in Obstetrics and Gynaecology* 12; 39-42.
26. **Menon U**, Jacobs IJ (2000). Ovarian cancer screening in the general population Ultrasound in obstetrics and gynaecology. 15; 350-353. ISSN: 0960-7692.
27. **Menon U**, Jacobs IJ (2000). The current status of screening for ovarian cancer. *Current Medical Literature*.
28. **Menon U**. Gynaecological ultrasonography: expertise counts. *Lancet Oncol*.2008 Feb;9(2): 88-9.

PUBLICATIONS – relating to oversight committee role

1. Walsh EI, Turner EL, Lane JA, Donovan JL, Neal DE, Hamdy FC, Martin RM; and the CAP & ProtecT Trial Groups; Investigators; Research staff; Management Committee; **CAP & ProtecT Trial Steering Committee**; Data Monitoring Committee; Administrative staff. Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. *Trials*. 2016 Oct 13;17(1):497. PubMed PMID: 27737692; PubMed Central PMCID: PMC5064919.
2. Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJ, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MK; **ICON6 collaborators**. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2016 Mar 12;387(10023):1066-74. doi: 10.1016/S0140-6736(15)01167-8. Erratum in: *Lancet*. 2016 Apr 23;387(10029):1722. PubMed PMID: 27025186.

PUBLICATIONS – correspondence

1. Jacobs IJ, Parmar M, Skates SJ, **Menon U**. Ovarian cancer screening: UKCTOCS trial - Authors' reply. *Lancet*. 2016 Jun 25;387(10038):2603-4. doi: 10.1016/S0140-6736(16)30849-2. PubMed PMID: 27353822.

2. Sharma A, Gentry-Maharaj A, Burnell M, Ryan A, Amso NN, Campbell S, Jacobs I, **Menon U**; UKCTOCS team. Reply: To PMID 23456790. *Ultrasound Obstet Gynecol*. 2014 May;43(5):600-1. doi: 10.1002/uog.13354. PubMed PMID: 24789307.

PUBLICATIONS – book chapters

1. Gentry-Maharaj A, Kalsi J, **Menon U**. (Feb 2015) Screening for gynaecological cancers. In *Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances*. Patel HRH, Mould T, Joseph JV and Delaney CP (Eds), chap 26, pp 267-282, Springer. ISBN 978-1-4471-4257-7
2. Gentry-Maharaj A, Jacobs I, **Menon U**. (Dec 2014) Ovarian cancer-tumor markers and screening. In *Berek & Hacker's Gynecologic Oncology, Sixth edition*, Berek JS and Hacker NF (Eds), chap 10, pp 443-463, Lippincott Williams and Wilkins. ISBN 978-1-4511-9007-6
3. Gentry-Maharaj A, **Menon U**. (Oct 2014) Early detection of hereditary gynaecological cancers. In *Genetics for Health Professionals in Cancer Care: From Principles to Practice*. Jacobs C, Webb P and Robinson L (Eds), chap 20, pp 173-179, Oxford University Press. ISBN 978-0-19-967284-4
4. Fourkala EO, Gentry-Maharaj A, **Menon U**. (2013) MUC16, alias CA125 and ovarian cancer. In: *Mucins and Cancer*. Taylor-Papadimitriou J, Burchell JM (Eds). Future Medicine, London, UK.
5. Gentry-Maharaj A, Jacobs I, **Menon U**. (2012) Development and identification of tumor serum markers. In Barakat,R.R., Berchuck, A., Markman, M., Randall,M.E. (eds). *Principles and Practice of Gynecologic Oncology, 6th edition*. Baltimore: Lippincott Williams & Wilkins.
6. Gentry-Maharaj A, **Menon U**. (2012) Screening for ovarian cancer in the general population. *Best Practice & Research Clinical Obstetrics & Gynaecology*, 26 (2), 243-256.
7. Manchanda,R., Jacobs,I.J., **Menon,U**. (2010) Tumour markers and screening. in Berek,j., Hacker,N (ed.) *Practical Gynecologic Oncology*. Philadelphia: Lippincott, Williams & Wilkin, 5th edition. 233-266.
8. Gentry Maharaj A, Jacobs IJ, **Menon U**, (2009). Development and identification of tumour markers. In: Barakat RR, Markman M, Randall ME, eds. *Principles and Practice of Gynecologic Oncology*. 5th ed. Philadelphia: Lippincott Williams & Wilkins. 145-166.
9. Manchanda,R., **Menon,U**.. (2008) Serum markers in gynaecological cancers in the reproductive years. in Kehoe,S., Jauniaux,E. (ed.) *Cancer and Reproductive Health*. 155-178. ISBN 978-1-904752-61-5
10. Sharma,A., **Menon,U**., Jacobs, IJ. (2007). Symptoms in the diagnosis of Ovarian Cancer. in Hillard,T. (ed.) *The Yearbook of Obstetrics and Gynaecology*, 159-170.
11. Rosenthal,A., **Menon,U**., Jacobs,I.J. (2006). Ovarian Cancer Screening. in Reznick,R. (ed.) *Contemporary Issues in Cancer Imaging: A Multidisciplinary Approach*. Cambridge: Cambridge University Press.
12. A Sharma, **Menon, U**, J Ledermann. *Advanced Ovarian Cancer* (Published online 3/10/06). *BMJ Clinical Evidence handbook*.

13. A Sharma, U Menon, I Jacobs. Symptoms in diagnosis of Ovarian Cancer. *New Horizons in Obstetrics and Gynaecology* (November 2007).
14. Alexander Sefre, F., **Menon, U.**, Jacobs, I.J. (2005). Ovarian cancer screening. in Farquharson, R. (ed.) *Vignettes for the MRCOG*. London: Quay Books, 57-62.
15. **Menon, U.**, Jacobs, I.J. (2005). Serum tumour markers. in Smith, J.R., Priore, G.D., Curtin, J., Monaghan, J. (ed.) *An atlas of gynaecological oncology*. London: Martin Dunitz, 21-43.
16. Reynolds, K., **Menon, U.**, Jacobs, I.J. (2005). Development and identification of tumour markers. in Hoskins, W.J., Perez, C.A., Young, R.C. (ed.) *Principles and Practice of Gynecologic Oncology*. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 157-178.
17. **Menon, U.**, Jacobs, I.J. (2004). Tumour markers and Screening. in Berek, J., Hacker, N. (ed.) *Practical Gynecologic Oncology*. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 43-66.
18. **Menon, U.**, Brinkman, D.A., Skates, S.J., Jacobs, I.J. (2003). Screening: Ovarian Cancer. in Cuzick, J. (ed.) *Evidence based oncology Part 3*.
19. **Menon, U.**, Jacobs, I.J. (2002). CA125 and other tumour markers in screening and monitoring of ovarian cancer. in Altchek, A., Deligdisch, L. (ed.) *Diagnosis and Management of Ovarian Disorders*. New York: Academic Press.
20. **Menon, U.**, Jacobs, I.J. (2002). Screening for ovarian cancer. in Arulkumaran, S. (ed.) *Baillière's Best Practice & Research Clinical Obstetrics & Gynaecology*. London: , 469-482.
21. **Menon, U.**, Jacobs, I.J. (2002). The current status of screening for ovarian cancer. in Jacobs, I.J., Shepherd, J.H., Oram, D.H., Blackett, A.D., Luesley, D., Berchuck, A., Hudson, C.N. (ed.) *Ovarian Cancer*. London: Oxford University Press, 171-178.
22. Rufford, B., **Menon, U.**, Jacobs, I.J. (2002). Screening for familial ovarian cancer. in Morrison, P.K., Hodgson, S.V., Haites, N.E. (ed.) *Familial Breast and Ovarian Cancer Genetics, Screening and Management*, 220-233.
23. Rufford B., **Menon, U.**, and Jacobs IJ (2001). Ovarian Cancer Screening. *Cancer Imaging* 1(2), 14-16.
24. **Menon, U.**, Jacobs, I.J. (2001). Serum tumour markers. in Smith, J.R., Priore, G.D., Curtin, J., Monaghan, J. (ed.) *An atlas of gynaecological oncology*. London: Martin Dunitz, 19-34.
25. Rufford, B., **Menon, U.**, Jacobs, I.J. (2001). Ovarian Cancer Screening in Familial Breast and Ovarian Cancer: Problems, Promises and Solutions.
26. **Menon, U.**, Jacobs, I.J. (2000). Ovarian cancer screening in the general population. *Ultrasound in Obstetrics and Gynaecology* 350-353. ISSN: 0960-7692
27. **Menon, U.**, Jacobs, I.J. (2000). Tumour markers and Screening. in Berek, J., Hacker, N. (ed.) *Practical Gynecologic Oncology*. 3rd ed.. Philadelphia: Lippincott Williams & Wilkins, 39-58.
28. **Menon, U.**, Jacobs, I.J. (2000). Tumour markers. in Hoskins, W.J., Perez, C.A., Young, R.C. (ed.) *Principles and Practice of Gynecologic Oncology*. 3rd ed.. Philadelphia: Lippincott Williams & Wilkins, 165-181.
29. **Menon U**, Jacobs IJ (1999) Ovarian cancer screening - a case study. *Royal College of Obstetrics and Gynaecology. DIALOG - CD ROM*.
30. **Menon U** (1998) Screening and Diagnosis of Gynaecological Cancers. *Minisymposium. Diplomat* 5;184-8.

PUBLICATIONS – published conference abstracts

Please see Appendix 1.

INVITED TALKS – national and international meetings

No	Date	Details
1	1 st Dec 2017	The 8 th Tropé-Kolstad Lecture: <i>Ovarian cancer screening: Past, present and future</i> , 8th Tropé-Kolstad meeting , Institute for Cancer Research, Norwegian Radium Hospital, Oslo, Norway
2	19 th May 2017	<i>Lessons from the UK Ovarian Cancer screening trials</i> , Ovarian Cancer – Molecular Aspects in Modern Diagnostics and Therapy , 19 – 20 May 2017, Radisson Blu Sobieski Hotel, Warsaw, Poland
3	6 th May 2017	<i>Early detection of ovarian cancer: What does the evidence show, how can we better our efforts?</i> 9th International Charité-Mayo-Conference , 3 – 6 May 2017, Langenbeck-Virchow-Haus, Berlin, Germany
4	24 th Apr 2017	<i>The gynaecologist's perspective</i> , The Manchester Consensus Meeting on the Management of Gynaecological Pathology Associated with Lynch Syndrome , 24 – 25 Apr 2017, The Chancellors Hotel and Conference Centre, Manchester, UK
5	29 th Oct 2016	Plenary lecture: <i>Are we able to effectively screen for ovarian cancer?</i> 16th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2016) , 29 – 31 Oct 2016, Lisbon Congress Centre, Lisbon, Portugal
6	14 th Oct 2016	<i>Clinical Academic Careers – a view from the ground</i> , LERU Research Careers Community Plenary Meeting , UCL, London, UK
7	6 th Oct 2016	<i>Ovarian cancer screening</i> , New Cancer Screening Programmes , Swedish Medical Society, Stockholm, Sweden
8	1 st Oct 2016	<i>Screening for Ovarian Cancer</i> , 15th IMS World Congress on Menopause , 28 Sep – 1 Oct 2016, Prague Congress Centre, Prague, Czech Republic
9	28 th Sep 2016	<i>The UK Collaborative Trial of Ovarian Cancer Screening – Outcomes</i> , UCL Frontiers of Oncology: Women's Health , Royal College of Physicians, London, UK
10	27 th Sep 2016	<i>Lynch Syndrome – management of gynaecological cancer risk</i> , XXXI International Congress of the International Academy of Pathology (IAP) and 28th Congress of the European Society of Pathology (ESP) , 25 – 29 Sep 2016, Congress-Centrum Ost Koelnmesse, Cologne, Germany
11	12 th Sep 2016	Plenary lecture: <i>UKTOCS – exploring the results</i> , 11th Biennial Ovarian Cancer Research Symposium , 12 – 13 Sep 2016, University of Washington, Seattle, Washington DC, USA
13	10 th Sep 2016	<i>Risk stratification and screening of ovarian cancer</i> , 2nd ESGO State of Art Conference: Prevention in Gynaecological Malignancies , 8 – 10 Sep 2016, Susesi Hotel, Antalya, Turkey
14	9 th Sep 2016	<i>Hereditary endometrial cancers and prevention</i> , 2nd ESGO State of Art Conference: Prevention in Gynaecological Malignancies , 8 – 10 Sep 2016, Susesi Hotel, Antalya, Turkey

No	Date	Details
15	20 th Jun 2016	<i>Screening for Ovarian Cancer – update from UK trials</i> , RCOG World Congress 2016 , 20 – 22 Jun 2016, The ICC, Birmingham, UK
16	18 th May 2016	<i>Advances in ovarian cancer screening</i> , Primary Care & Public Health 2016 , 18 – 19 May 2016, The NEC, Birmingham, UK
17	12 th May 2016	<i>Ovarian cancer screening – what do we know now?</i> British Gynaecological Cancer Society Annual Scientific Meeting (BGCS 2016) , 12 – 13 May 2016, The ICC, Birmingham, UK
18	27 th Apr 2016	<i>UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)</i> , Ovarian Cancer Association Consortium (OCAC) Meeting , Buckinghamshire, UK
19	16 th Apr 2016	<i>Mortality outcomes of the UK Ovarian Cancer Screening programme (UKCTOCS)</i> , British Society for Gynaecological Imaging (BSGI) Annual Scientific Meeting , RCOG, London, UK
20	3 rd Mar 2016	<i>UKCTOCS – the benefits and harms of ovarian cancer screening</i> , Annual Academic Meeting – Joint RCOG/BBRS Meeting RCOG, London, UK
21	29 th Feb 2016	<i>Current role of symptom awareness</i> , OvSTAT Event: Ovarian Cancer Tool Seminar , Park Plaza Cardiff, Wales, UK
22	25 th Feb 2016	Plenary lecture: <i>Ovarian cancer screening</i> , Northern Sweden Gynecologic Society , Umeå University, Sweden
23	8 th Feb 2016	<i>Update on the UKCTOCS trial: Compliance, performance of MMS & USS arms, stage distribution</i> , After UKCTOCS: Public Messaging on Screening and Early Detection of Ovarian Cancer , Banbury Center, Cold Spring Harbor Laboratory, USA
24	25 th Nov 2015	<i>UKCTOCS update</i> , RCOG Annual Professional Development Conference , RCOG, UK
25	4 th Nov 2015	<i>Ovarian Cancer screening – update from the UK trials</i> , 2015 NCRI Cancer Conference , Liverpool, UK
26	27 th Oct 2015	<i>Management of Ovarian Cancer risk</i> , 19th International Meeting of the European Society of Gynaecological Oncology Nice, France
27	19 th Oct 2015	Plenary lecture: <i>Ovarian cancer screening</i> , AACR Advances in Ovarian Cancer Research: Exploiting Vulnerabilities , 17 – 20 Oct 2015, Orlando, Florida, USA
28	8 th Oct 2015	<i>Ovarian cancer screening – role of biomarkers</i> , 4th Biomarkers in Diagnostics , Berlin, Germany
29	31 st May 2015	<i>Early Ovarian Cancer: Can We Find It, Can We Stop It, Can We Afford It?</i> 2015 American Society of Clinical Oncology Annual Meeting , Chicago, USA
30	17 th Apr 2015	<i>The UKCTOCS and UKFOCSS trials – what have we learnt so far?</i> 2nd International Ovarian Tumor Analysis Congress (IOTA 2015) , Leuven, Belgium

No	Date	Details
31	27 th Feb 2015	<i>Ovarian Cancer screening – any progress?</i> Oncology in obstetrics and gynaecology – “State of the art” , Royal Society of Medicine, London, UK
32	19 th Nov 2014	<u>Debate:</u> <i>Place of prophylactic salpingectomy during routine hysterectomy for benign indications</i> , RCOG, London, UK
33	13 th Sep 2014	<i>Familial risk and its management</i> , ESGO State of the Art Conference – Follow-up in gynaecological malignancies , Torino, Italy
34	12 th Sep 2014	<i>Familial risk and its management</i> , ESGO – Follow-up in gynaecological malignancies , Torino, Italy
35	8 th Sep 2014	<u>Keynote Lecture:</u> <i>Screening for Ovarian Cancer: The Way Forward</i> , 10th Biennial Ovarian Cancer Research Symposium , Seattle, USA
36	13 th Jul 2014	<i>Managing familial gynaecological cancer risk</i> , Association of Gynaecologic Oncologists of India (AGOI) annual meeting , Bangalore, India
37		<i>Ovarian cancer screening</i> , AGOI Annual meeting , Bangalore, India
38	27 th Jun 2014	<i>Screening for Ovarian Cancer</i> , Biennial Ovarian Cancer Symposium , National University of Singapore, Singapore
39	8 th May 2014	<i>Ovarian and endometrial ultrasound cancer screening</i> , 23rd European Congress of Obstetrics and Gynaecology (EBCOG 2014) , Glasgow, Scotland
40	25 th Apr 2014	<i>The evolution of invasive epithelial ovarian cancer – Insights from UKCTOCS</i> , BSGI, Annual Scientific Meeting , RCOG, London, UK
41	29 th Mar 2014	<u>Singapore Lecture:</u> <i>Managing Ovarian Cancer Risk</i> RCOG World Congress 2014 , Hyderabad, India
42	18 th Jan 2014	<i>Ovarian cancer symptoms - where to set the bar?</i> 39th Annual Conference of The Bengal Obstetric & Gynaecological Society , Kolkata, India
43	30 th Nov 2013	<i>Genes, lifestyle and risk of ovarian cancer</i> , Ranbaxy Science Foundation's 30th Round Table Conference on 'Lifestyle and Cancer with focus on Cancer Prevention' , All India Institute of Medical Sciences, New Delhi, India
44	29 th Nov 2013	<u>Keynote lecture:</u> <i>Ovarian cancer screening</i> , 46th Dr Subodh Mitra Memorial Oration, Bengal Obstetric & Gynaecological Society , Chittaranjan Seva Sadan College of Obstetrics, Kolkata, India
45	22 nd Nov 2013	<i>Ovarian cancer screening</i> , Indian Cancer Congress Annual Meeting , New Delhi, India
46	24 th Oct 2013	<i>Time series algorithms – what can we learn from UKCTOCS?</i> Ovarian Cancer: Developing Research-Based Public Messaging on Early Detection and Screening , Cold Spring Harbour, New York, USA
47	21 st Oct 2013	<i>Clinical Trials – management and implementation</i> , 18th International Meeting ESGO , Liverpool, UK

No	Date	Details
48	3 rd Oct 2013	<i>Screening for ovarian cancer – New insights, future directions</i> , Gynaecological Visiting Society (GVS) , London, UK
49	25 th Sep 2013	<i>Screening for ovarian cancer</i> , Annual General Meeting , The Royal Society of Medicine, London, UK
50	7 th Sep 2013	<i>Screening for ovarian cancer – new insights, future direction</i> , Indo-UK Oncology Summit , Chennai, India
51	11 th Apr 2013	<i>Rethinking screening strategies for ovarian cancer</i> , Nordic Society of Gynecologic Oncology (NSGO) Annual Meeting 2013 , Stockholm, Sweden
52	15 th Mar 2013	<i>Update from the UKCTOCS Trial</i> , Annual Scientific Meeting – Joint RCOG/BSGI , RCOG, London, UK
53	5 th Nov 2012	<i>Ovarian Cancer Screening – the future</i> , 8th NCRI Cancer Conference , Liverpool, UK
54	5 th Jul 2012	<i>Screening for ovarian cancer – new insights, future directions</i> , BGCS , The QEII Conference Centre, London, UK
55	30 th Nov 2011	<i>Quo Vadis? – Biomarker discovery for Ovarian Cancer Screening Consensus Workshop and Changing the clinical paradigm for ovarian cancer – insights from UKCTOCS</i> , Ovarian Cancer Screening Conference , The Royal College of Physicians, London, UK
56	29 th Nov 2011	<i>General population screening – current status and insights from the trials: UKCTOCS</i> , International Conference on Ovarian Cancer Screening , London, UK
57	18 th Nov 2011	<i>Morbidity in Gynaecological Oncology – United Kingdom Gynaecological Oncology Surgical Outcomes and Complications (UKGOSOC)</i> , BGCS Autumn Scientific Meeting , Birmingham, UK
58	10 th Sep 2011	<i>Screening for ovarian and endometrial cancer</i> , 9th Congress of the European Society of Gynecology , Copenhagen, Denmark
59	10 th Sep 2011	<i>Effect of screening on ovarian cancer mortality</i> , ASCO 11th annual Meeting , Chicago, USA
60	3 rd Jun 2011	<i>Surgery, Co-morbidity and Complications; Preliminary data from United Kingdom Gynaecological Oncology Surgical Outcomes and Complications</i> , BGCS meeting , Cardiff, UK
61	19 th May 2011	<i>Ultrasound scanning accuracy in UKCTOCS</i> , BSGI , Royal College of Obstetricians and Gynaecologists London, UK
62	16 th Jan 2011	<i>Serial CA125 can detect ovarian cancer in the absence of ultrasound abnormalities</i> , Helene Harris Memorial Trust 12th International Forum on Ovarian Cancer , Hallandale, Florida, USA
63	23 rd Sep 2010	<i>UKCTOCS – an update</i> , 13th Biennial IGCS Meeting , Prague, Czech Republic

No	Date	Details
64	6 th Sep 2010	<i>Biomarkers for Screening and Early Detection of Ovarian Cancer</i> , 38th International Society for Oncodevelopmental Biology Meeting , Munich, Germany
65	6 th Jun 2010	<i>High Risk Ovarian cancer Screening: Is It Useful?</i> ASGO Annual Meeting , Chicago, USA
66	15 th Apr 2010	<i>Screening for Ovarian Cancer – Biochemical Markers or Ultrasound</i> , Joint RCOG/BSGI Meeting and Workshop , London, UK
67	27 th Feb 2010	<i>Familial Ovarian Cancer – Risk Management</i> , AICC RCOG 25th Annual Conference , Kolkata, India
68	25 th Feb 2010	<i>Interactive case discussions with Cytology, colposcopy & histology correlation, and unedited video presentation</i> , AICC RCOG 25th Annual Conference , Kolkata, India
69	11 th Feb 2010	<i>Ovarian Cancer Screening Current Trials and Unanswered Questions</i> , Ovarian Cancer Research Forum , RCOG, London, UK
70	14 th Jan 2010	<i>Better outcomes for Ovarian Cancer Generating the evidence</i> , 8th CMC Winter Symposium Evidence for Better Health , Christian Medical College, Vellore, India
71	23 rd Jul 2009	<i>Does serum CA125 hold the key to decreasing deaths from ovarian cancer?</i> 10th International Mucin Meeting , Cambridge, UK
72	8 th Jun 2009	<i>The prevalence screen in UKCTOCS</i> , Early Origins of Ovarian Cancer Symposium , Norris Cancer Centre, Los Angeles, USA
73	29 th Nov 2008	<i>Ovarian Cancer Symptoms – where to set the bar</i> , Annual meeting of Sexual Health , London, UK
74	4 th Sep 2008	<i>The prevalence screen in the United Kingdom Collaborative Trial of Ovarian Cancer Screening</i> , 7th Biennial Ovarian Cancer Research Symposium , Seattle, USA
75	20 th May 2008	<i>Clinical aspects of ovarian cancer and current markers</i> , FOCUS 2008 Annual National Meeting of the Association of Clinical Biochemistry , Birmingham, UK
76	12 th Apr 2008	<i>Screening for Ovarian Cancer</i> , 2nd World Congress , International Society for Mild Approaches to Assisted Reproduction, London, UK
77	8 th Apr 2008	<i>Ovarian Cancer Symptoms – Studies underway in the UK</i> , Ovarian Cancer Consensus Meeting , RCOG, London, UK
78	7 th Apr 2008	<i>The State of Art in Ovarian Cancer Screening</i> , Innovations and progress in Healthcare for Women , 1 st International Conference of the UCL Institute for Women's Health, London, UK
79	5 th Oct 2007	<i>The relevance of screening clinical trials and their potential effect on the participants</i> , Clinical Research Nurses Association Annual Conference , Canterbury, UK

No	Date	Details
80	17 th Sep 2007	<i>Managing Familial Ovarian Cancer Risk</i> , British Human Genetics Society Annual Conference , York, UK
81	22 nd Jun 2007	<i>Ovarian Cancer Screening Can we Save Lives?</i> Christian Medical College Alumni Association Annual Meeting , Iowa, USA
82	2 nd Jun 2007	<u>Lead Discussant:</u> <i>Screening and Management of Early Stage Ovarian Cancer</i> , ASCO Annual meeting , Chicago, USA
83	18 th Apr 2007	<i>Ovarian Cancer Screening</i> , Royal College of Radiologists Screening Day , London, UK
84	17 th May 2007	<i>Update on UKCTOCS Trial, Female Malignancies – Imaging, Screening, Managing Treatment Meeting</i> , Institute of Physics, London, UK
85	14 th Dec 2006	<i>Ultrasound screening for ovarian cancer</i> , 38th Annual Scientific Meeting British Medical Ultrasound Society , RCOG, London, UK
86	24 th Oct 2005	<i>UKCTOCS: Design And Characteristics of the Study Population</i> , Ovarian Cancer Symposium , Pittsburgh, USA
87	20 th May 2004	<i>Will ovarian cancer screening save lives?</i> 25th Anniversary Meeting BGCS , London, UK
88	5 th Dec 2003	<i>Screening for Sporadic Ovarian Cancer</i> , 13th Annual Meeting in Honour of Professor Per Kolstad , Norwegian Radium Hospital, Oslo, Norway
89	15 th Oct 2003	<i>Screening for Ovarian Cancer – Current Trials</i> , Annual Joint Gynaecology Oncology Meeting , Institute of Molecular Medicine, Oxford, UK
90	8 th Sep 2003	<i>Screening Studies – UKCTOCS / UKFOCSS</i> , Joint National Conference of the National Cancer Research Network and British Oncology Data Manager's Association , University of Nottingham, UK
91	27 th Mar 2003	<i>Current Ovarian Cancer Screening Trials</i> , Helene Harris Memorial Trust Meeting , Stratford on Avon, UK
92	8 th Jan 2003	<i>Progress in Screening for Ovarian Cancer</i> , All India Congress of Obstetrics and Gynaecology , Bangalore, India
93	7 th Apr 2003	<i>Prevalence screening for ovarian cancer using Risk of Ovarian Cancer Algorithm</i> , ESGO Meeting , Brussels, Belgium
94	19 th Sep 2002	<i>Ovarian cancer screening</i> , 4th Ovarian Cancer Research Symposium , Swedish Medical Centre, Seattle, USA
95	17 th Jul 2002	<i>Screening for Ovarian Cancer</i> , Key Advances in the Effective Management of Ovarian Cancer , Royal College of Physicians, London, UK
96	17 th Jun 2002	<i>Screening for Ovarian Cancer</i> , Annual Meeting of the European Society of Urogenital Radiology , Genoa, Italy

No	Date	Details
97	7 th Nov 2001	<i>Sonography in ovarian cancer screenin – Review and update of ongoing trials, 4th Annual International Ovarian Cancer Screening Meeting, Fred Hutchinson Cancer Research Center, Seattle, USA</i>
98	6 th Mar 2001	<i>Developments in screening and preoperative diagnosis of ovarian cancer, Regional Scientific Meeting of Association of Clinical Biochemists, Edinburgh, UK</i>
99	9 th Sep 2000	<i>Risk of Ovarian Cancer Algorithm (ROCA) for the Early Detection of Ovarian Cancer, XXVIII International Society for Oncodevelopmental Biology Meeting, Munich, Germany</i>
100	10 th Nov 2000	<i>Screening for Ovarian Cancer, National Screening Committee Meeting on Screening for late onset genetic disorders – breast ovarian cancer, Cardiff, UK</i>

PATENTS

European Patent No: EP10178345.4

File Date: 22/09/2010

Applicant: Institute of Molecular Biotechnology GmbH (IMBA)

Title: Breast Cancer Diagnostics: This describes the implications of RANKL inhibition in prevention of hormone driven breast cancer.

Inventors: Widschwendter, Jacobs, Menon, Penninger, Schett and Schramek.

RESEARCH SUMMARY

The main focus of my research to date is risk prediction, screening and early detection of cancer with a particular focus on gynaecological malignancies. The core of the work is related to ovarian cancer. The research has involved widespread collaborations with groups in the UK, USA, Europe and Australia. Some of the key areas are:

A. OVARIAN CANCER SCREENING

General population – UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS):

Role – Co-Principal Investigator and Trial Co-ordinator main trial

Chief Investigator for extended follow-up

UKCTOCS is the largest individual randomised controlled trial (RCT) ever undertaken that we are aware of. It is at the heart of sustained efforts to impact on ovarian cancer mortality through earlier diagnosis. The trial has involved 1.2 million invitations, 202,638 participants, 673,765 annual screens between 2001-2011 and 2.2 million women-years of follow-up. At censorship on 31st December 2014, there was a significant stage shift but the mortality reduction was not definitive as the effect size at 15% was smaller than anticipated. Extended follow-up is now underway till 31st Dec 2018. The outcome of this trial will affect

practice throughout the world and will determine whether the UK has an ovarian screening programme akin to breast and cervical screening.

**High-risk population – UK Familial Ovarian Cancer Screening Study (UK FOCSS):
Role – Co-Investigator**

This is the largest screening study undertaken in women at risk of familial ovarian cancer due to a genetic predisposition. The aim is to optimise screening. Over 5,700 high-risk women were recruited and screened through 47 trial centres between 2002-2011. The results published in 2017 show that 4 monthly multimodal screening can result in detection of earlier stage and lower volume disease with significant higher rates of cytoreduction at surgery. Results are being evaluated by independent bodies and will determine how high-risk women are managed in the UK and elsewhere.

B. IMPROVING CANCER RISK PREDICTION

Improved risk prediction strategies are crucial to targeting the prevention and screening efforts. My work in this area has involved:

UK Ovarian Cancer Population Study (UKOPS): Role – Principal Investigator

This is a 10-centre biobanking study where high quality biological samples and detailed epidemiological data was collected from 1,200 women with ovarian cancer and 2,500 healthy controls to better understand risk factors for the disease and explore biomarkers. This cohort is one of the largest in the OCAC and has contributed to over 80 publications to date.

Exploring genetic and epigenetic risk: Role – Founding member Ovarian Cancer Association Consortium (OCAC)

As part of this international collaborative effort, now involving 76 studies from around the world, numerous analyses have been completed with more underway to identify single nucleotide gene polymorphisms and gene environment interactions that increase risk of ovarian cancer in the general population. My team has contributed to OVER 75 papers many in leading journals, including the first genome wide association study for ovarian cancer.

Building new risk prediction algorithms – PROMISE: Role – Co-Investigator

A collaborative multidisciplinary CRUK programme is underway to build new risk and screening ovarian cancer algorithms for both general and high-risk populations, using the data collected in the course of UKCTOCS. I lead the work stream on screening and novel biomarkers. Novel markers and new longitudinal algorithms have been discovered and multiple publications are being drafted.

Improving implementation of current risk prediction strategies – Genetic Cancer Prediction through Population Screening (GCaPPS): Role – Co-Investigator

Currently individuals at high-risk of cancer are identified by their family history. The current strategy however misses a proportion of high-risk individuals. GCaPPS is a RCT where Ashkenazi Jewish individuals were randomised to population testing for BRCA gene (study

arm) versus testing based on family history (standard arm). It has shown definitively that in populations with high prevalence of BRCA mutations, population testing does not cause psychological harm, identifies more carriers at risk and is highly cost-effective. Additionally, DVD based counselling was found to be non-inferior, time efficient and cost-saving compared to standard genetic counselling. It has led to ongoing efforts to change the current paradigm of family history based testing in the Jewish population.

C. BIOBANKING AND SECONDARY STUDIES

Building and utilising trial biobanks. Role – Principal Investigator

I have built a mega biorepository of high quality samples and associated epidemiological, clinical and long term ongoing follow up data from the two ovarian cancer screening trial cohorts described above – UKCTOCS (544,808 serum samples from 189,452 postmenopausal women, including median of 9(IQR 6-10) annual serum samples from 50,262) and UKFOCSS (76915 samples from 5000 high risk women aged >35) alongside the multicenter UKOPS (11519 samples from 4,600 women) collection. To date the focus has been on case control studies to identify and validate cancer biomarkers and has included 18 successful grant applications, 48 research projects and 108 peer reviewed publications. However explicit consent for secondary studies, established electronic health record linkage (eHR) to national cancer, death and hospital administration databases with the potential for further comprehensive eHR phenotyping, provides the potential to recreate all medical conditions and syndromes of relevance to women. Going forwards the aim is to transform these banks into biorepositories for study of chronic conditions. Proposals for genotyping of the entire UKCTOCS cohort to establish a platform for genomics enabled drug target identification and discovery as well as expanding case-control studies for the identification/validation of proteomic and metabolomics biomarkers for non-cancer diseases are underway. Utilisation of the samples and sustainability of biobanks is a core interest. The UKCTOCS Biobank has been the basis of a UCL spin-out company, Abcodia Pvt Ltd.

Facilitating Cancer biobanking in India: Role – Principal Investigator

I have led setting up the of a cancer biobank at Tata Medical Center (TMC), Kolkata, India – a tertiary cancer hospital serving the east and northeast of India to enable collection of high quality biological samples and detailed epidemiological and clinical data from patients. The work has involved setting up the bank with dedicated core staff, standard protocols, ethical approval, specialised biobanking software, sample processing laboratory and a cryofacility. I facilitated training of the biobank officer who spent time with my UCL team, as well as visited the Royal Free and Manchester biobanks. The aim is for local PIs to use the bank for their research and over the last three years multiple groups – gynaecological oncology, breast, paediatric oncology, head and neck – have used it to bank over 1000 samples for their research projects and to support their grant applications. The bank is overseen on a day-to-day basis by a Biobank Oversight Committee. I worked with the local team to organise a cancer Biobank Workshop in Kolkata, held from 12th – 13th January 2017. The plan is for me in 2018 to hand over full governance of the bank to the TMC faculty.

D. DISCOVERY AND VALIDATION OF NEW CANCER BIOMARKERS

A number of studies are underway in collaboration with glycobiology, proteomics and epigenetics groups both within UCL, as well as nationally and internationally using a variety of technologies to discover and validate novel cancer biomarkers and algorithms. All use samples and data from the team biobanks – UKCTOCS, UK FOCSS and UKOPS. Currently the focus is on discovery and validation of markers in ovary, breast, lung, colon and pancreas. The work involves both academic collaborations and in the case of UKCTOCS, industrial collaborations led by Abcodia (details below).

E. EARLIER DIAGNOSIS OF CANCER THROUGH BETTER UNDERSTANDING OF SYMPTOMS

Delays and misdiagnosis of persistent non-specific symptoms are recurring themes in many common cancers. Work to date has involved:

Ovarian cancer symptoms: Role – Principal Investigator

A nested case control study in UKOPS involving patient questionnaire and telephone interviews, as well as GP notes review of symptoms in women with newly diagnosed with ovarian cancer.

Prospective study of ovarian cancer symptoms: Role – Principal Investigator

In the UKCTOCS cohort 100,000 apparently healthy postmenopausal women were invited to report on a week's symptoms and are being followed up prospectively to determine cancer diagnosis. Data analysis is planned for 2018.

Detailed analysis of ovarian cancer symptoms and routes to diagnosis in a population based cohort – the control arm of UKCTOCS: Role – Principal Investigator

Detailed data on all women diagnosed with ovarian cancer in the course of the trial have been retrieved and collated. Data analysis is underway.

International Cancer Benchmarking Partnership (ICBP) Module 4: Role – Co-Chair

The ICBP is a unique and innovative international partnership of clinicians, academics and policymakers seeking to determine how cancer survival varies between countries which spend similar amounts on health and to explore reasons that could explain any differences. Module 4 is a prospective survey of 8,000 newly diagnosed patients with bowel, lung, breast and ovarian cancer to determine root causes of delay in diagnosis and treatment across ten jurisdictions in Canada, Australia, Norway, Sweden, Denmark and the UK. Data analysis is complete and a series of publications are in the process of being submitted. It is likely that these will have a significant impact on the patient pathways in the jurisdictions that participated.

F. IMPROVING DELIVERY OF GYNAECOLOGICAL ONCOLOGY IN UK

UK Gynaecological Oncology Surgery Outcomes and Complications (UKGOSOC):

Role – Principal Investigator

This was a prospective study of outcomes following major gynaecological oncology surgery involving 10 NHS Trusts during 2009 – 2011. Data was collected on 3,000 operations using

web based data entry on to a central bespoke management system with individual follow up of patients to document any morbidity not captured by the clinical teams. Complication rates for benchmarking surgery were published, as well as models for comparing centres.

Short term ovarian cancer mortality: Role – Co-Investigator

Factors associated with excess mortality in the first year after diagnosis of primary invasive epithelial ovarian, tubal and primary peritoneal cancer were investigated using routinely collected national data for patients diagnosed in England in 2008 – 2010. Our results supported the need to increase symptom awareness, promote timely general practitioner referral and optimise diagnostic and early treatment pathways within secondary care to increase access to treatment for these women.

EDUCATION

HIGHER RESEARCH DEGREES - SUPERVISION

Name	Degree, date awarded, university, submission due	Supervisory role	Funding
Mr Matthew Izett	MD(Res) ongoing, UCL, submission due 2021	Primary	Self
Mr Darren Thomas	PhD ongoing, UCL, submission due Nov 2018	Primary	MRC Case PhD Studentship
Ms Lindsay Fraser	PhD ongoing, UCL, submission due Sep 2020	Primary	Women’s Cancer, UCL
Dr Paul Trembling	PhD ongoing, UCL, submission due 2020	Secondary	Self
Dr Will Stott	PhD, Nov 2016, UCL	Primary	The Eve Appeal grant
Dr Rema Iyer	MD(Res), Apr 2016, UCL	Primary	Women’s Cancer, UCL
Dr Stephanie Smits	PhD, Sep 2014, Cardiff University	Tertiary	MRC / Cardiff University
Dr Emma Low	PhD, Sep 2013, UCL	Tertiary	IMPACT PhD Studentship
Dr Aarti Sharma	PhD, Sep 2013, UCL	Primary	MRC grant
Dr Ranjit Manchanda	PhD, Aug 2013, UCL	Secondary	The Eve Appeal grant
Dr Evangelia-Ourania Fourkala	PhD, Dec 2010, UCL	Primary	MRC PhD Studentship
Dr Penny Allen	PhD, Feb 2010, UCL	Primary	MRC PhD Studentship
Dr Anita Lim	PhD, Jun 2009, QMUL	Secondary	CRUK

I have also supervised two MSc dissertation projects.

HIGHER RESEARCH DEGREES - EXAMINATION

Date	Name	Degree	Title	University
25 th Nov 2016	Thangesweran Ayakannu	PhD	Investigation of endocannabinoid system signalling pathways and their regulations in endometrial carcinoma	University of Leicester, UK
19 th Feb 2016	Laura King	PhD	Investigating the transformative potential of different <i>TP53</i> mutations in cell line models of early high-grade serous ovarian cancer	Queen Mary University of London, UK
16 th Apr 2015	Jeroen Kaijser	PhD	Towards an evidence-based approach for diagnosis and management of adnexal masses	Katholieke Universiteit Leuven, Belgium
6 th Dec 2010	Evelien Vaes	PhD	Mathematical models for differential diagnosis of ovarian cancer	Katholieke Universiteit Leuven, Belgium
1 st Apr 2010	Dr B J Hermsen	PhD	Risk profile of women at hereditary high risk for breast and ovarian cancer	VU University, Amsterdam, The Netherlands
31 st Mar 2009	Dr A Ahmed	MD	Tumour M2-PK, a novel marker in ovarian cancer	King's College London, UK
18 th Dec 2006	Clare Allen	PhD	Autoantibodies and breast cancer	University of Nottingham, UK

Integrated Clinical Academic Training: I oversee the research training of the Academic Foundation Programme doctors, Academic Clinical Fellows and Academic Clinical Lecturers in the IfWH and the appointment and assessment of the same in the North East and Central London Deanery.

TAUGHT COURSES

Undergraduate teaching: I have always taught the Medical Students in Obstetrics and Gynaecology and regularly examine on the Obs and Gynae Objective Structured Clinical Examination at UCL. I also teach on the iBSc in Women's Health and the BSc Population Health programmes.

I have had Medical Students working alongside the research team on a variety of projects and they have been co-authors on a number of papers. I mentor the undergraduate MBBS students and currently am tutor to eight students (four each from the 5th and 6th years).

Postgraduate teaching: I teach on a regular basis on the IfWH MSc Reproductive Science and Women's Health course and am often invited to teach on others in the UK, such as the Postgraduate Oncology MSc, IfWH MSc Breast and Reproductive Cancers module, MSc

Clinical Trials lecture, IfWH Director's Epidemiological Study Design Lecture Series, MSc Cancer Genetics and MSc Population Health. I regularly mentor IfWH MSc students.

Other teaching: I regularly contribute to teaching in a variety of settings as outlined below.

Date	Title / organisation
20 th Oct 2017	<i>Academic training and research, London Speciality School of Obstetrics & Gynaecology ST1 Induction & Welcome Day, Stewart House, London, UK</i>
7 th Nov 2016	<i>Managing the academic workload, IfWH Autumn Meeting, UCL School of Slavonic and Eastern European Studies, London, UK</i>
2 nd Nov 2016	<i>Screening for gynaecological cancer – cervical, endometrial and ovarian cancer – current knowledge, challenges and future, BSc Population Health programme (Frontiers of Knowledge in Population health module), Birkbeck College, UCL, London, UK</i>
20 th Oct 2016	<i>Lynch Syndrome – management of gynaecological cancer risk, London Cancer Gynaecology Annual Education Open Meeting 2016, London Cancer, London, UK</i>
4 th Oct 2016	<i>Timing and management of RRSO in premenopausal high risk women, London Risk Reducing Mastectomy (LRRM) Multi-Disciplinary Team (MDT) Meeting, Great Omond Street Hospital for Children NHS Foundation Trust, London, UK</i>
13 th Sep 2016	<i>Steps to Academic Success, 11th Biennial Ovarian Cancer Research Symposium, 12 – 13 Sep 2016, University of Washington, Seattle, Washington DC, USA</i>
7 th Apr 2016	<i>UKCTOCS – ovarian cancer screening trial results and next steps, London Cancer Gynaecology Pathway Research Day, UCLPartners, London, UK</i>
30 th Mar 2016	<i>Ovarian cancer screening – the long journey, Department of Biological Sciences Colloquium, Presidency University, Kolkata, India</i>
26 th Mar 2016	<i>Management of women at risk of ovarian and endometrial cancer, Gynaecological Oncology for the Trainees, Tata Medical Center, Kolkata, India</i>
21 st Mar 2016	<i>Ovarian cancer screening – the long journey, TALES Session, Tata Medical Center, Kolkata, India</i>
27 th Nov 2015	<i>Ovarian cancer screening: where are we now? South Wales Gynaecological Oncology Group – 12th Educational Meeting, Innovations Hub, Cardiff, UK</i>
25 th Oct 2015	<i>Glass with the Expert session: <u>Management of familial gynaecological cancer risk</u>, 19th International Meeting ESGO 2015, Nice, France</i>
20 th Oct 2015	<i><u>Mentoring Roundtable session: <i>Becoming a successful clinical academic</i></u>, AACR Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, Orlando, USA</i>
18 th Jun 2015	<i>Ovarian screening latest news, London Cancer Gynaecology Annual Education Open Meeting, UCLPartners, London, UK</i>
5 th Feb 2015	<i>Risk reducing salpingo-oophorectomy in BRCA carriers – an update, Gynaecology and Breast Combined Research Day, UCLPartners, London, UK</i>
8 th Sep 2014	<i>“Meet the Expert” roundtable discussion: <i>Initiating and Maintaining Collaborations</i>, 10th Biennial Ovarian Cancer Research Symposium, Seattle, Washington, USA</i>

Date	Title / organisation
14 th May 2010	<i>Challenges of Running Large Trials</i> , OXSF0G 2010 , Wexham Park Hospital, Slough, Berkshire, UK
27 th Aug 2009	<i>Managing clinical trials – the UKCTOCS experience</i> . Department of Biostatistics meeting, Massachusetts General Hospital, Boston, USA
19 th Jun 2008	<i>Innovative approaches to management of clinical trial – the UKCTOCS experience</i> , Junior Oncology Club , Royal Society, London, UK
12 th Oct 2005	<i>Screening for Ovarian Cancer</i> , Annual meeting of the Fothergill Club , RCOG, London, UK
3 rd Jul 2006	<i>Innovative approaches to management of clinical trials – the UKCTOCS experience</i> , MRC Cancer Clinical Trials Unit Seminar , London, UK
10 th May 2006	<i>Innovative approaches to management of clinical trials – the UKCTOCS experience</i> , Public Health, Epidemiology & Biostatistics Unit meeting , University of Birmingham, UK
9 th Mar 2005	<i>Ovarian cancer: Will screening impact on mortality?</i> The Practical Management of Ovarian Cancer meeting , Westminster, London, UK
15 th Mar 2005	<i>Progress in Managing Ovarian Cancer</i> , GP Masterclass , London, UK
12 th Jan 2005	<i>Screening for Ovarian Cancer</i> , Joint Course in Clinical Oncology , Royal College of Radiologists, London, UK
14 th Sep 2004	<i>Screening for Ovarian Cancer</i> , Gynaecological Ultrasound Course , Royal College of Obstetricians and Gynaecologists, London, UK
8 th May 2003	<i>Screening for Ovarian Cancer</i> , Gynaecology Nursing Forum Conference of Royal College of Nursing , Leeds, Yorkshire, UK
24 th Sep 2002	<i>Screening for Ovarian Cancer</i> , Gynaecological Ultrasound Course , RCOG, London, UK
7 th Nov 2001	<i>Screening for Ovarian Cancer</i> , Screening in Gynaecological Oncology , Sint-Augustinus Hospital, Antwerp, The Netherlands
24 th Sep 2001	<i>Screening for Ovarian Cancer</i> , The silent disease – Ovarian Cancer , Royal Surrey County Hospital NHS Foundation Trust, Guildford, Surrey, UK
19 th Sep 2001	<i>Screening for Ovarian Cancer</i> , Gynaecological Ultrasound Course , RCOG, London, UK
3 rd May 2001	<i>Ovarian cancer – Screening and risk reducing strategies</i> , Cancer Genetics for the Non-Specialist , St George's Hospital Medical School, London, UK
30 th Mar 2001	<i>Screening for Ovarian Cancer</i> , Principle and practice of screening in obstetrics and gynaecology , North West Wales NHS Trust, UK
30 th Oct 2000	<i>Familial Ovarian Cancer – the essential facts</i> , Key Issues in the care of Women with Gynaecological Cancers , Imperial College School of Medicine, London, UK
24 th Nov 2000	<i>Further thoughts on ovarian cancer screening</i> , Gynaecological Oncology – Cervical and Ovarian Cancer , St George's Hospital Medical School, London, UK

LEADERSHIP

I was appointed Interim Director IfWH job-share with Professor Judith Stephenson in July 2016. During the 9-month period we were in post, we instituted a senior staff meeting, greater transparency on all issues and a more proactive approach to supporting middle rung staff in their careers. We submitted and were awarded the only Athena SWAN gold awarded in 2016.

I was a member of the UCL/UCLH IfWH Strategic Planning Board since inception in 2004 till 2009, contributing to the vision and strategy of the early days.

I have been group leader from 2000. The group has numbered from 40 when all the large trials were active to currently 10. The group has always been multidisciplinary and diverse with an excellent balance of gender, ethnicity and age. Over the past 15 years, I have overseen a budget of ~£35 million and always achieved considerable savings while delivering targets.

For most part, my leadership role has been in the research arena and I have led implementation of a number of multicentre studies involving numerous senior investigators and many organisations. The most challenging of them was UKCTOCS which involved six other senior investigators, 18 senior consultants/academics leading the 13 regional centres and interaction with numerous NHS and other governmental organisations. The successful completion of UKCTOCS was hailed as a major achievement for clinical science in the NHS and a tribute to widespread collaboration in the accompanying Lancet editorial.

KNOWLEDGE TRANSFER / EXCHANGE ACTIVITY

Patient and public engagement

In all our trials, I have been innovative in our approach to informing and including participants. In the ovarian cancer screening trials, at the end of screening, I commissioned an artist to paint a 'Graafian follicle' which she then digitised such that each point represented 8 trial participants. Each of the over 205,000 women who participated in UKCTOCS / UK FOCSS were sent a personal 'thank-you' card with the images.

I work closely with the UK ovarian cancer patient support groups/charities. I am on the medical board of the ovarian cancer support group, OVACOME and support both them, The Eve Appeal, Ovarian Cancer Action and Target Ovarian Cancer by speaking at their members' days, attending 'all party parliamentary' meetings on their behalf, contributing articles to their newsletters. I speak regularly at the BRCA carrier days organised by multiple hospitals. I have forged links with the Indian Cancer Society, Delhi and spoken at their annual meeting on familial cancer to lay audiences in India.

Date	Title / organisation
5 th Mar 2016	<i>Prevention and detection: Update on UKCTOCS study</i> , Ovacom Members' Day , St Luke's Community Centre, London, UK

17 th Dec 2015	<i>UKCTOCS results explained, UKCTOCS Charity Event</i> , RCOG, London, UK
17 th Nov 2015	<i>Management of gynaecological cancer in Lynch Syndrome, Information Evening for Lynch Syndrome Carriers</i> , London, UK
24 th Oct 2015	<i>Ovarian Cancer – UKCTOCS study: the outcomes, 3rd ENGAGe Patient Seminar</i> , Nice, France
30 th Oct 2012	<i>Ovarian Cancer Screening, All Party Parliamentary Group on Ovarian Cancer, Target Ovarian Cancer</i> , The House of Commons, Westminster, London, UK
25 th Oct 2011	<i>Hereditary Cancer – an overview, Indian Cancer Society, Annual meeting 2011</i> , Delhi, India
22 nd Sep 2011	<i>Managing gynaecological Cancer Risk, BRCA Patient Day</i> , The Royal Marsden Hospital, Chelsea, London, UK
7 th Mar 2008	<i>Ovarian Cancer Symptoms, What has Research Shown? Challenge of Ovarian Cancer Conference</i> , Angels of Hope Charity, Belfast, Northern Ireland, UK
24 th Apr 2006	<i>Risk Reducing Salpingo-Oophorectomy & Familial Ovarian Cancer Screening, The Royal Marsden Hospital Patient Education Day</i> , Chelsea, London, UK
18 th Jan 2006	<i>Reducing the risk of ovarian cancer, BRCA Carrier Day</i> , Guy's Hospital, London, UK
15 th Jan 2006	<i>Ovarian Cancer – Screening and risk reducing strategies, Cancer BACUP meeting</i> , London, UK
6 th May 2004	<i>High risk families – UK Familial Ovarian Cancer Screening Study, OVACOME meeting</i> , London, UK
3 rd Nov 2003	<i>United Kingdom Familial Ovarian Cancer Screening Study, Annual Meeting of the Traveller's Society</i> , London, UK
10 th May 2003	<i>Screening And Risk Reducing Surgery, BRCA Carrier Day</i> , Guy's and St Thomas' NHS Foundation Trust, London, UK

Informing Public Policy

Between 2009 – 2015, as a member of the gynaecological oncology oversight committees at the National Cancer Intelligence Network, I contributed to their annual reports which have helped inform policy decisions with regard to delivery of gynaecological cancer care. In the absence of good data on surgical outcomes, I set up a prospective national audit, UKGOSOC at the behest of the gynaecological oncological surgeons to set benchmarking standards for surgical outcomes for UK.

I was a member of the Gynaecological Oncology working group set up by the Department of Health in 2008 to facilitate roll out of the Cancer Reform Strategy in Gynaecological Oncology and kick start the National Awareness and Early Detection Initiative in cancer. Currently I am a member of the working group in the Department of Health 'Be Clear on Cancer' campaign.

Enabling activity

The trial biobanks have enhanced the ability of laboratory based researchers within the department to explore new ideas, set up successful collaborations, and apply for major grants. Professor Martin Widschwendter, Dr John Timms, as well as Prof Ian Jacobs and Prof

Simon Gayther (previously in Women’s Cancer) have all used the banked samples and data to both generate and validate hypotheses and successfully apply for large CRUK / EU grants.

The high quality UKCTOCS biobank has also contributed towards the research of many UCL groups (listed below) in areas beyond my core research interest – women’s cancer. My team and I have spent significant time and effort in the design of nested case control studies and the identification of cases, matching of controls and organising of research governance in order to help the groups below. This has enhanced the ability of researchers especially the Cardiovascular group to set up successful collaborations and apply for major grants.

Title	Collaborations
Identifying biomarkers and risk factors for colorectal cancer	Dr John Timms (UCL EGA Institute for Women’s Health)
Interrogation of UKCTOCS serum bank for existing and novel markers of Pancreatic, Biliary Tract and Liver Cancer	Prof Stephen Pereira (UCL Institute for Liver and Digestive Health), Dr John Timms (UCL EGA Institute for Women’s Health)
An investigation of novel biomarkers for cardiac disease and stroke screening and diagnosis	Prof Aroon Hingorani, Prof Philippa Talmud (UCL Institute of Cardiovascular Science), Prof JP Casas Romero (UCL Institute of Health Informatics)
Identification of novel biomarkers of heavy alcohol use and liver fibrosis in primary care	Prof William Rosenburg, Dr Paul Trembling (UCL Institute for Liver and Digestive Health)
Cardiometabolic disease prediction using high-resolution 1 H-nuclear magnetic resonance metabolomics (The UCLEB consortium)	Prof Aroon Hingorani (UCL Institute of Cardiovascular Science), Prof JP Casas Romero (UCL Institute of Health Informatics)
Heritage in Hospitals: An investigation of the therapeutic and enrichment potential of object handling in hospitals and other healthcare organisations	Prof Helen Chatterjee (Grant Museum of Zoology, UCL Culture), Guy Noble (Arts and Heritage, ULCH), Dr Anne Lanceley (UCL EGA Institute for Women’s Health)

Contributing to industry / enterprise

The UKCTOCS biobank led to the set-up of a UCL start-up Abcodia Pvt Ltd. Abcodia has exclusive commercial rights to a serum biobank to undertake discovery and validation studies of early detection biomarkers. It has teamed with Cancer Research UK to explore comprehensively early detection markers in bowel and lung cancers. The work is facilitated by myself as Chief Investigator and my team, overseeing governance for the various nested case control studies, identification of appropriate sample/data sets and anonymization of all data.

More recently Abcodia has acquired the commercial licence from Massachusetts General Hospital for the use of the Risk of Ovarian Cancer Algorithm (ROCA) which is core to the multimodal ovarian cancer screening strategy that has shown initial promise in UKCTOCS and UKFOCSS. I have worked with Abcodia in preparing the datasets for FDA submissions and am on the Steering committee of their new Cancer Vanguard project.

I have set up close collaborations with the not-for-profit cancer hospital, TMC in Kolkata. I regularly visit the hospital where I hold an honorary senior consultant contract. In addition to facilitating biobanking (details above) I have been mentoring and helping clinicians in gynaecological oncology and psycho oncology to set up independent research programmes.

CLINICAL ACTIVITY

My core clinical interest is management of women at increased risk of familial gynaecological cancer. I run a tertiary level gynaecological familial cancer service at University College Hospital with referrals from all over London and beyond. Management of high-risk women is based on the latest research findings.

APPENDIX 1

PUBLICATIONS – published conference abstracts

1. The preclinical detection of non-Hodgkin's lymphoma through serial measurements of serum CA 125 among postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Woolas RP, Skates S, Gentry-Maharaj A, Ryan A, Kalsie T, Mintah-Sem A, Woolas J, Kapinskyj C, **Menon U**, Jacobs IJ. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Volume 12 Supplement S5, 80-80, Meeting Abstract 49, Nov 2016.
2. Cost-effectiveness of systematic population based screening for BRCA1, BRCA2, RAD51C, RAD51D and BRIP1 gene mutations in unselected general population women. Manchanda R, Gordeev V, Antoniou A, Smith S, Lee A, Hopper J, Macinnis R, Paul P, Simon G, Susan R, **Menon U**, Jacobs I, Legood R. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Volume 26 Supplement 3, 59-60, Meeting Abstract IGCS-1198, Oct 2016.
3. Specifying the threshold of 'ovarian cancer risk' for undertaking risk reducing surgery for ovarian cancer prevention in premenopausal women. Manchanda R, Legood R, Antoniou A, Gordeev V, **Menon U**. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Volume 26 Supplement 3, 767-767, Meeting Abstract IGCS-1181, Oct 2016.
4. Early Detection Biomarkers and Risk Estimation Models for Ovarian Cancer. Russell MR, D'Amato A, Gentry-Maharaj A, Ryan A, Kalsi J, **Menon U**, Jacobs I, Graham RLJ. 9th Joint Meeting of the British-Division of the International-Academy-of-Pathology and the Pathological-Society-of-Great-Britain-and-Ireland, Nottingham, Jun 28-Jul 1 2016, JOURNAL OF PATHOLOGY, Volume 240 Supplement 1, 3-3, Oct 2016.
5. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): A randomised controlled trial. Jacobs IJ, **Menon U**, Ryan A, Gentry-Maharaj, A, Burnell M, Kalsi JK, McGuire AJ, Farmer M, Skates SJ. AACR 107th Annual Meeting on Bioinformatics and Systems Biology, New Orleans, LA, Apr 16-20 2016, CANCER RESEARCH, Volume 76 Supplement 14, Meeting Abstract CT104, Jul 2016.
6. A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. Lee AW, Bomkamp A, Bandera EV, Jensen A, Ramus SJ, Goodman MT, Rossing MA, Modugno F, Moysich KB, Chang-Claude J, Rudolph A, Gentry-Maharaj A, Terry KL, Gayther SA, Cramer DW, Doherty JA, Schildkraut JM, Kjaer SK, Ness RB, **Menon U**, Berchuck A, Mukherjee B, Roman L, Pharoah PD, Chenevix-Trench G, Wu AH, Pike MC, Pearce CL. AACR 107th Annual Meeting on Bioinformatics and Systems Biology, New Orleans, LA, Apr 16-20 2016, CANCER RESEARCH, Volume 76 Supplement 14, Meeting Abstract 797, Jul 2016
7. Refining Ovarian Cancer Test accuracy Scores (ROCKeTS) trial update. Sundar S, Rick C, Dowling F, Au P, Snell K, Rai N, Champaneria R, Neal R, Davenport C, Mallet S, Sutton A, Stobart H, Kehoe S, Timmerman D, Bourne T, Calster BV, Gentry-Maharaj A, **Menon U**, Deeks J. BJOG-AN International Journal Of Obstetrics And Gynaecology, Volume 123 Special Issue SI Supplement, 102-102, Meeting Abstract EP3.062, Jun 2016.
8. Ovarian Cancer Screening and Mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A Randomized Controlled Trial. Jacobs IJ, **Menon U**, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E,

- Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ. *Obstetrical & Gynecological Survey*, Volume 71 Issue 6, 346-348, Jun 2016.
9. Validation of a multi-marker panel for early detection of ovarian cancer. Bast RC, Raamanathan A, Gentry-Maharaj A, Skates S, Baggerly KA, Fourkala R, Ryan A, Zhang Z, **Menon U**, Jacobs I. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, Jun 03-07 2016, *Journal of Clinical Oncology*, Volume 34 Issue 15 Supplement S, Meeting Abstract 5570, 20 May 2016.
 10. Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers in UKCTOCS. **Menon U**, Ryan A, Burnell M, Gentry-Maharaj A, Kalsi JK, Skates SJ, Parmar MKB, Jacobs IJ. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, Jun 03-07 2016, *Journal of Clinical Oncology*, Volume 34 Issue 15 Supplement S, Meeting Abstract 5507, 20 May 2016.
 11. Ovarian cancer screening. **Menon U**. AACR Special Conference on Advances in Ovarian Cancer Research - Exploiting Vulnerabilities, Orlando, FL, Oct 17-20 2015, *Clinical Cancer Research*, Volume 22 Supplement 2, Meeting Abstract IA23, 15 Jan 2016.
 12. Decreased Serum Thrombospondin-1 Levels in Pancreatic Ductal Adenocarcinoma Patients: An Early Indicator of Cancer or Diabetes Development? Jenkinson C, Elliott VL, Evans A, Oldfield L, Timms JF, Gentry-Maharaj A, **Menon U**, Cox T, Campbell F, Sutton R, Pereira SP, Tuveson DA, Greenhalf W, Neoptolemos JP, Costello E. *Pancreas*, Volume 44 Issue 8, 1383-1383, Nov 2015.
 13. Overdiagnosis of borderline ovarian cancer in ovarian cancer screening: the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) experience Gentry-Maharaj A, Karpinskyj C, Taylor H, Ryan A, Singh N, Benjamin E, Widschwendter M, Burnell M, Davies S, Kalsi J, Skates S, Campbell S, Parmar M, Jacobs I, **Menon U**. *International Journal Of Gynecological Cancer*, Volume 25 Issue 9 Supplement 1, 22-23, Meeting Abstract ESGO-0903, Oct 2015.
 14. A non-inferiority cluster randomised trial comparing traditional face-to-face and dvd-based genetic counselling in systematic population based brca1/2 testing Manchanda R, Loggenberg K, Burnell M, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Tomlinson L, Taylor R, Jacobs C, McGuire A, Beller U, **Menon U**, Jacobs I. *International Journal Of Gynecological Cancer*, Volume 25 Issue 9 Supplement 1, 48-49, Meeting Abstract ESGO-1259, Oct 2015.
 15. Symptoms reported by women with screen detected invasive epithelial ovarian cancer in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Dilley J, Allen P, Gentry-Maharaj A, Apostolidou S, Ryan A, Kalsi J, Burnell M, Davies S, Singh N, Widschwendter M, Campbell S, Parmar M, Skate S, Jacobs I, **Menon U**. *International Journal Of Gynecological Cancer*, Volume 25 Issue 9 Supplement 1, 423-424, Meeting Abstract ESGO-0951, Oct 2015.
 16. Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women Manchanda R, Legood R, Pearce L, **Menon U**. *International Journal of Gynecological Cancer*, Volume 25 Issue 9 Supplement 1, 600-601, Meeting Abstract ESGO-1258, Oct 2015.

17. Quality of life in endometrial cancer survivors - a cohort study nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Karpinskyj CL, Taylor J, Lewis D, Keller C, Pennington M, Ryan A, Manchanda R, Iyer R, Griffin M, Devine A, Jacobs I, Legood R, **Menon U**, Gentry-Maharaj A. *International Journal Of Gynecological Cancer*, Volume 25 Issue 9 Supplement 1, 610-611, Meeting Abstract ESGO-1307, Oct 2015.
18. Quality metrics from software analysis of transvaginal sonography (TVS) images in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) ultrasound record archive Stott W, Jones C, Ryan A, Campbell S, Burnell M, Gentry-Maharaj A, Fletcher G, Kalsi K, Jacobs I, **Menon U**. *International Journal Of Gynecological Cancer*, Volume 25 Issue 9 Supplement 1, 643-643, Meeting Abstract ESGO-029, Oct 2015.
19. Whole exome and targeted resequencing, of population based ovarian cancer cases and controls, identifies susceptibility genes for ovarian cancer Ramus SJ, Song H, Dicks E, Intermaggio M, Hayward J, Tyrer JP, Gronwald J, Kjaer SK, Wittemore A, Karlan B, Odunsi K, **Menon U**, Bowtell DD, Goode EL, Pharoah PDP, Gayther SA. 10th Biennial Ovarian Cancer Research Symposium, Seattle, WA, Sep 8-9 2014, *Clinical Cancer Research*, Volume 21 Supplement 16, Meeting Abstract CTRL-1213, Aug 15 2015.
20. TP53 autoantibody can detect CA125 screen negative ovarian cancer cases and can be elevated prior to CA125 in preclinical ovarian cancer Yang W-L, Simmons A, Lu Z, Baggerly K, Lu K, Gentry-Maharaj A, **Menon U**, Jacobs I, Bast RC. 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia, PA, Apr 18-22 2015, *Amer Assoc Canc Res. Cancer Research*, Volume 75 Supplement 15, Meeting Abstract 2838, Aug 1 2015.
21. Datta, S., Tripathi, L., Verghese, R., Logan, J., Gessler, S., **Menon, U.**, & Chatterjee, S. Jul 2015. Pivotal Role of Family in Cancer Care: Mixed-method Study of 'Truth Sharing' with Cancer Patients, Their Relatives and Oncologists in a Tertiary Cancer Centre. *Psycho-Oncology*, 24, 166.
22. McDermott, J., Gentry-Maharaj, A., Singh, N., Karpinskyj, C., Cross, P., Koslowski, M., Sundaresan, M., Houghton, O., Benjamin, E., Faruqi, A., Ryan, A., McCluggage, W.G., Gilks, B., & **Menon, U**. Feb 2015. Ovarian Cancer Histotype Diagnosis in the UK: A Review of Cases From 5 Hospitals From 2002-2008. *Modern Pathology*, 28, 297A-298A.
23. McDermott, J., Gentry-Maharaj, A., Singh, N., Karpinskyj, C., Cross, P., Koslowski, M., Sundaresan, M., Houghton, O., Benjamin, E., Faruqi, A., Ryan, A., McCluggage, W.G., Gilks, B., & **Menon, U**. Feb 2015. Ovarian Cancer Histotype Diagnosis in the UK: A Review of Cases From 5 Hospitals From 2002-2008. *Laboratory Investigation*, 95, 297A-298A.
24. Davis, S.J., Sheppard, K.E., Anglesio, M.S., **Menon, U.**, Gronwald, J., Wu, A., Kommos, S., Pfisterer, J., du Bois, A., Hilpert, F., Ramus, S.J., Huntsman, D.G., Pearson, R.B., Simpson, K.J., Campbell, I.G., & Goringe, K.L. Nov 2014. Enhanced Gab2 Expression Is Characteristic of A Clinically Distinct Pi3K-Dependent Subtype of High-Grade Serous and Endometrioid Ovarian Cancer. *International Journal of Gynecological Cancer*, 24, (9) 256-257.
25. **Menon, U.**, Ryan, A., Kalsi, J., Gentry-Maharaj, A., Dawnay, A., Hibib, M., Apostolidou, S., Singh, N., Benjamin, E., Burnell, M., Davies, S., Sharma, A., Williamson, K., Woolas, R., Campbell, S., Amso, N., Parmar, M., & Jacobs, I.J. Nov 2014. Serial Ca125 Can Detect Ovarian Cancer in the Absence of Ultrasound Abnormalities. *International Journal of Gynecological Cancer*, 24, (9) 467.

26. **Menon, U.**, Ryan, A., Kalsi, J., Gentry-Maharaj, A., Dawnay, A., Habib, M., Apostolidou, S., Singh, N., Benjamin, E., Burnell, M., Davies, S., Sharma, A., Gunu, R., Godfrey, K., Lopes, A., Oram, D., Herod, J., Williamson, K., Seif, M., Jenkins, H., Mould, T., Woolas, R., Murdoch, J., Dobbs, S., Nazar, N., Leeson, S., Cruickshank, D., Scott, I., Fallowfield, L., Widschwendter, M., Reynolds, K., Campbell, S., Parmar, M., Skates, S.J., & Jacobs, I. Nov 2014. A Time Series Algorithm Doubles Sensitivity of Population Screening for Ovarian Cancer in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (Ukctocs). *International Journal of Gynecological Cancer*, 24, (9) 1587-1588.
27. Graham, R., Russell, M., Gentry-Maharaj, A., Ryan, A., Fourkala, E., Humphryes, P., Walker, M., Williamson, A., **Menon, U.**, Whetton, A., & Jacobs, I.J. Nov 2014. Proteomic Discovery of Candidate Serum Biomarkers for Early Detection of Ovarian Cancer. *International Journal of Gynecological Cancer*, 24, (9) 1589.
28. Manchanda, R., Sanderson, S., Loggenberg, K., Burnell, M., Wardle, J., Gessler, S., Side, L., Balogun, N., Deshai, R., Kumar, A., Dorkins, H., Wallis, Y., Chapman, C., Taylor, R., Jacobs, C., Tomlinson, I., McGuire, A., Beller, U., **Menon, U.**, & Jacobs, I.J. Nov 2014. Population Prevalence of Uk Ashkenazi Brca-Mutations, Performance of and Estimated Time-To, Family-History Based Identification of All Brca Carriers. *International Journal of Gynecological Cancer*, 24, (9) 30-31.
29. **Menon, U.**, Ryan, A., Kalsi, J., Gentry-Maharaj, A., Dawnay, A., Habib, M., Apostolidou, S., Singh, N., Benjamin, E., Burnell, M., Davies, S., Sharma, A., Gunu, R., Godfrey, K., Lopes, A., Oram, D., Herod, J., Williamson, K., Seif, M., Jenkins, H., Mould, T., Woolas, R., Murdoch, J., Dobbs, S., Nazar, N., Leeson, S., Cruickshank, D., Scott, I., Fallowfield, L., Widschwendter, M., Reynolds, K., Campbell, S., Parmar, M., Skates, S.J., & Jacobs, I. Nov 2014. Serial Ca125 Can Detect Ovarian Cancer in the Absence of Ultrasound Abnormalities. *International Journal of Gynecological Cancer*, 24, (9) 46-47.
30. Manchanda, R., Legood, R., Burnell, M., McGuire, A., Loggenberg, K., Wardle, J., Sanderson, S., Gessler, S., Side, L., Balogun, N., Desai, R., Kumar, A., Dorkins, H., Wallis, Y., Chapman, C., Taylor, R., Jacobs, C., Beller, U., **Menon, U.**, & Jacobs, I. Nov 2014. Population-Based Testing for Brca Mutations (Compared to Family-History Based Testing) May be Cost Saving in Ashkenazi-Jews: A Health-Economics Decision Analytical Model. *International Journal of Gynecological Cancer*, 24, (9) 470-471.
31. Manchanda, R., Gessler, S., Loggenberg, K., Sanderson, S., Burnell, M., Wardle, J., Side, L., Balogun, N., Desai, R., Kumar, A., Dawkins, H., Wallis, Y., Chapman, C., Taylor, R., Jacobs, C., Tomlinson, I., MacGuire, A., Beller, U., **Menon, U.**, & Jacobs, I. Oct 2014. Population Testing for Inherited, Cancer Predisposing BRCA 1 and BRCA2 Founder Mutations in the Ashkenazi Jewish Community in London: The Psychological Impact on Participants of a Randomised Controlled Trial. *Psycho-Oncology*, 23, 120-121.
32. Iyer R, Gentry-Maharaj A, Nordin A, Burnell M, Liston R, Das N, Nevin J, Leeson S, Mould T, Wood N, Linder A, Shanbhag S, Gornall R, Desai R, Meechan D, Beardmore-Grey A, Varkey S, Manchanda R, Reynolds K, **Menon U.** UK Gynaecology Oncology Surgical Outcomes and Complications (UKGOSOC), *International Journal of Gynaecological Cancer*. 23:8:1. Oct 2013.
33. Rosenthal AN, Fraser L, Philpott S, Manchanda R, Badman P, Hadwin R, Evans DG, Eccles D, Skates S, Mackay J, **Menon U.**, Jacobs IJ. Results of intensive algorithm-based screening in the uk familial ovarian cancer screening study (uk focss phase 2). *International Journal of Gynaecological Cancer*. 23:8:1. Oct 2013.

34. Manchanda R, Legood R, Burnell M, McGuire A, Legood R, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Jacobs C, Tomlinson I, Beller U, **Menon U**, Jacobs I. Population based testing for brca mutations is highly cost-effective compared to family history based approach: a health-economic decision analytical model from the GCaPPS trial. *International Journal of Gynaecological Cancer*. 23:8:1. Oct 2013.
35. Philpott S, Rizzuto I, Fraser L, Manchanda R, Hadwin R, Burnell M, Mackay S, Skates S, **Menon U**, Jacobs I, Rosenthal A. Detection of non-ovarian cancers on phase 2 of the UK familial ovarian cancer screening study (UKFOCSS). *International Journal of Gynaecological Cancer*. 23:8:1. Oct 2013.
36. Trembling PM, Apostolidou S, Parkes J, Ryan A, Gentry-Maharaj A, Tanwar S, **Menon U**, Rosenberg WM. Influence of BMI and Alcohol on Liver-Related Morbidity and Mortality in a Cohort of 108,000 Women from the General Population from UKCTOCS. *Journal of Hepatology*. 58: S51-S52. Apr 2013.
37. **Menon U**, Kalsi J, Jacobs I; International Conference on Ovarian Cancer Screening: 29th-30th November 2011, Royal College of Physicians, London. Foreword. *Int J Gynecol Cancer*. 2012 May;22 Suppl 1:S1.
38. Woolas R, Talaat A, Anderson M, Brinkmann D, Gardner F, Gentry-Maharaj A, Ryan A, Rosenthal A, **Menon U**, Jacobs I. Significant endometrial pathology detected during a transvaginal ultrasound screening trial for ovarian cancer. *Gynecol Oncol* 121(1):S39-S39 Mar 2011.
39. Manchanda R, Loggenberg K, Gessler S, Sanderson S, Balogun N, Wardle J, Tomlinson I, McGuire A, Beller U, Side L, **Menon U**, Jacobs I. Population based testing for high-penetrance dominant gene mutations: initial results from the pilot phase of GCaPPS *International Journal Of Gynaecological Cancer* 22:S42-S43 May 2012.
40. Izatt L, Jacobs C, Jacobs I, **Menon U**, Manchanda R, Johnson M, Hamed H, Firth C, Evison M, Tutt A, de Silva L, Langman C, Picher G. Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers. British Human Genetics Conference, Warwick, RI, 06 Sep 2010 - 08 Sep 2010. *Journal of Medical Genetics*. BMJ Publishing Group. 47: S116-S116. Sep 2010.
41. **Menon U**. Biomarkers for screening and early detection of ovarian cancer. 38th Meeting of the International Society of Oncology and BioMarkers (ISOBM), Munchen, Germany, 03 Sep 2010 - 08 Sep 2010. *Tumor Biology*. Springer. 31: S20-S21. Aug 2010.
42. Sandanayake NS, Andreola F, Camuzeaux S, Sinclair J, Chapman MH, Webster GJ, Gentry-Maharaj A, **Menon U**, Jacobs I, Smith RC, Pereira SP, Timms JF. Serum CEACAM1 in the preclinical diagnosis of pancreatic adenocarcinoma. Annual General Meeting of the British Society of Gastroenterology, Liverpool, England, 22 Mar 2010 - 25 Mar 2010. *GUT*. BMJ Publishing Group. 59: A82-A82. Apr 2010.
43. Stott W, Ryan A, Jacobs IJ, **Menon U**, Bessant C, Jones C. OSPACS: Ultrasound image management system. *Source Code Biol Med*. 2008 Jun 20;3:11.
44. Vaes E, Manchanda R, Nir R, Nir D, Bleiberg H, Robert A, **Menon U**. A sequential use of the Risk of Malignancy Index and Ovarian HistoScanning for the differential diagnosis of adnexal masses. 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, GERMANY, 20 Sep 2009 - 24 Sep 2009. *EJC Supplements*. Pergamon-Elsevier Science Ltd. 7: 147-147. Sep 2009.

45. Jacobs IJ, Mackay J, **Menon U**, Skates SJ, Rosenthal AN, Fraser L. Familial ovarian screening--effective or ineffective? *Br J Cancer* 95(8):1124 23 Oct 2006.
46. Ayhan A, Singh N, **Menon U**, Gayther S, Jacobs IJ. The incidence of morphological 'transition' in serous and mucinous ovarian neoplasia. *International Journal of Gynecological Cancer*. 14: 32-32. 2004.
47. Skates SJ, Jacobs IJ, Macdonald N, **Menon U**, Rosenthal AN. Estimated duration of pre-clinical ovarian cancer from longitudinal CA 125 levels. *Proceedings of the American Association for Cancer Research Annual Meeting*, Mar 3999. 40. 1999